UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)  

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 20212022.

 

 

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from [—Date—] to [—Date—]

 

Commission File Number: 001-40578

AGRIFORCE GROWING SYSTEMS LTD.

(Exact name of registrant as specified in its charter)

 

British Columbia Not Applicable

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

  

 

00-0000000

300 – 2233 Columbia Street

Vancouver, BC, Canada

 V5Y 0M6
(Address of principal executive offices) (Zip Code)

(604(604)) 757-0952

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Shares AGRI NASDAQ Capital Market
Series A Warrants AGRIW NASDAQ Capital Market

Securities registered pursuant to Section 12(g) of the Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No

Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from their obligations under those Sections.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such fi les). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 Large accelerated filer ☐ Accelerated filer ☐
 Non-accelerated filer Smaller reporting company
 Emerging growth company   

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No No

 

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, computed by reference to the price at which the common equity was 0t a public companylast sold, or the average bid and asked price of such common equity, as of June 30, 2021,2022 was approximately $28,755,938. Shares of the last business day of its most recently completed second fiscal quarter and therefore, cannot calculate the aggregate market value of itsregistrant’s common stock held by non-affiliates. each officer and director and each person known to the registrant to own 10% or more of the outstanding voting power of the registrant have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determination for other purposes.

APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

 

(APPLICABLE ONLY TO CORPORATE REGISTRANTS)

As of March 29, 2022,13, 2023, the registrant has 15,176,698 18,156,154shares of common stock, no par value per share, outstanding.

 

DOCUMENTS INCORPORATED BY REFERENCE

List hereunder the following documents if incorporated by reference and the Part of the Form 10-K (e.g., Part I, Part II, etc.) into which the document is incorporated: (1) Any annual report to security holders; (2) Any proxy or information statement; and (3) Any prospectus filed pursuant to Rule 424(b) or (c) under the Securities Act of 1933. The listed documents should be clearly described for identification purposes (e.g., annual report to security holders for fiscal year ended December 24, 1980).

 

 

 

 

 

Table of Contents

 PART I 
Item 1.Business4
Item 1A.Risk Factors2415
Item 1B.Unresolved Staff Comments3728
Item 2.Properties3728
Item 3.Legal Proceedings3728
Item 4.Mine Safety Disclosures3728
 PART II 
Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities3829
Item 6.Selected Financial Data3930
Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations4030
Item 7A.Quantitative and Qualitative Disclosures About Market Risk4834
Item 8.Financial Statements and Supplementary DataF-1
Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure4935
Item 9A.Controls and Procedures4935
Item 9B.Other Information4935
 PART III 
Item 10.Directors, Executive Officers and Corporate Governance4936
Item 11.Executive Compensation5440
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters5541
Item 13.Certain Relationships and Related Transactions, and Director Independence5541
Item 14.Principal Accounting Fees and Services5642
 PART IV 
Item 15.Exhibits, Financial Statement Schedules5743

 

2

 

Cautionary Note Regarding Forward-Looking Information

 

This report on Form 10-K contains certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements represent our expectations, beliefs, intentions or strategies concerning future events, including, but not limited to, any statements regarding our assumptions about financial performance; the continuation of historical trends; the sufficiency of our cash balances for future liquidity and capital resource needs; the expected impact of changes in accounting policies on our results of operations, financial condition or cash flows; anticipated problems and our plans for future operations; and the economy in general or the future of the defense industry, all of which were subject to various risks and uncertainties.

 

When used in this Report on Form 10- K and other reports, statements, and information we have filed with the Securities and Exchange Commission (“Commission” or “SEC”), in our press releases, presentations to securities analysts or investors, in oral statements made by or with the approval of an executive officer, the words or phrases “believes,” “may,” “will,” “expects,” “should,” “continue,” “anticipates,” “intends,” “will likely result,” “estimates,” “projects” or similar expressions and variations thereof are intended to identify such forward-looking statements. However, any statements contained in this Report on Form 10-K that are not statements of historical fact may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, certain of which are beyond our control, and actual results may differ materially depending on a variety of important factors.

 

We do not assume the obligation to update any forward-looking statement. You should carefully evaluate such statements in light of factors described in this annual report. In this Form 10-K, AgriFORCE Growing Systems Ltd. (“AgriFORCE”AgriFORCE™” or the “Company”) has identified important factors that could cause actual results to differ from expected or historic results. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete list of all potential risks or uncertainties.

 

3

 

PART I

Item 1. Business

Overview

 

AgriFORCE Growing Systems Ltd.AgriFORCE™ was incorporated as a private company by Articles of Incorporation issued pursuant to the provisions of the Business Corporations Act (British Columbia) on December 22, 2017. The Company’s registered and records office address is at 300 – 2233 Columbia Street, Vancouver, BC, Canada, V5Y 0M6. On February 13, 2018, the Company changed its name from 1146470 B.C. Ltd to Canivate Growing Systems Ltd. On November 22, 2019 the Company changed its name from Canivate Growing Systems Ltd. to AgriFORCE Growing Systems Ltd.

 

Our Business

AgriFORCEAgriFORCE™ is dedicated to positively transforming farm, food, and family every day, everywhere. We aim to achieve this goal by providing novel agriculturally focused consulting, facility solutions, and products & services through our Solutions division, and by leveraging innovative technologies and processes to deliver healthier more nutritious food to consumers through our Brands division.

The AgriFORCE™ Solutions division is dedicated to transforming modern agricultural development “Building from the Seed to Deliver sustainable, Efficient, and Healthier crops” through our proprietary patent pending facility designintegrated Agtech platform 2.0 combining knowledge and automated growing system throughIP with CEA equipment solutions, including our AgriFORCE Solutions division. Our methodsFORCEGH+™” solution, implementing solutions that are designedbest suited to produce high-quality, pesticide-free, locally cultivatedthe crops – cost-effectively and with the ability to quickly scale, in virtually any climate. Designed to European Union Good Manufacturing Practices and meet the United States Department of Agriculture organic equivalent standards, we intend for our platform to be utilized by our customers as an industry accepted standard for, among other things, controlled environment plant-based vaccine and crops including plant-based vaccines, pharmaceuticals, nutraceuticals, and food production.chosen.

 

Our AgriFORCEAgriFORCE™ Brands division is focused on the development and commercialization of plant-based ingredients and products that deliver healthier and more nutritious solutions.“Food to Table”. We will market and commercialize both branded consumer product offerings and ingredient supply.supplies.

 

AgriFORCEAgriFORCE™ Solutions

 

Understanding Our Approach – The AgriFORCEAgriFORCE™ Precision Growth Method

 

Traditional farming includes three fundamental approaches: outdoor, greenhouse and indoor. AgriFORCEAgriFORCE™ introduces a unique fourth method, the AgriFORCEAgriFORCE™ precision growth method, which is informed by cutting-edge science and leveraging the latest advances in artificial intelligence (AI) and Internet of Things (IoT).

 

4

 

 

With a carefully optimized approach to facility design, IoT, AI utilization, nutrient delivery, and micro-propagation, we have devised an intricate, scientific and high success-oriented approach designed to produce much greater efficacy yields using fewer resources. This method is intended to outperform traditional growing methods using a specific combination of new and traditional techniques required to attain this efficiency. We call it precision growth. The AgriFORCEAgriFORCE™ precision growth method focuses on addressing some of the most important legacy challenges in agriculture: environmental impact, operational efficiency and yield volumes.

 

The AgriFORCEAgriFORCE™ precision growth method presents a tremendous opportunity to positively disrupt all corners of the industry. The market size of just the nutraceutical and plant-based pharmaceutical and vaccine/therapeutics market is over $500 billion. Including the traditional hydroponics high value crops and controlled-environment food markets, the addressable market approaches nearly $1 trillion. (1)(2)(3).

 

While our patent pending intellectual property initially targeted the hydroponics sector of our customers high value crops to showcase its efficacy in a growing market, we are currently expanding operations to refine our technology and methodology for our customers’ vegetables and fruit food crops. Hydroponics was identified as an ideal sector to demonstrate proof of concept However, management has decided that the Company focus on evolving our intellectual property and applying our precision growth method to other agricultural areas so that we can be a part of the solution in fixing the severe issues with the global food supply chain.

The AgriFORCEAgriFORCE™ Model – Managing the Difficulties of Agricultural Verticals with Modern Technology and Innovation

 

Our intellectual property combines a uniquely engineered facility design and automated growing system to provide a clear solution to the biggest problems plaguing most high value crop agricultural verticals. It delivers a clean, self-contained environment that maximizes natural sunlight and offers near ideal supplemental lighting. It also limits human intervention and – crucially – it was designed to provide superior quality control. It was also created to drastically reduce environmental impact, substantially decrease utility demands, as well as lower production costs, while delivering customers daily harvests and higher crop yields.

 

Plants grow most robustly and flavorfully in full natural sunlight. While it may seem counterintuitive to some, even the clearest of glass greenhouses inhibit the full light spectrum of the sun. However, new translucent and transparent membrane materials have emerged recently that enable the near-full-transmission of the sun’s light spectrum.

 

(1) https://home.kpmg/pl/en/home/insights/2015/04/nutraceuticals-the-future-of-intelligent-food.html

(2) https://link.springer.com/article/10.1057/jcb.2010.37

(3) https://medium.com/artemis/lets-talk-about-market-size-316842f1ab27

Unlike plastic or glass, these new transparent membranes can help crops achieve their full genetic (and flavor) potential. Natural light also warms the microclimate when necessary, dramatically reducing heating energy requirements. And at times when the sun is not cooperating, advances in supplemental grow lighting can extend the plants’ photoperiod – even beyond natural daylight hours – to maximize crop growth, quality, and time to harvest by up to 50% or better.

Greenhouses and vertical farms are also compromised by outdoor and human-introduced contamination. The new model relies on creating a sealed, cleanroom-like microclimate that keeps pests, pesticides and other pollutants outside.

5

 

Thanks to artificial intelligence, the Internet of Things, and similar advances, farmers can now benefit from highly automated growing systems that reduce human intervention and its associated costs. Finely tuned convective air circulation systems enable the microclimate to remain sealed and protected. Natural temperature regulation using sunlight and organic foam-based clouds can significantly reduce air-conditioning electricity requirements. Highly automated hydration, fertilization and lighting are all continuously optimized by machine learning.

This new AgriFORCE model, which has been designed with more than four years of ongoing research and development, is set to be put into large scale practice when the first of three new grow facilities completes construction on a 41-acre site in Coachella, California we expect to purchase in the coming year. This unique approach, which included contributions from lighting experts who had previously worked at NASA sending plants into space, was developed to significantly improve local food security in an environmentally friendly way. It uses the best aspects of current our customers’ current growing methods – outdoor, greenhouse and indoor – and replaces their shortcomings with better technology and processes.

Any solution whether in agriculture, industry, or consumer goods is typically the integration of various disparate parts which, in and of themselves, require independent skill sets and levels of expertise to bring together the desired outcome. Controlled environment agriculture solutions such as our patent pending proprietary facility and automated grow system are no different. Centered around four pillars: facility and lighting; automation and AI; nutrients and fertigation and micropropagation and genetics, our business not only has a tremendous opportunity to grow organically by virtue of its existing contracts and a future pipeline of similar contracts, but also through accretive acquisitions.

 

Our Position in the Ag-Tech Sector

 

The Ag-Tech sector is severely underserved by the capital markets, and we see an opportunity to acquire global companies who have provided solutions to the industry and are leading innovation moving forward. We are creating a separate corporate office to aggressively pursue such acquisitions. The robustness of our engagement with potential targets has confirmed our belief and desire to be part of a larger integrated Ag-Tech solutions provider, where each separate element of the business has its existing legacy business and can leverage across areas of expertise to expand their business footprint. We believe that there is currently no one that we are aware of who is pursuing this model in the US capital markets environment at this time.

6

The AgriFORCEAgriFORCE™ Grow House

 

The Company is an agriculture-focused technology company that delivers innovative and reliable, financially robust solutions for high value crops through our proprietary facility design and automation IP to businesses and enterprises globally. The Company intends to operate in the plant based pharmaceutical, nutraceutical, and high value crop markets using its unique proprietarypatented facility design and hydroponics based automated growing system that enable cultivators to effectively grow crops in a controlled environment. The Company calls its facility design and automated growing system the “AgriFORCE grow house”environment (“FORCEGH+™”). The Company has designed its AgriFORCE grow houseFORCEGH+™ facilities to produce in virtually any environmental condition and to optimize crop yields to as near their full genetic potential possible while substantially eliminating the need for the use of pesticides, fungicides and/or irradiation. The Company is positioning itself to deliver solutions to a growing industry where end users are demanding environmentally friendly and sustainable, controlled growing environments and processes. The initial market focus is the cultivation of food and other high value crops in California, and proof of concept will be to apply the IP to biomass production of plant based vaccine materials. The Company believes that its IP will provide a lower cost cultivation solution for the indoor production of crops due to a combination of higher crop quality and yields, and reduced operating costs. The Company has designed its AgriFORCE grow house as a modular growing facility that it plans to build and license to licensed operators for the cultivation of food and high value crops. The AgriFORCE grow house incorporates a design and technology that is the subject of a provisional patent that the Company has submitted to the United States Patent and Trademark Office on March 7, 2019. On March 6, 2020, a New International Patent Application No. PCT/CA2020/050302 Priority Claim United States 62/815, 131 was filed. The Company’s IP can be adapted to a multitude of crops and required growing conditions where exacting environmental control and pharma grade equivalent cleanliness and processes are required to meet the highest cultivation standards. By delivering the first facility, the Company will be in a position to demonstrate the performance and to target Good Manufacturing Practices standards compliance necessary to engage the pharma industry as it moves into modifying its IP to meet the particular plant biomass requirements for vaccines and other pharma biomass.

 

As theThe Company commences construction of its micropropagation facility and grow house, it will startcontinues to develop its solution for fruits and vegetables focusing on the integration of its current structure with a new form of vertical grow technology. Although many of the components and elements will be the same or similar in nature, the automation and integration for going vertical and accommodating lighting, circulation, climate control and humidity control will be somewhat different. Therefore, the Company intends to develop a small working commercial facility as it moves to finalize design and engineering. The Company believes it can deliver new IP for vertical farming with a view to constructing its first commercial facility to serve the Southern California market for fresh local leafy greens (first crop) before rolling out its solution to address other crops and other local markets in the United States and internationally.

 

Our Intellectual Property Strategy

The Company’s IP and business is focused on four (4) key elements:

1)FACILITY AND LIGHTING DESIGN

-the facility utilizes a proprietary building envelope system that allows virtually the full light spectrum and substantial portions of the UV light spectrum through it. It is fully sealed and utilizes positive air pressure exchange to create a microclimate that optimizes temperature, humidity, CO2, air velocity, filtration, and sanitation through the process of biomimicry.

-Advanced proprietary supplemental grow lighting technologies achieving optimal luminous efficacy, spectrum, distribution characteristics, automated DLI management and fixture architecture.

7

2)AUTOMATION AND ARTIFICIAL INTELLIGENCE

-Proprietary automated grow system(s) and technology integrated through IOT and artificial intelligence.

-Self learning input factors to create the highest yield, lowest impact cultivation.

3)FERTIGATION AND NUTRIENTS

-white label and proprietary organic based blends/products tailored and focused on improved yields and reduced impact cultivation.

4)MICROPROPAGATION AND GENETICS

Optimized cellular cloning and tissue culture process tailored to facility environment optimization to ensure enhanced solution specific genetic outcomes.

To maximize the AgriFORCE grow house’s production capacity, each AgriFORCE grow house will incorporate its own tissue culture laboratory for micropropagation into the Company’s proprietary mechanized and automated growing system. AgriFORCE micropropagation laboratories will enable the micropropagation of healthy plantlets that will then be transplanted and grown to maturity in its facilities.

Our Business PlanBUSINESS PLAN

The Company plans to develop its business by focusing on both an organic growth plan and through M&A. The Company’s organic growth plan is focused on four distinct phases:

 

PHASE 1: COMPLETED: 2017-20211 (COMPLETED):

 

 

Conceptualization, engineering, and design of facility and systems. (complete)

 Completed selection process of key environmental systems with preferred vendors.
The signing of revenue contracts with the Exclusive Independent Operator (EIO) for the first three facilities completed.
The arrangement of three offtake agreements signed with Exclusive Independent Operator (EIO) for those three facilities when complete. (Subsequently these agreements were terminated in Q2 2021) (complete)
 Selection and Land Purchase agreement in Coachella, CA for 41.37-acre parcel subject to financing. (complete)
 

ForceFilm material ordered. (complete)

 

PHASE 2: 2022-2023:

 

 Complete the timing of financing for, and purchase of, the 41.37-acreselected parcel in Coachella, CA, subject to market conditions,
 Complete feasibility study for new contracts’ structures for those first three facilities with new independent operators.
 Site preparation and utilities infrastructure build out for the campus (up to eight facilities).
Fit out and complete genetics lab for micropropagation, breeding, and R&D to achieve near term revenue (8 months) of the sale of tissue culture clones for variant crops.
Additional raw materialsIdentify procurement of AgriFORCEAgriFORCE™ IP specific automated grow system, supplemental grow lighting and controls systems, and manufacture of the building envelope materials.
 Conceptualization and design of vertical grow solutions in order to develop a small-scale vertical grow house.
Focus on the delivery and installation of the first facility.solutions.
 Initiate the design of aan R&D facility for food solutions and plant-based pharma.

86

 

PHASE 3: 2023-2025:

 

 Focus onComplete the delivery and installation of the second and third facilities. Proof of quantitative and qualitative benefits will drive both sales pipeline acceleration for subsequent years.
 Complete the design and construction of aan R&D facility for food solutions and plant-based pharma. Commence engagement with universities and pharmaceutical companies.
Construct small scale vertical grow house and operate successfully.
FinalizeReview potential licensing opportunities for the design and engineering of vertical grow solution with construction commencement late in the third year. Commence engagement with local restaurants and grocery stores and develop a vertical grow house branding strategy.Solutions patent portfolio.

 

PHASE 4: 2026:

 

 Focus on delivery and installation of additional facilities.
 Expand geographic presence into other states whilst alsogeographies by introducing the grow houseFORCEGH+™ to other international markets with a view to securing additional locations and markets by year four.
Targeted additional contracts of three facilities.
Commence and complete first vertical grow commercial facility to serve Southern California market by end of year 4.markets.

The Company’s initial AgriFORCE grow houses are planned to be constructed in California.

AgriFORCEAgriFORCE™ Brands

 

The Company purchased Intellectual Property (“IP”) from Manna Nutritional Group, LLC (“MNG”Manna”), a privately held firm based in Boise, Idaho on September 10, 2021. The IP encompasses patent-pending technologiesa granted patent to naturally process and convert grain, pulses and root vegetables, resulting in low-starch, low-sugar, high-protein, fiber-rich baking flour produces as well as wide range of breakfast cereals, juices,produces a natural sweeteners and baking enhancers.sweetener juice. The core process is covered under a pending patent applicationthe Patent Nr. 11,540,538 in the U.S. and key international markets. The all-natural process is designed to unlock nutritional properties, flavorflavors and other qualities in a range of modern, ancient and heritage grains, pulses and root vegetables to create specialized All-Naturalall-natural baking and all-purpose flours, sweeteners, juices, naturally sweet cereals and other valuation products, providing numerous opportunities for dietary nutritional, performance and culinary applications.

Wheat and Flour Market

 

The Company will rebrand the consumer products and innovative ingredient offering for food manufacturers under the brand (un)Think foods.

Wheat and Flour Market

Modern diet is believed to be a contributor to health risks such as heart disease, cancer, diabetes and obesity, due in part to the consumption of highly processed foods that are low in natural fiber, protein and nutrition; and extremely high in simple starch, sugar and calories. These “empty carbs” produce glycemic swings that may cause overeating by triggering cravings for food high in sugar, salt and starch. As an example, conventional baking flour is low in natural fiber (about(~ 2-3%), low-to-average in protein (about(~ 9%), and very high in starch (about(~ 75%)(4). Whole wheat flour is only marginally better. Similarly, gluten-free products are often produced with sugar

(4) Based on protein, fiber, and starches suchstarch content figures from a nationally certified independent laboratory, as potato flour, rice flour, tapioca, etc. Gluten-free products are typically low-fiber, low-nutrition, high-starch and high-calorie.compared to standard all-purpose flour.

 

97

 

 

In contrast, foods high in fiber help to satiate hunger, suppress cravings and raise metabolism and require more calories to digest.(5). They also assist in weight loss, lower cholesterol, and may reduce the risk of cancer, heart disease and diabetes.

 

Advantages of the MNGUN(THINK)™ Foods IP

 

The Controlled Enzymatic Reaction & Endothermic Saccharification with Managed Natural Germination (“CERES-MNG) patented process allows for the development and manufacturing of All-natural Foursall-natural flours that are significantly higher in Fibers, Nutrientsfibers, nutrients and Proteinsproteins and significantly lower in Carbohydratescarbohydrates and Caloriescalories than Standard Baking Flour.standard baking flour.

 

As shown in the graph below, MNG Baking FlourCERES-MNG baking flour produced from Soft White Wheatsoft white wheat has 30 time40 times more fiber, 3three (3) times more protein 80%and 75% less starch and 50-60% less calories as compared to standardnet carbohydrates than regular all- purpose baking flour.flour8 (6).

 

 

Source: Independent analysis by Eurofins Food Chemistry Testing Madison, Inc, February 2022

The CERES-MNG patent pending process will help develop new flours and products from modern, ancient and heritage grains, seeds, legumes and tubers/root vegetables.

 

(5) https://my.clevelandclinic.org/health/articles/14400-improving-your-health-with-fiber

Why Manna NG versus Keto or Low Carb Flours(6) Based on protein, fiber, and Sprouted Grains Flours?starch content figures from a nationally certified independent laboratory, as compared to standard all-purpose flour.

 

108

 

 

-Versus Keto/Low Carb Flours, Manna NG has some clear positive distinctions:
Simple and clean ingredient list
Significantly higher protein values
Materially Higher Fiber content
Significantly lower carb content
More palatable and natural flavor without any additives
Works and tastes like All Purpose Wheat Baking Flour
-Versus Sprouted Grains Flours
Like Sprouted Grains Flours, Manna NG Nutrients are metabolized better;
Significantly Higher Protein content
Materially Higher Fiber content
Significantly Lower Carb content

Finally, the CERES-MNG Process creates a Liquid by-product which is a High Fiber, High Protein, Maltose Sweet Juice (Power Juice) from which we intend to develop Liquid and Crystallized Sweeteners, Juices etc.

Products that AgriFORCEAgriFORCE™ intends to develop for commercialization from the CERES/MNG Process:CERES-MNG patented process under the UN(THINK)™ foods brand:

-High protein, High Fiber, Low Carb Modern, Heritagehigh fiber, low carb modern, heritage and Ancientancient grain flours (for use in breads, baked goods, doughs, pastry, snacks, and pasta)
-Protein Floursflours and Protein Additivesprotein additives
-High Protein, High Fiber, Low Carbprotein, high fiber, low carb cereals and snacks
-High Protein, High Fiber, Low Carbprotein, high fiber, low carb oat based dairy alternatives
-Better Tasting, Cleaner Label High Protein, High Fiber, Low Carbtasting, cleaner label high protein, high fiber, low carb nutrition bars
-High Protein, High Fiber Low Carbprotein, high fiber low carb nutrition juices
-Sweeteners – Liquid, Granulatedliquid, granulated
-High Protein, High Fiber, Low Carbprotein, high fiber, low carb pet foods and snacks

We intend to commercialize these products behind 3three (3) main Go-to-Market strategies:sales channels:

-Ingredients
-Branded Ingredientsingredients
-Consumer Brandbrand

The Business Opportunitybusiness opportunity for AgriFORCEAgriFORCE™ to successfully commercialize Premium Specialized Productspremium specialized products from the MannaUN(THINK)™ foods IP - by capturing a conservatively very small percentage share of the category it is targeting to enter in the premium segments. We estimate these revenues to be between $500 million and $1 Billionbillion by 20252030 (excluding any potential revenues from the Maltose-Power Juice applications).

 

  Breads &Bakery  Functional Flours  Pulse Flours  Dairy Alternatives  Nutrition Bars  TOTAL 
Global Market Size of Target Categories $222B  $48B   $17B  $6B  $45B      
Potential Market Share  0.1%  1%  1%  1%  0.1%    
AgriFORCE Potential Net Revenues $100-200M  $200-480M  $100- 170M  $30-60M  $20-40M   $450-950M 

  Breads &Bakery  Functional Flours  Pulse Flours  Dairy Alternatives  Nutrition Bars  Total 
Global market size of target categories $222B  $48B  $17B  $6B  $45B     
Potential market share  0.1%  1%  1%  1%  0.1%    
AgriFORCEpotential net revenues $100-200M  $200-480M  $100- 170M  $30-60M  $20-40M  $450-950M 

 

Sources: Grand View Research Reports, San Francisco CA, 2018 Estimates.

Products from the MANNA IP address Consumer Trends in Health, Nutrition and Diet

The benefits of plant-based proteins, low-carbohydrates (particularly “empty” carbs) and natural high- fiber diets are key to good health and nutrition and are critically important in combating cancer, diabetes, digestive disorders, high-cholesterol, obesity and heart disease.

119

 

The High-Protein, High Fiber, Low Carb products from the CERES-MNG Process, allows to address these growing consumer needs.

Importantly, the Manna IP products would target primarily Millennials and Boomers, that increasingly look for healthier food alternatives.

Long-Term Future Applications – Product Development; Medical Research & Development

The following outlines future applications, research and development. This will include controlled studies on Type II Diabetes, in addition to a dedicated and completely independent Medical Research Organization (MRO) and research laboratory, supported by private and public research grants.

 

While we are working on setting up a pilot plant in Canada to produce the UN(THINK)™ power wheat flour for the end of 2023, our patented process allows us to develop a gold-standard sprouted wheat flour, which we have qualified and have made available for sale through brokers as of January 2023 in Canada and the USA, under the UN(THINK)™ Awakened Grains™ brand. This new Awakened Grains™ flour will provide enhanced nutrition with over five times more fiber, up to two times more protein and 77% of net carbs versus conventional all purpose flour (source: Eurofins Food Chemistry Madison, Inc, December 2022).

12

 

BUSINESS PLAN

 

AgriFORCE’sAgriFORCE™’s organic growth plan is to actively establish and deploy the commercialization of products, following the acquisition of the MNGManna IP, is focused on four distinct phases:

 

PHASE 1: COMPLETED: 2017-20201 (COMPLETED):

 

Product and Process Testingprocess testing and Validation (Completed)validation. (completed)
Filing of US and International Patent (Completed)international patent. (completed)
Conceptual Engineeringengineering and Preliminary Budgetingpreliminary budgeting on Commercial Pilot Plant (Completed)commercial pilot plant. (completed)
Creation of the UN(THINK)™ foods brand. (completed)
Qualification and operational and commercial set up of the Awakened Grains™ line of products (completed)

 

PHASE 2: 2021-2022

 

Launch of the UN(THINK)™ Awakened Grains™ sprouted flour range of products in business to business (“B2B”) and direct to consumers (“D2C”) channels.
Design, Build, Start-upbuild, start-up, and Operationoperation of the Pilot Plantpilot plant for the fully processed and patented flours
Develop Rangerange of Finished Products in Grain Flours, Protein Flours, Cerealsfinished products behind the wheat grain flours, qualify patented process for pulse/legume, and Juicesrice based protein flours.
Collaborate with Nutritional Flour Medical Research Institute (an IRS section 501(c)(3) Medical Research Organization) funded by private & public research grantsgrants.

 

PHASE 3: 2022-2023

 

Launch First Rangefirst range of Productsfully patent processed products in US/Canada (UN(THINK)™ power wheat flour.
Drive Businessbusiness with Finished Productsfinished products in direct to consumer (“D2C”), Retail, Food ServiceD2C, retail, food service.
Drive Businessbusiness as Ingredientsingredients for Bakery, Snackbakery, snack and Plant Based Protein Products Manufacturersplant based protein products manufacturers.
Develop Manufacturing Basemanufacturing base through Partnershipspartnerships and Licensinglicensing.
Conceptual Engineeringengineering and Preliminary Budgetingpreliminary budgeting on Large-Scale Processing Plantlarge-scale processing plant.

 

PHASE 4: 2024-2025

 

Expand Product Rangeproduct range in US/CanadaCanada.
Expand Businessbusiness to other Geographies (select Markets in Europe, Asia, Latin America)geographies internationally.
Design, Build Start-upbuild, start-up, and Operationoperation of Large-Scale Processing Planlarge-scale processing plan.

 

Merger and Acquisition (“M&A”)

 

With respect to M&A growth, the Company is creating a separate corporate office to aggressively pursue acquisitions. The Company will focus on identifying target companiespursuing acquisitions in the key four pillars of its platform where each separate element of the business has its existing legacy business and can leverage across areas of expertise to expand their business footprint.agriculture technology space. The Company believes that a buy and build strategy will provide unique opportunities for innovation across each segment of the Ag-Tech market we serve. Our unique IP combined with the know-how and IP of acquired companies will create additional value if the way we grow or produce crops. The Company believes there is currently no other public traded publicly in the United States pursing this model.

 

1310

 

 

Below isManna Nutritional Group Asset Acquisition

On September 10, 2021, the Company signed a diagramdefinitive asset purchase agreement to acquire food production and processing IP from Manna.

On May 10, 2022, the Company completed an amendment to its asset purchase agreement with Manna Nutritional Group LLC, dated September 10, 2021. The amendment required the issuance of prefunded warrants instead of shares over several tranches and contained covenants to obtain shareholder approval of the intended strategy with respectacquisition transactions before the prefunded warrants can be exercised into Company common shares.

The transaction was fully approved by the shareholders on December 15, 2022. The Company paid consideration of $1,475,000 in cash and issued 7,379,969 prefunded warrants valued at $12,106,677 adjusted for foreign exchange differences of $492,300. Subject to a 9.99% stopped and SEC Rule 144 restrictions, the Company’s M&A strategy:prefunded warrants will vest in tranches up until March 10, 2024. When vested the tranches of prefunded warrants will be converted into an equal number of common shares.

Delphy Groep BV Acquisition

 

Delphy Groep BV Acquisition

On February 10, 2022, the Company signed a definitive share purchase agreement (the “Delphy Agreement”) to acquire Delphy, Groep BV (“Delphy”), a Netherlands-based AgTech consultancy firm, for $26€23.5 million through a combination of cash and stock. The closing of the transaction is expected to occur within 60 days of the signing date. The definitive agreement follows the binding letter of intent (“LOI”) as previously announced in the Company’s press release in October 2021. Delphy, which optimizes production of plant-based foods and flowers, has multinational operations in Europe, Asia, Russia, Kazakhstan, and Africa, with approximately 200 employees and consultants. Delphy’s client list includes agriculture companies, governments, universities, and leading AgTech suppliers, who turn to the company to drive agricultural innovation, solutions, and operational expertise. The Delphy Agreement was negotiated at arm’s length and is not a related party transaction.

 

On September 22, 2022, the Company entered an amendment to the Delphy Agreement, pursuant to which the parties agreed to reduce the total purchase from €$23.5 million to €17.7 million, plus a potential earnout of up to €6.0 million over two (2) years, based on achieving future performance milestones. The Company also agreed to pay interest in the amount of €0.2 million on the purchase price and additional interest from November 15, 2022 up to January 15, 2023 (the “Long Stop Date”).

Management is currently in negotiating an amendment which will extend the Long Stop Date past January 15, 2023. Neither party has provided notice to terminate the agreement.

Deroose Plants NV Binding Letter of Intent

On February 23, 2022, the Company signed a binding letter of intent (the “LOI”“Deroose LOI”) with Deroose Plants NV (“Deroose”), one of the largest tissue culture propagation companies in the world with a leadership position in horticulture, plantation crops, and fruit and vegetables. Founded in 1980, Deroose has multi-national operations in Europe, North America, and Asia, and over 800 employees.

 

The Deroose LOI is subject to completion of standard due diligence and entry into a definitive purchase agreement, which shall include commercially standard terms and conditions, including, but not limited to, representations and warranties, covenants, events of default and conditions to closing.

 

The net purchase price by the Company is expected to be approximately US$69€61 million. The purchase price represents approximately $46.4€41 million for the Deroose business on a cash and debt free basis and $22.6€20 million for the genetic IP portfolio.

 

Corporate StructureThe parties are working through the Letter of Intent. Neither party has provided notice to terminate the agreement.

Stronghold Land Acquisition

On August 30, 2022, the Company entered into a Purchase and Sale Agreement (“PSA”) with Stronghold Power Systems, Inc. (“Stronghold”) to purchase approximately 34 acres of land in Coachella California. The purchase price is $4,300,000, payable as follows: (i) $1,500,000 in cash and (ii) $2,800,000 in restricted shares of common stock of the Company. The stock is being issued in the form of prefunded warrants in two tranches: (i) $1,700,000 (695,866 prefunded warrants) issued within five days of entry into the PSA, and (ii) $1,100,000 (450,266 prefunded warrants) at closing of the transaction. The first tranche shall be void if closing of the transaction does not occur by March 31, 2023. The prefunded warrants per share exercise price is $2.443 which is subject to certain adjustments. Issuance of all securities in this transaction are exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended. Under the terms of the agreement, Stronghold must complete certain permitting, zoning, and infrastructure work by March 31, 2023, to close the transaction.

 

Corporate Structure

The Company currently has the following wholly-owned subsidiaries, which perform the following functions – AgriFORCE Investments will handle anyholds the Company’s U.S. investments, in the U.S., West Pender Holdings will holdretains real estate assets, West Pender Management will manage those assets andis a management company, AGI IP will holdholds the Company’s intellectual property in the U.S., un(Think) Food Company will manufacture food products in the U.S. and DayBreak is dormant:un(Think) Food Company Canada Ltd. manufactures food products in Canada:

 

Name of Subsidiary Jurisdiction of IncorporationDate of Incorporation
AgriFORCE Investments Inc. (US) DelawareApril 9, 2019
West Pender Holdings, Inc. DelawareSeptember 1, 2018
AGI IP Co. NevadaMarch 5, 2020
West Pender Management Co. NevadaJuly 9, 2019
DayBreak Ag Systemsun(Think) Food CompanyNevadaJune 20, 2022
un(Think) Food Company Canada Ltd.* British ColumbiaDecember 4, 2019

*un(Think) Food Company Canada Ltd. changed its name from Daybreak AG Systems Ltd. during the year ended December 31, 2022.

 

Summary Three Year History

 

From the date of Incorporation (December 22, 2017) to the date of this filing, the Company has largely been engaged in completion of its initial corporate organization, assembling its management team, completing the design and engineering of its IP and filing the appropriate intellectual property protection and taking the initial steps to implement its business plan through the commencement of initial operations in California.operations. Significant milestones during this period are as follows:

 

 The Company completed its initial seed round financings in early 2018.
From November 2018 to August 2019,has substantially finalized the Company engaged architectural, lightingfinal design engineering and tensile structure engineering consultants to advance “Concept Solution” to an “Engineered Solution” for the AgriFORCE grow houses, and the Company’s consultants completed testing and verification of its proprietary solutions, as described below in detail under “Advancement from Concept Solution to Engineered Solution”.

14

In December 2018, the Company selected FabriTec as its primary contractor for the growing portion of the AgriFORCE grow houses, which will be constructed of tensile steel and the high strength flexible covering material.
In January 2019, the Company received from FabriTec the initial engineering drawings for the greenhouse enclosure for the AgriFORCE grow house.
In February 2019, the Company arranged for PharmHaus, as its initial EIO, to enter into three offtake agreements with well-known California high value crop producers for the potential offtake purchase of an aggregate of 19,500 kilograms of production, which has since been increased to 21,878 kilograms of production per year under a replacement offtake agreement executed in September 2019 (terminated in April 2021 as per the below description)FORCEGH+™.
   
 On March 7, 2019, the Company filed an initial provisional patent application for the original concept related to the AgriFORCE grow house.
In July 2019, the Company entered into a master “Design/ Build” construction contract with FabriTec for the construction of the greenhouse enclosure (subject to final agreement on pricing).
In August 2019, the Company submitted an amended provisional patent application for its Structure Technology that reflects the “engineered solution” and related technology and intellectual property developed by the Company through the testing and verification process with FabriTec and the Company’s other architectural, engineering and technical consultants.
On March 6, 2020, a New International Patent Application No. PCT/CA2020/050302 Priority Claim United States 62/815, 131 was filed. The Company’s IP can be adapted to a multitude of crops and required growing conditions where exacting environmental control and pharma grade equivalent cleanliness and processes are required to meet the highest cultivation standards.
On April 22, 2021, the Company terminated its agreement with PharmHaus, its initial exclusive Independent Operator, as PharmHaus failed to demonstrate the business wherewithal to serve in its capacity as an exclusive Independent Operator.
The Company has substantially finalized the final design and engineering drawings for the AgriFORCE grow house.
On November 30, 2021, the Company signed an offtake agreement with Humboldt Bliss, Ltd., a Barbadian limited company (“Humboldt”). Under the terms of the contract, AgriFORCEAgriFORCE™ is responsible for constructing its proprietary facility and providing the full Standard Operating Procedures (SOPs)(“SOP”s) of the AgriFORCE Grow HouseFORCEGH+™ and Humboldt is responsible for securing the project’s land as well as operating the facility. Upon production, Humboldt has committed to remit an IP licensing, management services and equipment leasing fee to AgriFORCE for up to 14,300 pounds (6,500 kgs) of high value medical and agricultural crops per year. David Welch, a director of the Company, owns a controlling interest in Humboldt am dos thisand is a related party. Mr. Welch recused himself from the final deliberation and approval of the agreement by the board.
On February 18, 2022, the Company signed a license agreement with Radical Clean Solutions Ltd (“Radical”), a New York corporation that has development an advanceddeveloped a patent pending product line consisting of “smartsmart hydroxyl generation systems” focused on numerous industry verticals that is provensystems to eliminate 99.99+% of all pathogens, virus, mold, volatile organic compounds (VOCs) and allergy triggers, to commercialize their newthe proprietary hydroxyl generating devices within the controllercontrolled environment agriculture (“CEA”)and food manufacturing industries. The patent pending system seeks out and destroys both airborne and surface-based mold, bacteria, virus, odorous and volatile organic compounds and allergy triggers, as well as other pathogens and pollutants in real-time. The license grants the rights to AgriFORCEAgriFORCE™ in perpetuity as well as joint patent ownership rights for application in CEA. The Company has been working on commercializing these devices for food manufacturing plants, greenhouses, vertical growing facilities, as well as food, storage, and produce transportation. This is with a goal to drive food security, improve product freshness, and lengthen shelf-life.
On May 18, 2022, the Company completed the acquisition of the food processing intellectual property of Manna Nutritional Group (Manna).

Debt Financing

The Company signed a Term Sheet with Capital Funding Group on April 8, 2020 for the provision of debt related to the potential purchase of a property in Coachella, CA and all site improvements and infrastructure. The Term Sheet was further renewed on February 5, 2021. The terms of the debt are to provide 50% of the value of the land purchase price and 80% of the value of the site improvements and infrastructure. The value of the debt is expected to be approximately $12,000,000. The interest rate applicable to the land purchase is 10.5% per annum and for the site improvements and infrastructure it is 15.5% annum. In order to complete the debt facility agreement, the Company will need to raise approximately $4,500,000 in equity by February 1, 2021. The term of the loan is eighteen months. The Company expects to re-finance at the completion of the improvements and infrastructure through traditional lending sources. The Company is also in discussions with respect to debt financing for the grow house structure as well as the associated equipment including but not limited to the HVAC system and the automated growing system through the same debt broker used to secure the Capital Funding Group loan facility term sheet. Capital Funding Group has agreed to provide such debt financing subject to the completion of a development appraisal and final approval by its board of directors. There can be no assurance as to whether the Company will be able to secure further debt or secure such debt on commercially reasonable terms.

1511

 

 

Financing

On March 24, 2021, the Company entered into a securities purchase agreement with certain accredited investors for the purchase of $750,000 in principal amount ($600,000 subscription amount) of senior secured debentures originally due June 24, 2021 (the “Bridge Loan”). On June 24, 2021, the due date was extended to July 12, 2021. The imputed interest rate is encompassed within the original issue discount of the debentures and no additional cash interest shall bewas due. The debentures were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, to certain purchasers who are accredited investors within the meaning of Rule 501 under the Securities Act of 1933, as amended. Each debenture holder will receive a warrant to purchase shares of common stock in an amount equal to 50% of the principal amount divided by 80% of the initial public offering price of the Company’s common stock. The warrants are exercisable at 80% of the initial public offering price. Transaction costs of $69,000 have been recorded in connection with the Bridge Loan. The Bridge Loan was fully repaid on July 13, 2021.

On June 30, 2022, the Company entered into security purchase agreements with certain accredited investors (the “Convertible Debt Investors”) for the purchase of $14,025,000 in convertible debentures (the “Debentures”) due December 31, 2024. The interest rates on the Debentures are 5% for the first 12 months, 6% for the subsequent 12 months, and 8% per annum thereafter. Principal repayments will be made in 25 equal monthly installments and began on September 1, 2022. The Debenture may be extended by six months at the election of the Company by paying a sum equal to six months interest on the principal amount outstanding at the end of the 18th month, at the rate of 8% per annum. The Debentures are convertible into common shares at $2.22 per share. The Convertible Debt Investors have the right to purchase additional tranches of $5,000,000 each, up to a total additional principal amount of $33,000,000. In addition, the Convertible Debt Investors received 4,106,418 warrants at a strike price of $2.442, which expire on December 31, 2025 (the “Debenture Warrants”). The Debenture Warrants and Debentures each have down round provisions whereby the conversion and strike prices will be adjusted downward if the Company issues equity instruments at lower prices. On January 17, 2023, the Convertible Debt Investors purchased an additional tranche of $5,076,923. The convertible debt and warrants were issued with an exercise price of $1.24. The issuance of the additional tranche triggered the down round provision, adjusting the exercise prices of the Debentures and the Debenture Warrants to $1.24.

 

The Company’s Initial California EIO (Exclusive Independent Operator)Intellectual Property

The Company has terminated its EIO agreements (the “PharmHaus Agreements”) with PharmHaus, a private company that is arms-length to AgriFORCE. The Company had entered into each of the following agreements, on the terms outlined above, with PharmHaus as the EIO (the “PharmHaus Agreements”):

Cultivation Facility Lease Agreement;
IP License Agreement; and
Management Services Agreement.

PharmHaus required additional financing in order to achieve its business plan and objectives and in order to perform its contractual obligations under the Company’s agreements with PharmHaus. There was no assurance that PharmHaus would be able to obtain such funding. As a result of PharmHaus’ inability to secure funding and the Company’s focus on food and pharma applications of its IP as well as acquisition opportunities outside of the cannabis market, the Company chose to terminate its contract with PharmHaus on April 22, 2021. 

 

Micropropagation Laboratories

The Company has undertaken the steps described below in connection with the design and deployment of the Company’s micropropagation laboratories. These laboratories will ultimately be deployed at the Company’s AgriFORCE grow houses. However, the Company has identified a business opportunity through a current micropropagation lab which requires additional capacity for deployment of the micropropagation laboratories for plantlet growth in advance of the completion of the initial AgriFORCE grow houses. The advantage of the Company for pursuing this opportunity is that it enables the Company to achieve initial revenues in advance of incurring the full construction expenditure required for the initial AgriFORCE grow houses, thereby providing internally generated funding for the Company’s expenditures and tests of the micropropagation process with the selected crops:

the Company has completed the evaluation of options for construction of the micropropagation facility;
the Company has completed the determination of the most suitable low capital expenditure option providing flexibility;
Acquired in-house expertise through Dr. Laila Benkrima, the Company’s Chief Scientific Officer, who has a PhD from the University of Paris in horticulture with a specialization in tissue culture and the hybridization and selection of plant varietals;
completed the design of full facility and equipment scope and layout;
identified potential vendors and received final quotations; and
Research and preparation for permitting and licensing requirements.

16

The Company is presently proceeding with selecting vendors from whom we obtained quotations for the fit out of the micropropagation laboratories in order that these laboratories can be constructed. Concurrently, the Company is engaging in discussions with respect to the commercial arrangement of providing micropropagation services for another micropropagation lab’s excess volume requirements as well as exploring opportunities to provide such services to potential customers.

Intellectual Property

The Company’s intellectual property rights are important to its business. In accordance with industry practice, the Company protects its proprietary products, technology and its competitive advantage through a combination of contractual provisions and trade secret, copyright and trademark laws in Canada, the United States and in other jurisdictions in which it conducts its business. The Company also has confidentiality agreements, assignment agreements and license agreements with employees and third parties, which limit access to and use of its intellectual property.

Patents

Patent Applications

Date filed or
Information received
Registration DateTitleSerial #Registration#

Prov.

Patent
Application #

PCT Patent ApplicationPatent #CommentExpiry Date for Either Application or RegistrationApplicant
7/Mar/2019Structures For Growing Plants and Related Apparatus and Methods62/815,131

Expired replaced with 56288979-

7PCT

Canivate Growing Systems Ltd
26/Aug/2019AUTOMATED GROWING SYSTEMS62/891,562

Expired replaced with 56288979-

10PCT

6/Mar/2020Structures For Growing Plants56288979-7PCT

PCT/CA2020/

050302

Published: 10/Feb/20225/Sep/2022AgriFORCE Growing Systems Ltd.
26/Aug/2020AUTOMATED GROWING SYSTEMS56288979-10PCT

PCT/CA2020/

051161

Prior Claim date: 08/26/2019 - Pending25/Feb/2022AgriFORCE Growing Systems Ltd.

17

Trademarks

Date filed or
Information received
 Registration Date Title Serial # US Trade Mark
Application #
 CDN Trade Mark
Application #2
 Trademark International Registration # US Trade Mark # Comment Expiry Date Owner
24/Jan/2019   PLANET LOVE     1942554     IS&EDC 25/Jul/2029 Canivate Growing Systems Ltd
19/Dec/2019   PLANET LOVE 79274347 1504091         Awaiting examination in US Canivate Growing Systems Ltd
21/Jan/2020 25/Jul/2019 PLANET LOVE 806/1273879901     1504091     25/Jul/2029 AgriFORCE Growing Systems Ltd.
24/Jan/2019   HYDROFILM     1942547     IS&EDC Formalized; awaiting examination Canivate Growing Systems Ltd
21/Jan/2020 24/Jul/2019 HYDROFILM       1506916       AgriFORCE Growing Systems Ltd.
7/Dec/2018   HYDROHAUS     1934896     IS&EDC Formalized; awaiting examination Canivate Growing Systems Ltd
7/Dec/2018   HYDROHOUSE     1934895     IS&EDC Formalized; awaiting examination Canivate Growing Systems Ltd
1/Mar/2019   CANIVATE     1949210 1494234   CLASS 6: Greenhouses of metal, CLASS 19: Greenhouses of plastic, CLASS 44: Greenhouse services; horticultural services Formalized; awaiting examination Canivate Growing Systems Ltd
21/Jan/2020 30/Aug/2019 CANIVATE       1494234       AgriFORCE Growing Systems Ltd.
1/Mar/2019   THE CANIVATE WAY     1949209     IS&EDC Formalized; awaiting examination Canivate Growing Systems Ltd
1/Mar/2019 27/Oct/2020 THE CANIVATE WAY 79-270,261     1494231 6,182,017 CLASS 6: Greenhouses of metal, CLASS 19: Greenhouses of plastic, CLASS 44: Greenhouse services; horticultural services 26/Oct/2030 AgriFORCE Growing Systems Ltd.
26/Nov/2019   AgriFORCE Trademark application     1997835     CLASS 6: Greenhouses of metal, CLASS 19: Greenhouses of plastic, CLASS 44: Greenhouse services; horticultural services Formalized; awaiting examination AgriFORCE Growing Systems Ltd.
22/May/2020   AgriFORCE
Trademark application
 88930218 88930218       CLASS 6: Greenhouses of metal, CLASS 19: Greenhouses of plastic, CLASS 44: Greenhouse services; horticultural services Awaiting examination in US AgriFORCE Growing Systems Ltd.
18/Sep/2020   AgriFORCE Trademark application       18243244   CLASS 6: Greenhouses of metal, CLASS 19: Greenhouses of plastic, CLASS 44: Greenhouse services; horticultural services 22/May/2030 AgriFORCE Growing Systems Ltd.
19/Aug/2020   FORCEFILM Trademark application 90124842 90/124842         Awaiting examination in US AgriFORCE Growing Systems Ltd.
7/Aug/2020   FORCEFILM Trademark application     2044675       Formalized; awaiting examination AgriFORCE Growing Systems Ltd.

18

Our Competitive Conditions

Both indoor and greenhouse growing facilities have come to the forefront in recent years. With the advent of new business opportunities and the necessity and demand for increasing efficiency and yields, the facility design for both indoor and greenhouse has been significantly improved through advancing technologies and operational procedures, even more importantly in hybrid facility environments.

In recent decades, the greenhouse industry has been transforming from small scale facilities used primarily for research and aesthetic purposes (i.e. botanic gardens) to significantly more large-scale facilities that compete directly with land-based conventional food and ornamental plant production. While indoor growing allows production throughout the year and in most geographical locations, the energy used for lighting and climate control is costly while those systems are critical to the success, efficiency and yield of the operation. In large part due to the recent improvements in growing technology, the industry is witnessing a blossoming like no time before. Greenhouses today are increasingly emerging that are large-scale, capital-infused, more resource conscientious and urban-centered.

A major part of this recent transformationWe hold seven (7) patents in the greenhouse industry has been the rise of a technology-infused Smart Greenhouse Market. Smart Greenhouses feature new levels of technologyUnited States and automated control systems that allow for further optimization of growing conditions.15 international patents. We also have 18 pending patent applications. These patents and patents applications are directed to, among other things, technologies include LED grow-lights that provide energy efficient supplemental lighting during cloudy conditions and at night, as well as an array of smart sensors that can detect issues with plants or the growing environment as they arise and trigger responses from different control systems.

No matter the country or region, one universal trend is that modern greenhouses are being built closer to metropolitan areas and large transportation hubs. One reason for this shift is to locate greenhouses closer to universities where research opportunities and skilled labor abound. As greenhouses become more tech-heavy, having this close proximity to research institutions will continueplanned to be an important factorutilized in location.FORCEGH+™ and UN(THINK)™ foods.

19

As the market has grown dramatically, it has also experienced clear trends in recent years. Modern greenhouses are becoming increasingly tech-intensive, using LED lightsCompetitor Comparison and automated control systems to tailor optimal growing environments. Successful greenhouse companies are scaling significantly and locating their growing facilities near urban hubs to capitalize on the ever-increasing demand for local (sustainable, conscientious, nutritious) food, no matter the season. To accomplish these feats, the greenhouse industry is also becoming increasingly capital-infused, using venture funding and other sources to build out the infrastructure necessary to compete in the current market.

As the smart greenhouse market continues to expand, new technologies are also coming online that will shape the future of production. Like before, many of these technologies are being developed for the greenhouse industry in particular. However, perhaps recently more than ever, innovation is also coming from other sectors. From artificial intelligence to Solar PV, new technologies from a wide range of industries are now finding their way into the modern greenhouse.

Past and current deficiencies with indoor farming in general have already signaled two important messages. First, there is logical reasoning to support the argument that indoor agriculture will become the norm and play a vital role to our current food (water intensive, non-grain) landscape. It will not be an easy journey, but the industry is growing and evolving at a fascinating speed. Second, technology advancements play a key role in leading the industry to continue to mature and reach greater efficiencies, production, and profitability.

As the global population continues to grow, and resources like land and water become more restricted, greenhouse (and hybrid) farming will be a dominant contributor for feeding global population that is just as important as land-based farming.

As a whole, the solutions provided to the agriculture industry have been driven by the integration of disparate components predominately lead by the client / farmer, major greenhouse vendors such as Kubo, Van der Hoeven, Certhon and Havecon or by major automation vendors such as Codema Systems or Ridder Group. This has resulted in fragmentation and sub-optimal IP that has not been fully integrated in a form as the Company is endeavoring to provide. Additionally, many solutions often are an amalgamation of disparate parts and vendors that are not necessarily optimized for a particular crop. In the indoor growing space, this is even more pronounced as the facility is often a simple warehouse which is in and of itself suboptimal and the draw backs are more pronounced. Often the integration is led by the cultivators themselves, who often do not possess the necessary skills to effectively manage such a process or it is led by one of the main vendors.Differentiation

 

TechnologySolutions

The future: hardware, software, & plant physiology

Currently innovation is steered by three main drivers: in-house development within companies, technology providers, and “cross-industry pollination”. New and upcoming companies have great potential to create innovative products. When companies showcase how their innovative technology can be applied, other companies can either adapt or further develop these ideas. There are also technology providers who specialize in specific areas of Ag-Tech. Through cross-industry pollination, we can acquire existing technology from other industries for use in greenhouse application.

Lighting/materials

Energy costs—primarily associated with lighting—are of major significance in the operation of a greenhouse facility. Lighting is a critical component for growing plants in fully closed environments because it is the primary energy input used by plants for photosynthesis. Light-emitting diodes (LEDs) were first adopted for indoor growing in the 1970s to supplement natural sunlight more efficiently than previously used incandescent bulbs. With the advancement of LED technology, the cost has dropped significantly over the last 10 years—specifically, LED lighting costs have halved, while their efficacy, or light energy, has more than doubled. We can expect costs to continue to drop as technology develops and this trend continues. Additionally, precise control of lighting can enable the discovery and dissemination of reproducible “light recipes” that are tailored to crops specifically grown indoors. These light recipes are being developed and used by cultivators to manipulate how plants grow, what they taste like, and their nutrient composition.

20

In addition to lighting, improvements related to materials can also help further efficiency. Companies like Soliculture, are paving the way for a revolution of greenhouse materials. Their LUMO solar panel contains a low density of silicon photovoltaic (PV) strips arranged with space in between to allow light to transmit between the strips. A thin layer of luminescent material is adhered to the backside of the glass, enhancing light quality by converting green light to red light. Red light has the highest efficiency for photosynthesis in plants, and therefore this optimized light spectrum increases yield faster maturation rate, and has proven to contribute to more disease resistant plants.

Data/AI

Artificial intelligence (“AI”) is expected to grow significantly in the coming years, where humans are certainly not obsolete but essential in leading innovation to significantly enhance results. AI-powered tools are gaining popularity across several industries including agriculture. In the future, we expect AI to be used in operations by means of automation and for predictive analytics.

Robots are increasingly replacing humans as we see more fully automated operations. Robots excel at repetitive, precision mundane tasks such as seeding, weeding, and harvesting. Start-up Iron Ox uses robots every step of the way from seed to harvest.

This allows allocation of resources elsewhere to focus on their overall production. Robotics also reduce labor costs while increasing efficiency. Currently farming is facing a labor shortage for reasons ranging from immigration policy to a lack of desire to work in the industry. Robots can help fill in the gaps in missing labor.

AI and machine learning technologies are developed to integrate and deliver more precise control of comprehensive growing operations. Ag-Tech company, Autogrow, provides intelligent automation systems including pH sensors, irrigation, and climate control products. Both hardware and software are improving to become more analytical and help detect and solve problems such as pest management, nutrient solution maintenance, and disease prevention.

Automation will become more feasible and available as AI technology improves and becomes less expensive. Reduced labor costs will allow product prices to decrease, making local food more accessible.

Biological Development

While improved environmental control and cultivation practices will undoubtedly lead to greater crop yields, biological alterations can more specifically tailor plants to growing environments and consumer needs. Indoor growing environments and processing facilities reduce the need for plant traits which provide stability in the face of environmental fluctuations, pests, pathogens, and post-harvest injury. New plant breeding techniques and genome-editing technologies such as CRISPR/Cas9 can be used to promote new plant traits focused on rapid plant growth, performance in low-light environments, plant stature, nutrition, and flavor. Coupling heightened environmental control with biological control also opens the door for variable gene expression under different growing conditions. This could lead to crop varieties that are distinct from their outdoor counterparts for new culinary applications and create unique markets for produce grown indoors.

Industrial synergies

With the rise of abundant tech providers and cross-disciplinary innovators, we can expect collaboration and knowledge sharing to become more common. In addition to delivering more effective indoor growing technologies, collaboration may also substantiate partnerships between companies which reduce their ecological footprints. For instance, co-locating greenhouses with industrial power plants can divert carbon dioxide and heat—by products of combustion—from the atmosphere to crops for photosynthesis enhancement and climate control. Furthermore, composted food waste may be diverted from landfills to fertilize crops in soil-based greenhouses. In the other direction, transparent solar panels may enable greenhouses to become net producers of energy to supply nearby buildings without sacrificing crop performance.

21

New technologies and ideas will better integrate agricultural businesses with the world around them, helping urban and industrial communities become more productive and sustainable.

Innovation in technology and practice will be the key drivers of new developments in indoor and greenhouse ag businesses. While these developments will be diverse and multidimensional, their effects will be focused on improvements to the potential scale and efficiency of, and quality of food from, indoor agriculture. Following the greenhouse’s historical trajectory, we believe it is safe to assume its relevance to global food systems will continue to expand as we progress into the future.

Competitor Comparison

 

The Company believes that it has no direct competitors who provide a proprietary facility design and automated grow system as well as a system of operational processes designed to optimize the performance of the Company’s grow houses. On a broader basis, the competitive landscape includes greenhouse vendors, agriculture systems providers, automated grow system vendors, and system/solutions consultants.

 

Competitive Differentiation

12

The Company believes it has developed one of the world’s most technologically advanced indoor agriculture systems by focusing on competitive differentiators to deliver vastly improved results beyond conventional indoor approaches. By conceiving new IP, as well as utilizing tried trued tested existing Ag-Tech and Bio-Tech solutions, the Company delivers integrated unique architectural design, intelligent automation and advanced growing processes to create precisely controlled growing environments optimized for each nominated crop variety. These precision ecosystems should enable the Company to cost-effectively produce the cleanest, greenest and most flavorful produce, as well as consistent medical-grade plant-based nutraceuticals and pharmaceuticals, available.

Brands

Our patented technology naturally processes and converts grains, pulses, and root vegetables into low-starch, low-sugar, high-protein fiber-rich baking flour products. The key pointsCompany is developing a range of differentiation areconsumer products to transform the consumers’ diet in multiple verticals.

The Company’s UN(THINK)™ power flour has 40 times more fiber, 3 times more protein, and 75% less net carbs than regular all-purpose flour8.

(8) Based on protein, fiber, and starch content figures from a nationally certified independent laboratory, as follows:compared to standard all purpose flour.

Recent Developments

Convertible Debt Financing

On January 17, 2023, the Convertible Debt Investors purchased an additional tranche of $5,076,923 in convertible debentures and received 2,661,289 warrants. The convertible debt and warrants were issued with an exercise price of $1.24. The issuance of the additional tranche triggered the down round provision, adjusting the exercise prices of the Debentures and the Debenture Warrants to $1.24.

Berry People LLC Binding Letter of Intent

On January 24, the Company announced it has entered into a binding letter of intent (“BP LOI”) to acquire Berry People LLC, (“Berry People”), a berry business with an increasingly international footprint and a scalable business model. The acquisition bolsters the AgriFORCE™ Brands division and allows the Company to realize commercial synergies with UN(THINK)™.

Berry People was founded in 2017 by berry industry veterans to create a new platform to meet market demand for a branded, year-round supply of organic and conventional berries. Berry People quickly established a recognized global trade brand and scalable operations, comprised of over 200 retail and foodservice clients and over 100 grower and exporter clients across the US, Canada, Mexico, and Peru. Berry People had net revenues of USD $37 (unaudited) million for the year ended December 31, 2022.

The LOI states, among other things that:

 

CropsOpsthe transaction will be subject to completion of due diligence to the Company’s satisfaction and, after satisfactory due diligence, the reaching of agreement on the terms of the purchase pursuant to a definitive purchase agreement, including conditions precedent for closing of the transaction;
the parties will sign the definitive purchase agreement no later than April 30, 2023, unless agreed to by both parties; and
Optimized genetics through advanced tissue culture and micropropagation.Advanced propagation/cultivation/harvest SOP’s.
Higher yields.Minimal workforce.
Improved nutrition/efficacy values.Enhanced automation.
Lower production costs.Substantive capital, resource, and operational savings.
Patents, future pending and provisional.Reduced ecological impacts.
Trade-marks, EU registered and Canada + US pending.
Patents, pending and provisional.Berry People will not enter into any negotiations with other parties for a period of three months following the execution of the BP LOI.

 

2213

 

 

Facilities

The BP LOI sets forth a purchase price of $28.0 million, consisting of $18.2 million in cash and $9.8 million in AgriFORCE™ restricted shares, will be paid at closing to acquire 70% of Berry People’s equity interests. Berry People will have the opportunity for future earnouts during the five years after closing based on future revenue and EBITDA targets associated with agreed upon growth targets.

In collaboration with AgriFORCE™, Berry People aims to further develop backward integration into agricultural production via farming joint ventures and deploy licensed and developed IP as part of a scalable franchising model. The berries market was $9.65 billion in 2021 in the U.S. alone7, with growth rates of around 10% or more each year since 2019— a trend that is expected to continue.

(7) As per IRI Integrated Fresh, Latest 52 WE 3/20/2022

Manna Patent Issuance

On January 3, 2023, Manna satisfied all its contractual obligations when the patent was approved by the US Patents Office and title was transferred to the Company. The Company issued 1,637,049 shares upon exercise of vested tranches of Manna’s prefunded warrants in relation to this transaction on January 3, 2023.

 

SystemsEnvironment
High-tech high efficiency building envelope.IoT to AI integrated facility/systems controls.High efficiency climate control equipment.
Proprietary building engineering and materials.Critical sensing and monitoring interface equipment.Micro-climate delivery materials and systems.
Natural sunlight, indoors.Advanced Ag-tech Automated Grow Systems.Automated chronological/meteorological/biological integrated controls.
Proprietary supplemental grow lighting. Dynamic foam solar gain control. Significantly reduced utility demands. Alternative clean energy sourcing. Green Building Initiative/Green Globe certification. Patents, pending and provisional.

Proprietary high efficiency grow channels.

Sealed environment.

Hybrid hydroponic-aeroponic nutrient systems.

Herbicide and pesticide free cultivation. Patents, pending and provisional.
Patents, pending and provisional.

Employees

 

As of March 29, 2022,13, 2023, the Company has 1315 employees and fivethree consultants. The Company also relies on consultants and contractors to conduct its operations. The Company anticipates that it will be hiring additional employees to support its planned activities.

 

Operations

 

The Company primary operating activities are in California.California, USA and Saskatoon, Canada. The Company’s head office is located in Vancouver, British Columbia, Canada with a second office in the Rotterdam, Netherlands. The Company intends to open a project office near Coachella, CA and maintain an administrative office in Los Angeles. The Company also plans to construct its initial AgriFORCE micropropagation laboratories and its initial AgriFORCE grow houses in the State of California.Canada.

 

Description

Status as an Emerging Growth Company

On April 5, 2012, the Jumpstart Our Business Startups Act of Property2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for private companies.

The Company currently leases office space at 2233 Colombia Street, Suite 300, Vancouver, B.C., V5Y 0M6 as its principal office. The Company believes the office is in good condition and satisfy its current operational requirements. The Company also leases an office space at Weena 505 Rotterdam, Netherlands

Litigation

We are subjectin the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions from, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the legal proceedingauditor’s report providing additional information about the audit and claims described in detail in “Note 16. Commitments and Contingencies” to the audited financial statements, includedknown as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (a) the last day of our fiscal year following the fifth anniversary of the closing of this offering, (b) the last day of the first fiscal year in this filing. Althoughwhich our annual gross revenues exceed $1.07 billion, (c) the resultslast day of litigation and claims cannotour fiscal year in which we are deemed to be predicted with certainty,a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, or Exchange Act (which would occur if the market value of our equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter), or (d) the date of this filing,on which we do not believehave issued more than $1 billion in nonconvertible debt during the outcome of such legal proceeding and claims, if determined adversely to us, would be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.preceding three-year period.

2314

 

Item 1A. Risk Factors

Risks Relating to the Company’s Business

The Company is an early stage company with little operating history, a history of losses and the Company cannot assure profitability.

The Company currently has no revenues and does not have any history of revenue generating operations. The Company has been involved to date in the design and development of its AgriFORCE grow houseCEA FORCEGH+™ facility which incorporates the Company’s AgriFORCEAgriFORCE™ micropropagation laboratories.laboratories, acquisition and advancement of the UN(THINK)™ foods IP, product base, development of its pilot plant, and transacting with potential revenue generating acquirees. While the Company has invested considerably in this development and design process,these business plans, no AgriFORCE grow houseFORCEGH+™ facility has been constructed to date, and accordingly, the Company has not generated revenue from UN(THINK)™, nor has the Company completed any acquisition of revenue generating companies. The commercial or operating viability of the AgriFORCE grow house hasCompany’s business plans have not been proven, or when, if ever,proven. There is no assurance that the Company will generate revenue generated from its operations, and if those revenues, when and if generated, will be sufficient to sustain operations, nonetheless achieve profitability.

 

There is no assurance that the Company’s AgriFORCE grow housesFORCEGH+™ facilities or micropropagation laboratories will operate as intended.

The Company’s initial state of its business operations will be to construct and deploy its initial AgriFORCE grow houseFORCEGH+™ facility and micropropagation laboratories. However, the Company has yet to complete construction of any laboratories. Accordingly, this component of the Company’s business plan is subject to considerable risks, including:

 

 there is no assurance that the laboratories will achieve the intended plantlet production rates;
 the costs of constructing and operating the laboratories may be greater than anticipated;
 the potential offtake partners who have indicated a willingness to deploy the laboratories at their existing cultivation operations may withdraw and determine not to deploy the laboratories;
 there is no assurance that the facilities will deliver the intended benefits of high production yields, lower crop losses and reduced operation costs;
 if the company is not able to fully develop the grow house or it does not operate as intended, it could prevent the company from realizing any of its business goals or achieving profitability;
 the costs of constructing the AgriFORCE grow houses may be greater than anticipated and the Company may not be able to recover these greater costs through increases in the lease rates, license fees and services fees that it charges to its customers; and
 the costs of operating the AgriFORCE grow house may be greater than anticipated.

 

COVID-19There is no assurance that UN(THINK)™ will operate as intended.

The Company’s plans for developing and advancing the UN(THINK)™ are in its preliminary stages. The Company has yet to fully launch their range of products in either the B2B or any pandemic, epidemic or outbreakD2C channels. Accordingly, this component of an infectious disease in the United States or elsewhereCompany’s business plan is subject to considerable risks, including:

the costs of constructing and operating the pilot plant may be greater than anticipated;
the potential B2B and D2C sales may not achieved the planned levels of sales;
there is no assurance that the pilot plant will deliver the planned production levels or scale;
if the company is not able to fully develop the pilot plan, it could prevent the company from realizing any of its business goals or achieving profitability;
the costs of operating the AgriFORCE™ pilot plant may be greater than anticipated.
the quality of product from the co-manufacturing may not be sufficient.
the cost from co-manufacturing may be greater than anticipated.
the demand for the products may not be as high as predicted.
the pricing of the products may deter potential buyers and may not cover the cost of production.
the brand may not attract sufficient volume.

We may adversely affect our business.not realize the anticipated benefits of, and synergies from, acquisitions and may become responsible for certain liabilities and integration costs as a result.

 

The COVID-19 virus has hadbusinesses we have proposed to acquire have previously operated independently from us. The proposed integrations of our operations with the proposed businesses acquisitions are intended to result in financial and operational benefits, and business synergies. There can be no assurance, however, regarding when or the extent to which we will be able to realize these and other benefits. Integration may also be difficult, unpredictable, and unprecedented impacts insubject to delay because of possible company culture conflicts, system integrations, regulatory compliance, and other factors. Difficulties associated with the United States and around the world. The World Health Organization has declared the outbreak of COVID-19 as a “pandemic,” or a worldwide spread of a new disease. Many countries around the world have imposed quarantines and restrictions on travel and mass gatherings to slow the spreadintegration of the virus. In the United States, federal, state and local governmentsproposed business acquisitions could have enacted restrictions on travel, gatherings, and workplaces, with exceptions made for essential workers and businesses. As of the date of this filing, we have not been declared an essential business. As a result, we may be required to substantially reduce or cease operations in response to governmental action or decree as a result of COVID-19. We are still assessing thematerial adverse effect on our business from COVID-19 and any actions implemented by the federal, state and local governments. We have implemented safety protocols to protect our staff, but we cannot offer any assurance that COVID-19 or any other pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere, will not materially and adversely affect our business.

 

Fluctuations in the exchange rate of foreign currencies could result in losses.

 

We incur a portion of our operating expenses in Canadian dollars, and in the future, as we expand into other foreign countries, we expect to incur operating expenses in other foreign currencies. We are exposed to foreign exchange rate fluctuations as the financial results of our international operations are translated from the local functional currency into U.S. dollars upon consolidation. A decline in the U.S. dollar relative to foreign functional currencies would increase our non-U.S. revenue and improve our operating results. Conversely, if the U.S. dollar strengthens relative to foreign functional currencies, our revenue and operating results would be adversely affected. We have not previously engaged in foreign currency hedging. If we decide to hedge our foreign currency exchange rate exposure, we may not be able to hedge effectively due to lack of experience, unreasonable costs or illiquid markets.

 

2415

 

The Company will require additional financing and there is no assurance that additional financing will be available when required.

The Company will require substantial additional capital in order to acquire or lease the Coachella land, develop the Coachella lands for use, develop the micropropagation laboratories and operate them, and complete construction ofexecute its initial AgriFORCE grow house which is anticipated to be commenced in the second quarter of 2022. Thebusiness plan. Existing funds raised in this offering will not be sufficient and additional financing will be needed for this purpose and for other purposes. The Company plans to achieve this additional financing through equity and/or debt financing which will likely be dilutive to the position of then current shareholders. However, there is no assurance that this financing will be available at favorable terms, if at all, when required. Specifically, there is no assurance that the Company will be able to raise any additional equity financing through its sharesrequired, given that the viability of the Company’s AgriFORCE grow houses will not be demonstrated until after construction is complete. In addition, there is no assurance that the Company will be able to secure debt financing given its lowsmall asset base and its current lack of revenues.revenue.

 

The Company had negative cash flow for the year ended December 31, 2021.2022.

The Company had negative cash flows from operating activities for year ended December 31, 2021.2022. To the extent that the Company has negative cash flows from operating activities in future periods, it may need to allocate a portion of its cash reserves to fund such negative cash flow. The Company may also be required to raise additional funds through the issuance of equity or debt securities. There can be no assurance that the Company will be able to generate a positive cash flow from operating activities, that additional capital or other types of financing will be available when needed or that these financings will be on terms favorable to the Company. The Company’s actual financial position and results of operations may differ materially from the expectations of the Company’s management.

 

The Company’s actual financial position and results of operations may differ materially from the expectations of the Company’s management.

The Company’s actual financial position and results of operations may differ materially from management’s expectations. The process for estimating the Company’s revenue, net income and cash flow requires the use of judgment in determining the appropriate assumptions and estimates. These estimates and assumptions may be revised as additional information becomes available and as additional analyses are performed. In addition, the assumptions used in planning may not prove to be accurate, and other factors may affect the Company’s financial condition or results of operations. As a result, the Company’s revenue, net income and cash flow may differ materially from the Company’s projected revenue, net income and cash flow.

 

The Company expects to incur significant ongoing costs and obligations related to its investment in infrastructure, growth, regulatory compliance and operations.

The Company expects to incur significant ongoing costs and obligations related to its investment in its initial AgriFORCE grow houses.planned investments. To the extent that these costs may be greater than anticipated or the Company may not be able to generate revenues or raise additional financing to cover these costs, these operating expenses could have a material adverse impact on the Company’s results of operations, financial condition and cash flows. In addition, future changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to the design and operation of the Company’s AgriFORCE grow houses, which could increase construction costs and have a material adverse effect on the business, results of operations and financial condition of the Company. The Company’s efforts to construct its AgriFORCE grow houses and grow its business may be costlier than the Company expects, and the Company may not be able to recover sufficient revenues to offset its higher operating expenses.expenses or to recoup its initial capital investment. The Company may incur significant losses in the future for a number of reasons, including, unforeseen expenses, difficulties, complications and delays, and other unknown events. If the Company is unable to achieve and sustain profitability, the market price of our securities may significantly decrease.

2516

 

There is no assurance the Company will be able to repatriate or distribute funds for investment from the United States to Canada or elsewhere.

In the event that any of the Company’s investments, or any proceeds thereof, any dividends or distributions there from, or any profits or revenues accruing from such investments in the United States were found to be in violation of money laundering legislation or otherwise, such transactions may be viewed as proceeds of crime under applicable federal laws, rules and regulations or any other applicable legislation. This could restrict or otherwise jeopardize the ability of the Company to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada or elsewhere.

 

The Company may not be able to effectively manage its growth and operations, which could materially and adversely affect its business.

If the Company implements it business plan as intended, it may in the future experience rapid growth and development in a relatively short period of time. The management of this growth will require, among other things, continued development of the Company’s financial and management controls and management information systems, stringent control of costs, the ability to attract and retain qualified management personnel and the training of new personnel. The Company intends to utilize outsourced resources, and hire additional personnel, to manage its expected growth and expansion. Failure to successfully manage its possible growth and development could have a material adverse effect on the Company’s business and the value of the Shares.shares.

 

The Company may face significant competition from other facilities.

Many other businesses in California engage in similar activities to the Company, leasing commercial space to agricultural producers generally, and providing additional products and services to similar customers. The Company cannot assure you that it will be able to compete successfully against current and future competitors. Competitive pressures faced by the Company could have a material adverse effect on its business, operating results and financial condition.

 

The Company may face significant competition from other facilities.

Many other businesses in California engage in similar activities to the Company, leasing commercial space to agricultural producers generally, and providing additional products and services to similar customers. The Company cannot assure you that it will be able to compete successfully against current and future competitors. Competitive pressures faced by the Company could have a material adverse effect on its business, operating results and financial condition.

The Company may face significant competition from other nutritious food companies.

We face significant competition from other nutritious food companies. Many of our competitions may have established brands, more experience and competency in the industry, larger fulfillment infrastructure, significantly more marketing and other financial resources, and larger customers bases than we do. These factors may allow our competitions to achieve greater net sales and profits. The significant competition faced by the Company could have a material adverse effect on its business, operating results and financial condition.

If we are unable to protect our intellectual property, our business may be adversely affected.

We must protect the proprietary nature of the intellectual property used in our business. There can be no assurance that trade secrets and other intellectual property will not be challenged, invalidated, misappropriated or circumvented by third parties. Currently, our intellectual property includes provisional patents, patent applications, trademarks, trademark applications and know-how related to business, product and technology development. We plan on taking the necessary steps, including but not limited to the filing of additional patents as appropriate. There is no assurance any additional patents will issue or that when they do issue they will include all of the claims currently included in the applications. Even if they do issue, those new patents and our existing patents must be protected against possible infringement. Nonetheless, we currently rely on contractual obligations of our employees and contractors to maintain the confidentiality of our products. To compete effectively, we need to develop and continue to maintain a proprietary position with respect to our technologies, and business. The risks and uncertainties that we face with respect to intellectual property rights principally include the following:

 

 Currently, we only have provisionalProvisional protection which may not result in full patents being granted, and any full patent applications that we file may not result in issued patents or may take longer than expected to result in issued patents;
   
 we may be subject to interference proceedings;
   
 other companies may claim that patents applied for by, assigned or licensed to, us infringe upon their own intellectual property rights;
   
 we may be subject to trademark opposition proceedings in the U.S. and in foreign countries;

 

2617

 

 any patents that are issued to us may not provide meaningful protection;
   
 we may not be able to develop additional proprietary technologies that are patentable;
   
 other companies may challenge patents licensed or issued to us as invalid, unenforceable or not infringed;
   
 other companies may independently develop similar or alternative technologies, or duplicate our technologies;
   
 other companies may design around technologies that we have licensed or developed;
   
 any patents issued to us may expire and competitors may utilize the technology found in such patents to commercialize their own products; and
   
 enforcement of patents is complex, uncertain and expensive.

 

It is also possible that others may obtain issued patents that could prevent us from commercializing certain aspects of our products or require us to obtain licenses requiring the payment of significant fees or royalties in order to enable us to conduct our business. If we license patents, our rights will depend on maintaining our obligations to the licensor under the applicable license agreement, and we may be unable to do so. Furthermore, there can be no assurance that the work-for-hire, intellectual property assignment and confidentiality agreements entered into by our employees and consultants, advisors and collaborators will provide meaningful protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure of such trade secrets, know- how or other proprietary information. The scope and enforceability of patent claims are not systematically predictable with absolute accuracy. The strength of our own patent rights depends, in part, upon the breadth and scope of protection provided by the patent and the validity of our patents, if any.

 

We operate in an industry with the risk of intellectual property litigation. Claims of infringement against us may hurt our business.

Our success depends, in part, upon non-infringement of intellectual property rights owned by others and being able to resolve claims of intellectual property infringement without major financial expenditures or adverse consequences. Participants that own, or claim to own, intellectual property may aggressively assert their rights. From time to time, we may be subject to legal proceedings and claims relating to the intellectual property rights of others. Future litigation may be necessary to defend us or our clients by determining the scope, enforceability, and validity of third-party proprietary rights or to establish its proprietary rights. Some competitors have substantially greater resources and are able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. Regardless of whether claims that we are infringing patents or other intellectual property rights have any merit, these claims are time-consuming and costly to evaluate and defend and could:

 

 adversely affect relationships with future clients;
   
 cause delays or stoppages in providing products;
   
 divert management’s attention and resources;
   
 require technology changes to our platform that would cause our Company to incur substantial cost;
   
 subject us to significant liabilities; and
   
 require us to cease some or all of itsbusiness activities.

 

2718

 

 

In addition to liability for monetary damages, which may be tripled and may include attorneys’ fees, or, in some circumstances, damages against clients, we may be prohibited from developing, commercializing, or continuing to provide some or all of our products unless we obtain licenses from, and pay royalties to, the holders of the patents or other intellectual property rights, which may not be available on commercially favorable terms, or at all.

 

We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.

We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on devices in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents, but enforcement is not as strong as that in the United States.

 

Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. To date, we have not sought to enforce any issued patents in these foreign jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Certain countries in Europe and developing countries, including China and India, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

 

If we are unable to obtain or defend our patents, our business could be materially adversely affected.

Our patent position is highly uncertain and involves complex legal and factual questions. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced under our patents or in third-party patents. For example, we might not have been the first to make the inventions covered by each of our pending patent applications and provisional patents; we might not have been the first to file patent applications for these inventions; others may independently develop similar or alternative technologies or duplicate any of our technologies; it is possible that none of our pending patent applications will result in issued patents; our issued patents may not provide a basis for commercially viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated by third parties; and, we may not develop additional proprietary technologies that are patentable.

 

As a result, our owned and licensed patents may not be valid and we may not be able to obtain and enforce patents and to maintain trade secret protection for the full commercial extent of our technology. The extent to which we are unable to do so could materially harm our business.

 

We have applied for and will continue to apply for patents for certain products. Such applications may not result in the issuance of any patents, and any patents now held or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible that patents issued or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because of such patents, such preferred position would be lost. If we are unable to secure or to continue to maintain a preferred position, we could become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration of our patents would adversely affect our business and operations.

2819

 

 

Patents issued or licensed to us may be infringed by the products or processes of others. The cost of enforcing our patent rights against infringers, if such enforcement is required, could be significant, and we do not currently have the financial resources to fund such litigation. Further, such litigation can go on for years and the time demands could interfere with our normal operations. We may become a party to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor, could be substantial. Many of our competitors may be able to sustain the costs of such litigation more effectively than we can because of their substantially greater financial resources. Litigation may also absorb significant management time.

 

Unpatented trade secrets, improvements, confidential know-how and continuing technological innovation are important to our scientific and commercial success. Although we attempt to and will continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of confidentiality agreements with our partners, collaborators, employees and consultants, as well as through other appropriate means, these measures may not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain access to, the same or similar information.

 

International intellectual property protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to expend substantial sums and management resources.

Patent and other intellectual property law outside the United States is more uncertain and is continually undergoing review and revisions in many countries. Further, the laws of some foreign countries may not protect intellectual property rights to the same extent as the laws of the United States. For example, certain countries do not grant patent claims that are directed to business methods and processes. In addition, we may have to participate in opposition proceedings to determine the validity of its foreign patents or its competitors’ foreign patents, which could result in substantial costs and diversion of its efforts and loss of credibility with customers.

 

If we are found to be infringing on patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license to continue the development or sale of our products, and/or pay damages.

Our processes and potential products may violate proprietary rights of patents that have been or may be granted to competitors, universities or others, or the trade secrets of those persons and entities. As our industry expands and more patents are issued, the risk increases that our processes and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other persons could bring legal actions against us claiming damages and seeking to enjoin manufacturing and marketing of the affected product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required to obtain a license in order to continue to manufacture or market the affected product or use the affected process. Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain. If we become involved in litigation or other proceedings, it could consume a substantial portion of our financial resources and the efforts of our personnel.

 

We rely on confidentiality agreements to protect our trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our competitors.

We rely on trade secrets that we seek to protect through confidentiality agreements with our employees and other parties. If these agreements are breached, our competitors may obtain and use our trade secrets to gain a competitive advantage over us. We may not have any remedies against our competitors and any remedies that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure. In addition, we may have to expend resources to protect our interests from possible infringement by others.

2920

 

We have a limited operating history on which to judge our business prospects and management.

Our company was incorporated and commenced operations in 2017. Accordingly, we have only a limited operating history upon which to base an evaluation of our business and prospects. Operating results for future periods are subject to numerous uncertainties and we cannot assure you that we will achieve or sustain profitability. Our prospects must be considered in light of the risks encountered by companies in the early stage of development, particularly companies in new and rapidly evolving markets. Future operating results will depend upon many factors, including increasing the number of affiliates, our success in attracting and retaining motivated and qualified personnel, our ability to establish short term credit lines, our ability to develop and market new products, control costs, and general economic conditions. We cannot assure you that we will successfully address any of these risks.

 

We may not be able to continue as a going concern.

The Company has incurred substantial operating losses since its inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. As reflected in the financial statements, the Company had an accumulated deficit of approximately $19.9$32.8 million at December 31, 2021,2022, a net loss of approximately $6.6$12.9 million, and approximately $5.1$12.1 million of net cash used in operating activities for the year ended December 31, 2021.2022. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company anticipates incurring additional losses until such time, if ever, that it can obtain marketing approval to sell, and then generate significant sales, of its technology that is currently in development. As such it is likely that additional financing will be needed by the Company to fund its operations and to develop and commercialize its technology. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is seeking additional financing to support its growth plans. The sale of additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding common shares.

 

Our management team has limited experience managing a public company, andwill be required to devote substantial time to regulatory compliance which may divert our attention from the day-to-day management of our business.

Our management team has limited experience managing a publicly-traded company and limited experience complying with the increasingly complex laws pertaining to public companies. These obligations typicallywill require substantial attention from our senior management and could divert our attention away from the day-to-day management of our business. Regulatory compliance is increasingly complex and management may not have experience in all areas of public company compliance. The management team will seek assistance from external resources when appropriate for public company regulatory compliance and tax regulatory compliance for applicable jurisdictions.

 

The Company may become subject to litigation, which may have a material adverse effect on the Company’s reputation, business, results from operations, and financial condition.

The Company may be named as a defendant in a lawsuit or regulatory action. The Company may also incur uninsured losses for liabilities which arise in the ordinary course of business, or which are unforeseen, including, but not limited to, employment liability and business loss claims. Any such losses could have a material adverse effect on the Company’s business, results of operations, sales, cash flow or financial condition.

If the Company is unable to attract and retain key personnel, it may not be able to compete effectively.

The Company’s success has depended and continues to depend upon its ability to attract and retain key management, including the Company’s Chief Executive Officer and technical experts. The Company will attempt to enhance its management and technical expertise by continuing to recruit qualified individuals who possess desired skills and experience in certain targeted areas. The Company’s inability to retain employees and attract and retain sufficient additional employees or engineering and technical support resources could have a material adverse effect on the Company’s business, results of operations, sales, cash flow or financial condition. Shortages in qualified personnel or the loss of key personnel could adversely affect the financial condition of the Company, results of operations of the business and could limit the Company’s ability to develop and market its intellectual property. The loss of any of the Company’s senior management or key employees could materially adversely affect the Company’s ability to execute the Company’s business plan and strategy, and the Company may not be able to find adequate replacements on a timely basis, or at all. The Company does not maintain key person life insurance policies on any of the Company’s employees.

3021

 

The size of the Company’s initial target market is difficult to quantify and investors will be reliant on their own estimates on the accuracy of market data.

Because high growth crop technology is in an early stage with uncertain boundaries, there is a lack of information about comparable companies available for potential investors to review in deciding about whether to invest in the Company and, few, if any, established companies whose business model the Company can follow or upon whose success the Company can build. Accordingly, investors will have to rely on their own estimates in deciding about whether to invest in the Company. There can be no assurance that the Company’s estimates are accurate or that the market size is sufficiently large for its business to grow as projected, which may negatively impact its financial results. The Company regularly follows market research.

 

The Company’s industry is experiencing rapid growth and consolidation that may cause the Company to lose key relationships and intensify competition.

The agriculture industry and various verticals within it are undergoing rapid growth and substantial change, which has resulted in an increase in competitors, consolidation and formation of strategic relationships. Acquisitions or other consolidating transactions could harm the Company in a number of ways, including by losing strategic partners and or customers if they are acquired by or enter into relationships with a competitor, losing customers, revenue and market share, or forcing the Company to expend greater resources to meet new or additional competitive threats, all of which could harm the Company’s operating results. As competitors enter the market and become increasingly sophisticated, competition in the Company’s industry may intensify which could negatively impact its profitability.

 

The Company will be reliant on information technology systems and may be subject to damaging cyberattacks.

The Company’s operations depend, in part, on how well it and its suppliers protect networks, equipment, information technology systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism and theft. The Company’s operations also depend on the timely maintenance, upgrade and replacement of networks, equipment, IT systems and software, as well as pre-emptive expenses to mitigate the risks of failures. Any of these and other events could result in information system failures, delays and/or increase in capital expenses. The failure of information systems or a component of information systems could, depending on the nature of any such failure, adversely impact the Company’s reputation and results of operations.

 

The Company has not experienced any material losses to date relating to cyber-attacks or other information security breaches, but there can be no assurance that the Company will not incur such losses in the future. The Company’s risk and exposure to these matters cannot be fully mitigated because of, among other things, the evolving nature of these threats. As a result, cyber security and the continued development and enhancement of controls, processes and practices designed to protect systems, computers, software, data and networks from attack, damage or unauthorized access is a priority.risk. As cyber threats continue to evolve, the Company may be required to expend additional resources to continue to modify or enhance protective measures or to investigate and remediate any security vulnerabilities.

3122

 

The Company’s officers and directors may be engaged in a range of business activities resulting in conflicts of interest.

Although certain officers and board members of the Company are expected to be bound by anti-circumvention agreements limiting their ability to enter into competing and/or conflicting ventures or businesses, the Company may be subject to various potential conflicts of interest because some of its officers and directors may be engaged in a range of business activities. In addition, the Company’s executive officers and directors may devote time to their outside business interests, so long as such activities do not materially or adversely interfere with their duties to the Company. In some cases, the Company’s executive officers and directors may have fiduciary obligations associated with these business interests that interfere with their ability to devote time to the Company’s business and affairs and that could adversely affect the Company’s operations. These business interests could require significant time and attention of the Company’s executive officers and directors.

 

In addition, the Company may also become involved in other transactions which conflict with the interests of its directors and the officers who may from time to time deal with persons, firms, institutions or companies with which the Company may be dealing, or which may be seeking investments similar to those desired by it. The interests of these persons could conflict with those of the Company. In addition, from time to time, these persons may be competing with the Company for available investment opportunities. Conflicts of interest, if any, will be subject to the procedures and remedies provided under applicable laws. In particular, if such a conflict of interest arises at a meeting of the Company’s directors, a director who has such a conflict will abstain from voting for or against the approval of such participation or such terms. In accordance with applicable laws, the directors of the Company are required to act honestly, in good faith and in the best interests of the Company.

 

There is no guarantee that how the Company uses its available funds will yield the expected results or returns which could impact the business and financial condition of the Company.

The Company cannot specify with certainty the particular uses of available funds. Management has broad discretion in the application of its proceeds. Accordingly, a holder of Sharesshares will have to rely upon the judgment of management with respect to the use of available funds, with only limited information concerning management’s specific intentions. The Company’s management may spend a portion or all of the available funds in ways that the Company’s shareholders might not desire, that might not yield a favorable return and that might not increase the value of a purchaser’s investment. The failure by management to apply these funds effectively could harm the Company’s business. Pending use of such funds, the Company might invest the available funds in a manner that does not produce income or that loses value.

Our Articles of incorporation, by-laws and certain Canadian legislation, contain provisions that may have the effect of delaying or preventing a change in control.

 

Certain provisions of our by-laws, together or separately, could discourage potential acquisition proposals, delay or prevent a change in control and limit the price that certain investors may be willing to pay for our common shares. For instance, our by-laws to be effective upon the completion of this offering, contain provisions that establish certain advance notice procedures for nomination of candidates for election as directors at shareholders’ meetings.

 

The Investment Canada Act requires any person that is non-Canadian (as defined in the Investment Canada Act) who acquires “control” (as defined in the Investment Canada Act) of an existing Canadian business to file either a pre-closing application for review or notification with Innovation, Science and Economic Development Canada. An acquisition of control is a reviewable transaction where prescribed financial thresholds are exceeded. The Investment Canada Act generally prohibits the implementation of a reviewable transaction unless, after review, the relevant Minister is satisfied that the acquisition is likely to be of net benefit to Canada. Under the national security regime in the Investment Canada Act, the federal government may undertake a discretionary review of a broader range of investments by a non-Canadian to determine whether such an investment by a non-Canadian could be “injurious to national security.” Review on national security grounds is at the discretion of the federal government and may occur on a pre- or post-closing basis.

 

3223

 

 

Furthermore, limitations on the ability to acquire and hold our common shares may be imposed by the Competition Act (Canada). This legislation permits the Commissioner of Competition to review any acquisition or establishment, directly or indirectly, including through the acquisition of shares, of control over or of a significant interest in us. This legislation grants the Commissioner of Competition jurisdiction, for up to one year, to challenge this type of acquisition before the Canadian Competition Tribunal on the basis that it would, or would be likely to, substantially prevent or lessen competition. This legislation also requires any person who intends to acquire our common shares to file a notification with the Canadian Competition Bureau if (i) that person (and their affiliates) would hold, in the aggregate, more than 20% of all of our outstanding voting shares, (ii) certain financial thresholds are exceeded, and (iii) no exemption applies. Where a person (and their affiliates) already holds, in the aggregate, more than 20% of all of our outstanding voting shares, a notification must be filed if (i) the acquisition of additional shares would bring that person’s (and their affiliates) holdings to over 50%, (ii) certain financial thresholds are exceeded and (iii) no exemption applies. Where a notification is required, the legislation prohibits completion of the acquisition until the expiration of the applicable statutory waiting period, unless compliance with the waiting period has been waived or the Commissioner of Competition provides written notice that he does not intend to challenge the acquisition. The Commissioner of Competition’s review of a notifiable transaction for substantive competition law considerations may take longer than the statutory waiting period.

 

We are governed by the corporate laws of British Columbia, Canada which in some cases have a different effect on shareholders than the corporate laws of the United States.

 

We are incorporated under the Business Corporations Act (British Columbia) (the “BC Act”) and other relevant laws, which may affect the rights of shareholders differently than those of a company governed by the laws of a U.S. jurisdiction, and may, together with our charter documents, have the effect of delaying, deferring or discouraging another party from acquiring control of our company by means of a tender offer, a proxy contest or otherwise, or may affect the price an acquiring party would be willing to offer in such an instance. The material differences between the Business CorporationsBC Act (British Columbia) and Delaware General Corporation Law or DGCL,(“DGCL”) that may have the greatest such effect include, but are not limited to, the following: (i) for certain corporate transactions (such as mergers and amalgamations or amendments to our articles) the Business CorporationsBC Act (British Columbia) generally requires the voting threshold to be a special resolution approved by 66 2/3% of shareholders, or as set out in the articles, as applicable, whereas DGCL generally only requires a majority vote; and (ii) under the Business CorporationsBC Act (British Columbia) a holder of 5% or more of our common shares can requisition a special meeting of shareholders, whereas such right does not exist under the DGCL. We cannot predict whether investors will find our company and our common shares less attractive because we are governed by foreign laws.

 

Risks Related to the Ownership of Our Common Shares

 

New laws, regulations, and standards relating to corporate governance and public disclosure may create uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming.

These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, may evolve over time as new guidance is provided by the courts and other bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.

 

As a public company subject to these rules and regulations, we may find it more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our Board of Directors, particularly to serve on its audit committee and compensation committee, and qualified executive officers.

3324

 

The market price of our common shares and Series A Warrants may be volatile, and you may not be able to resell your common shares and Series A Warrants at or above the initial public offeringacquisition price.

The market price for our common shares and Series A Warrants may be volatile and subject to wide fluctuations in response to factors including the following:

 

 actual or anticipated fluctuations in our quarterly or annual operating results;
   
 changes in financial or operational estimates or projections;
   
 conditions in markets generally;
   
 changes in the economic performance or market valuations of companies similar to ours;
   
 general economic or political conditions in the United States or elsewhere;
   
 any delay in development of our products or services;
   
 our failure to comply with regulatory requirements;
   
 our inability to commercially launch products and services and market and generate sales of our products and services,
   
 developments or disputes concerning our intellectual property rights;
   
 our or our competitors’ technological innovations;
   
 general and industry-specific economic conditions that may affect our expenditures;
   
 changes in market valuations of similar companies;
   
 announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments, new technologies, or patents;
   
 future sales of our common shares or other securities, including shares issuable upon the exercise of outstanding warrants or convertible securities or otherwise issued pursuant to certain contractual rights;
   
 period-to-period fluctuations in our financial results; and
   
 low or high trading volume of our common shares due to many factors, including the terms of our financing arrangements.

 

In addition, if we fail to reach an important research, development or commercialization milestone or result by a publicly expected deadline, even if by only a small margin, there could be significant impact on the market price of our common shares. Additionally, as we approach the announcement of anticipated significant information and as we announce such information, we expect the price of our common shares to be particularly volatile and negative results would have a substantial negative impact on the price of our common shares and Series A Warrants.

 

In addition, in recent years, the stock market in general has experienced extreme price and volume fluctuations. This volatility has had a significant effect on the market price of securities issued by many companies, including for reasons unrelated to their operating performance. These broad market fluctuations may adversely affect our stock price, notwithstanding our operating results. The market price of our common shares and Series A Warrants will fluctuate and there can be no assurances about the levels of the market prices for our common shares and Series A Warrants.

 

In some cases, following periods of volatility in the market price of a company’s securities, shareholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our business operations and reputation.

3425

 

As an “emerging growth company” under applicable law, we will be subject to lessened disclosure requirements, which could leave our shareholders without information or rights available to shareholders of more mature companies.

For as long as we remain an “emerging growth company” as defined in the JOBS Act, we have elected to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to:

 

 not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;
   
 being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;
   
 reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and
   
 taking advantage of an extension of time to comply with new or revised financial accounting standard; and
   
 exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

We expect to take advantage of these reporting exemptions until we are no longer an “emerging growth company.” Because of these lessened regulatory requirements, our shareholders would be left without information or rights available to shareholders of more mature companies. We cannot predict whether investors will find our common shares less attractive if we rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our stock price may be more volatile.

 

We are also a “smaller reporting company” as defined in Rule 12b-2 of the Exchange Act and have elected to follow certain scaled disclosure requirements available to smaller reporting companies.

 

Because we have elected to use the extended transition period for complying with new or revised accounting standards for an “emerging growth company” our financial statements may not be comparable to companies that comply with public company effective dates.

We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates and may contain less or more modified disclosure than those public companies. Because our financial statements may not be comparable to companies that comply with public company effective dates, investors may have difficulty evaluating or comparing our business, performance or prospects in comparison to other public companies, which may have a negative impact on the value and liquidity of our common shares.

 

FINRA sales practice requirements may also limit your ability to buy and sell our common shares, which could depress the price of our shares.

Financial Industry Regulatory Authority, Inc. (FINRA) rules require broker-dealers to have reasonable grounds for believing that an investment is suitable for a customer before recommending that investment to the customer. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status and investment objectives, among other things. Under interpretations of these rules, FINRA believes that there is a high probability such speculative low-priced securities will not be suitable for at least some customers. Thus, FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common shares, which may limit your ability to buy and sell our shares, have an adverse effect on the market for our shares, and thereby depress our share price.

 

3526

 

If research analysts do not publish research about our business or if they issue unfavorable commentary or downgrade our common shares or Series A Warrants, our securities’ price and trading volume could decline.

The trading market for our securities may depend in part on the research and reports that research analysts publish about us and our business. If we do not maintain adequate research coverage, or if any of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, the price of our common shares and Series A Warrants could decline. If one or more of our research analysts ceases to cover our business or fails to publish reports on us regularly, demand for our securities could decrease, which could cause the price of our common shares and Series A Warrants or trading volume to decline.

 

We may issue additional equity securities, or engage in other transactions that could dilute our book value or relative rights of our common shares, which may adversely affect the market price of our common shares and Series A Warrants.

Our Board of Directors may determine from time to time that it needs to raise additional capital by issuing additional shares of our common shares or other securities. Except as otherwise described in this filing, we will not be restricted from issuing additional common shares, including securities that are convertible into or exchangeable for, or that represent the right to receive shares of our common shares. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future offerings, or the prices at which such offerings may be affected. Additional equity offerings may dilute the holdings of existing shareholders or reduce the market price of our common shares and Series A Warrants, or all of them. Holders of our securities are not entitled to pre-emptive rights or other protections against dilution. New investors also may have rights, preferences and privileges that are senior to, and that adversely affect, then-current holders of our securities. Additionally, if we raise additional capital by making offerings of debt or preference shares, upon our liquidation, holders of our debt securities and preference shares, and lenders with respect to other borrowings, may receive distributions of its available assets before the holders of our common shares.

 

An investment in our Series A Warrants is speculative in nature and could result in a loss of your investment therein.

The Series A Warrants offered in this offering do not confer any rights of common share ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire shares of our common shares at a fixed price for a limited period of time. Specifically, commencing on the date of issuance, holders of the Series A Warrants may exercise their right to acquire the common shares and pay an exercise price of $6.00 per share, (120% of the public offering price of our common shares and Series A Warrants in this offering), prior to three years from the date of issuance, after which date any unexercised Series A Warrants will expire and have no further value. Moreover, following this offering, the market value of the Series A Warrants is uncertain and there can be no assurance that the market value of the Series A Warrants will equal or exceed their public offeringinitial price. There can be no assurance that the market price of the common shares will ever equal or exceed the exercise price of the Series A Warrants, and consequently, whether it will ever be profitable for holders of the Series A Warrants to exercise the Series A Warrants.

 

Our Series A Warrants and contain a provision which only permits securities claims to be brought in federal court.

Section 11 of our Series A Warrants states in relevant part: “The Company hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in The City of New York, Borough of Manhattan (except for claims brought under the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, which must be brought in federal court)”. Therefore any claims with respect to our Series A Warrants brought under the Securities Act of 1933 or the Securities Exchange Act must be brought in federal court while all other claims may be brought in federal or state court. Proceedings in federal court may be more expensive than in state court due to more comprehensive rules on how discovery and motion and trial practice are handled. This provision may have a dampening effect on claims brought under these securities laws or limit the ability of the investor to bring a claim in the jurisdiction it deems more favorable. This provision is likely enforceable as requirements regarding bringing securities claims have been met, but it may have the overall effect of discouraging litigation due to the circumstances described herein.

3627

 

We do not currently intend to pay dividends on our common shares in the foreseeable future, and consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common shares.

We have never declared or paid cash dividends on our common shares and do not anticipate paying any cash dividends to holders of our common shares in the foreseeable future. Consequently, investors must rely on sales of their common shares after price appreciation, which may never occur, as the only way to realize any future gains on their investments. There is no guarantee that our common shares will appreciate in value or even maintain the price at which our shareholders have purchased their shares.

 

Item 1B. Unresolved Staff Comments

None.

 

Item 2. Properties

The Company currently leases office space at 2233 Colombia Street, Suite 300, Vancouver, B.C., V5Y 0M6 as its principal office. The Company leases a second office space at Weena 505, Rotterdam, Netherlands, 3013AL. The Company believes the offices are in good condition and satisfy its current operational requirements.

 

Item 3. Legal Proceedings

We are subject to the legal proceeding and claims described in detail in “Note 16.17. Commitments and Contingencies” to the audited financial statements included in this Annual Report on Form 10-K. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Annual Report on Form 10-K, we do not believe the outcome of such legal proceeding and claims, if determined adversely to us, would be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

Item 4. Mine Safety Disclosures

Not applicable.

3728

 

 

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market information

 

Our common stock is currently quoted on Nasdaq Capital Market under the symbol “AGRI”, and warrants under the symbol “AGRIW”. Trading in our common stock has historically lacked consistent volume, and the market price has been volatile.

 

On March 29, 2022,13, 2023, the closing price for our common stock as reported on the Nasdaq Capital Market was $3.60$0.87 per share.

Securities outstanding and holders of record

 

On March 29, 2022,13, 2023, there were approximately 305 shareholders of record for our common stock and 15,176,698 18,156,154 shares of our common stock issued and outstanding.

 

Dividend Policy

We have never paid any cash dividends on our common shares. However, we have paid common share dividends on our preferred stock. Our preferred stock was retired and there were no preferred shares outstanding after the IPO. We anticipate that we will retain funds and future earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends on our common shares in the foreseeable future following this offering. Any future determination to pay cash dividends on our common shares will be at the discretion of our Board of Directors and will depend on our financial condition, results of operations, capital requirements and other factors that our Board of Directors deems relevant. In addition, the terms of any future debt or credit financings may preclude us from paying dividends.

 

Information respecting equity compensation plans

 

The Company adopted a stock option plan originally on December 12, 2018 (the “Option Plan”), as amended, under which the compensation committee of the Board (the “Committee”“Compensation Committee”) may from time to time in its discretion, recommend changes to the Option Plan to grant to directors, officers, employees and consultants of the Company non-transferable options to purchase common shares (“Options”). The Board of Directors review recommendations and approve changes. As of the date of this filling, the Company has 717,0191,382,629 Options outstanding. The Option Plan was approved by the shareholders of the Company on June 10, 2019.

 

The following table provides information with respect to options outstanding under our Plan:Plan as at December 31, 2022:

 

Plan category Number of securities to be issued upon exercise of outstanding options*    

Weighted-

average exercise price of

outstanding options*

  Number of securities remaining available for future issuance   
                   
Equity compensation plans approved by security holders  717,019  $5.84   800,651 
Equity compensation plans not approved by security holders   -   -   - 
Total  717,019  $5.84   800,651 

* reflects the 1:4.75 reverse stock split effected on November 29, 2020.

Plan category Number of securities to be issued upon exercise of outstanding options    

Weighted-

average exercise price of

outstanding options

  Number of securities remaining available for future issuance 
              
Equity compensation plans approved by security holders  1,382,629  $3.30   431,986 
Equity compensation plans not approved by security holders   -   -   - 
Total  1,382,629  $3.30   431,986 

 

Recent Sales of Unregistered Securities

 

On March 29, 2021,The Company had the Company issued 30,000 common shares with a fair valuefollowing sales of $179,700 against consulting services from a third party.unregistered securities during the year ended December 31, 2022:

  # of shares  Amount 
Common shares issued for bonuses and compensation  266,765  $520,230 
Common shares issued for conversion of convertible debt  67,568   131,532 
Common shares issued to consultants  284,767   853,457 
Total common shares issued  619,100  $1,505,219 

 

On May 10, 2021, the Company declared, and on May 11, 2021 issued, 86,739 common shares as stock dividend to holders of Series A Preferred shares issued on May 2, 2019.

On May 10, 2021, the Company declared, and on May 11, 2021 issued, 48,791 common shares as stock dividend to holders of Series A Preferred shares issued on May 10, 2019.

On May 27, 2021, the Company issued to consultants a total of 7,237 common shares.

3829

 

 

On May 27, 2021,The Company had the Company issued 820,029 common shares as a resultfollowing sales of 1,113,701 stock options exercised on a cashless basis at various exercise prices.unregistered securities from January 1, 2023 to March 13, 2023:

 

On May 28, 2021, the Company’s officers opted to receive a total of 98,356 common shares as bonus compensation for services rendered and accrued for in 2019 and 2020.

On June 24, 2021, the Company issued to a consultant working with the senior secured debentures holders, a total of 10,000 common shares on their behalf, for the term extension of the Bridge Loan (see Note 6).

On July 13, 2021, the Company declared and issued, 53,474 common shares as final stock dividend to the holders of Series A Preferred shares.

On July 13, 2021, the Company issued to consultants a total of 15,000 common shares.

On July 15, 2021, the Company issued 39,800 common shares as a result of exercise of 39,800 Series A warrants on cash basis at an exercise price of $6 per warrant.

On July 28, 2021, 93,938 common stock purchase warrants were issued to the purchaser of the senior secured debentures, with a term of three years and a strike price per share of $3.99.

On September 01, 2021, the Company issued to Directors 19,992 common shares as settlement of accrued directors’ fee.

On October 1, 2021, the company issued 36,379 common share as part of compensation to Company’s officers and executives.

On October 1, 2021, the Company issued to a consultant 3,188 common shares against services.

On October 27, 2021, the Company issued 36,275 common shares as a result of cashless exercise of 93,938 common stock purchase warrants related to the senior secured debentures.

On November 27, 2021, the Company issued 7,018 common shares on as a result of exercise of 7,018 stock options at an exercise price of $1.30 (CAD $1.66).

On December 31, 2021, the Company issued 35,979 common share as part of compensation to Company’s officers.

During the year ended December 31, 2020, we issued an aggregate of 365,112 shares of common stock pursuant to the exercise of unregistered warrants to acquire common stock, pursuant to which exercise we received an aggregate of $666,878. The issuance of the shares was exempt from registration by virtue of Section 4(a)(2) of the Securities Act of 1933, as amended.

  # of shares  Amount 
Common shares issued for conversion of vested prefunded warrants  1,637,049  $2,959,108 
Common shares issued for conversion of convertible debt  71,807   1,038,073 
Common shares issued to consultants  12,500   26,000 
Total common shares issued  2,360,356  $4,023,181 

 

Purchases of Equity Securities by the Issuer or Affiliated Purchasers

There were no repurchases of shares of common stock made during the year ended December 31, 2021.2022.

 

Item 6. Selected Financial Data

As a registrant that qualifies as a smaller reporting company, AgriFORCEAgriFORCE™ is not required to provide the information required by this Item.

39

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Prospective investors should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements.” You should review the “Risk Factors” section of this Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. All share and per share numbers have been retroactively adjusted to reflect the 1-for-4.75 reverse stock split effected on November 29, 2020.

Company History and Our Business

 

AgriFORCE Growing Systems Ltd. was incorporated as a private company by Articles of Incorporation issued pursuant to the provisions of the British Columbia Business Corporations Act on December 22, 2017. The Company’s registered and records office address is at 300 – 2233 Columbia Street, Vancouver, British Columbia, Canada, V5Y 0M6. On February 13, 2018, the Company changed its name from 1146470 B.C. Ltd to Canivate Growing Systems Ltd. On November 22, 2019, the Company changed its name from Canivate Growing Systems Ltd. to AgriFORCE Growing Systems Ltd.

The Company is an innovative agriculture-focused technology company that delivers reliable, financially robust solutions for high value crops through our proprietary facility design and automation intellectual property to businesses and enterprises globally. The Company intends to operate in the plant based pharmaceutical, nutraceutical, and other high value crop markets using its unique proprietary facility design and hydroponics based automated growing system that enable cultivators to effectively grow crops in a controlled environment. The Company calls its facility design and automated growing system the “AgriFORCE grow house”. The Company has designed its AgriFORCE grow house to produce in virtually any environmental condition and to optimize crop yields to as near their full genetic potential as possible whilst substantially eliminating the need for the use of pesticides and/or irradiation.

Status as an Emerging Growth Company

On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for private companies.

We are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, as an “emerging growth company,” we intend to rely on certain of these exemptions from, without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board (PCAOB) regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an “emerging growth company” until the earliest of (a) the last day of our fiscal year following the fifth anniversary of the closing of this offering, (b) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (c) the last day of our fiscal year in which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, or Exchange Act (which would occur if the market value of our equity securities that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter), or (d) the date on which we have issued more than $1 billion in nonconvertible debt during the preceding three-year period.

4030

 

FOR THE YEARS ENDED DECEMBER 31, 20212022 AND 20202021

 

Revenues

 

The Company has not generated any revenue since inception.

 

Operating Expenses

 

Operating expenses primarily consist of wages and salaries, professional fees, consulting, office and wages, share-based compensation,administration, investor and public relations, research and development, consulting, professional fees, and office and administration.share-based compensation. Operating expenses increased in the year ended December 31, 20212022 by $6,727,450 as compared to December 31, 2020 by $3,583,447 or 107%,2021 primarily due to increase in wages and salaries by $694,624, increase in investor relations by $627,223, increase in consulting expenses by $647,392, increase in office and administrative expense of $590,322, increase in professional fees by $436,988 and increase in research and development expenses by $350,423 as the Company entered into growth phase post IPO and increased its staff and operations. This was partially offset by declines in shareholder and regulatory expenses of $194,783. We expect operating expenses to increase in the future as we hire additional staff to support anticipated growth in the business and due to incremental costs to comply with the requirements of being a publicly listed company.following:

 

Wages and salaries increased by $2,156,838 due to increased headcount for the Company’s expansion of operations including UN(THINK)™.
Professional fees and consulting increased by $1,786,876 and $1,473,495, respectively due to increased legal and financial consulting services fees incurred for significant M&A activity.
Office and administrative increased by $547,604 due to increase in operational costs from the Company’s operational growth, increased headcount, and public company insurance and administration costs.
Investor and public relations expense increased by $159,087 due to increased Company campaigns during 2022 to increase Company awareness and provide information to the public.
Sales and marketing increased by $387,130 to support the ramp up of UN(THINK)™. Costs include brand development, marketing campaigns, and other miscellaneous marketing costs.
Share based compensation expense decreased by $375,426 due to previous issued options becoming fully vested during the 2022, decreasing the share based compensation recognized for graded vesting as well as lower market prices for 2022 option issuances.
Travel and entertainment increased by $211,240 due to increase in international travel for expanded Company operations and M&A activity.
Lease expense increased by $150,647 due to full year of Vancouver office lease for 2022. Vancouver office lease was entered into July 2021.
Shareholder and regulatory expense increased by $77,988 due to increased costs for public company regulatory and shareholder expenses for the full 2022 year. The Company completed their listing on July 12, 2021, as such 2021 had increased expense for 6 months of 2021.

Other expenditures amount to an additional $151,971 between 2021 and 2022.

Research and Development

 

During the year ended December 31, 2021,2022, the Company spent $474,338$615,693 as compared to $123,915$474,338 for the year ended December 31, 20202021 in research and development costs in relation to the development of a biosphere facilitylicense agreement with Radical, the testing, nutrient, and micro analysis for UN(THINK)™ food product development, in relation toas well as costs of design and construction for the IP asset purchase from Manna Nutritional Group, LLC (see Note 7 to the Financial Statements).Coachella land and its future structure. The following represents the breakdown of research and development activities:

 

  December 31, 2021  December 31, 2020 
Architectural fees $-  $28,397 
Engineering consultants  -   16,962 
Design and construction  177,407   4,406 
Product development  296,931   74,150 
  $474,338  $123,915 

  December 31, 2022  December 31, 2021 
License agreement $256,703  $- 
Product development  179,563   296,931 
Design and construction  179,427   177,407 
  $615,693  $474,338 

The increase in research and development expenses was due to product development costs for UN(THINK)™ food products.

Other (Income) / Expenses

 

Other Incomeincome for the year ended December 31, 2021 mainly includes change in fair value of warrant liability amounting to $1,191,383 and foreign exchange gains of $162,976. These were partially offset by other expenses related to accretion of interest amounting to $483,529 and loss on extension of the term related2022 increased due to the senior secured debentures issuedfollowing:

Change in fair value of derivative liabilities showed a larger gain by $2,528,486 due to decreased derivative liabilities fair values.
Issuance cost related to warrants decreased by the Company on March 24, 2021 amounting to $58,952, issue costs of public offer related to Series A Warrants amounting to $374,465 due to no warrant issuance costs incurred during 2022.
Foreign exchange gain increased by $127,103 due to an increase in USD to CAD foreign exchange rates compared to 2021.
Gain on debt conversion of $93,973 (nil – 2021) from the conversion of $150,000 of convertible debentures into the Company’s common shares.
Other income increased by $75,823 from interest earned on cash deposited into savings accounts during the year.
Offset by an increase of accretion interest on debentures of $2,913,049 from the issuance of $14,025,000 in convertible debentures during the year.

31

Critical Accounting Policies and write-off of land deposit of $151,711. Other income for year ended December 31, 2020 mainly included Scientific Research and Experimental Development (“SR&ED”) tax incentive income of $106,195 representing amounts received from the Canada Revenue Agency.Estimates

 

Net Loss

The Company recorded a net loss of $6,643,116 for the year ended December 31, 2021 as compared to a net loss of $3,221,526 for the year ended December 31, 2020. The increase in net loss is due to the total increase in operating expenses and other expenses outlined above.

Liquidity and Capital Resources

The Company’s primary need for liquidity is to fund working capital requirements, capital expenditures, and for general corporate purposes. The Company’s ability to fund operations and make planned capital expenditures and debt service obligations depends on future operating performance and cash flows, which are subject to prevailing economic conditions, financial markets, business and other factors. We have recorded a net loss of $6,643,116 for the year ended December 31, 2021 compared to $3,221,526 for the prior year; and recorded an accumulated deficit of $19,900,992 as of December 31, 2021. Net cash used in operating activities for the year ended December 31, 2021 was $5,136,947 compared to $1,851,711 for year ended December 31, 2020.

We had $7,775,290 in cash as at December 31, 2021 as compared to $653,410 as at December 31, 2020.

41

Our future capital requirements will depend on many factors, including:

the cost and timing of our regulatory activities, especially the process to obtain regulatory approval for our intellectual properties in the U.S. and in foreign countries
the costs of R&D activities we undertake to further develop our technology
the costs of constructing our grow houses, including any impact of complications, delays, and other unknown events
the costs of commercialization activities, including sales, marketing and production
the level of working capital required to support our growth
our need for additional personnel, information technology or other operating infrastructure to support our growth and operations as a public company

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company is at the stage of development of its first facility and other IP. As such it is likely that additional financing will be needed by the Company to fund its operations and to develop and commercialize its technology. These factors raise substantial doubt about the Company’s ability to continue as a going concern.

For the next twelve months from issuance of these financial statements, the Company will seek to obtain additional capital through the sale of debt or equity financings or other arrangements to fund operations; however, there can be no assurance that the Company will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding common shares. Issued debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to shareholders. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued. Due to the uncertainty in the Company’s ability to raise capital, management believes that there is substantial doubt in the Company’s ability to continue as a going concern for twelve months from the issuance of these financial statements.

Cash Flows

The net cash used by operating activities for the year ended December 31, 2021 is attributable to a net loss of $6,643,116 due to operating costs associated with wages, investor relations, consulting expenses, professional fees, research and development, and general administrative expenses. The net loss was adjusted primarily by non-cash expenses related to shared based compensation of $796,141, shares issued for consulting services amounting to $321,121, accretion of interest on senior secured debentures amounting to $483,529 and change in fair value of warrants amounting to $1,191,383. For the year ended December 31, 2020 net cash used by operating activities was attributable to net loss of $3,221,526 owing to wages, consulting expenses, professional fees, research and development expenses and general administrative expenses. The net loss was adjusted primarily by non-cash expenses of shared based compensation of $571,210 and shares issued for consulting services amounting to $438,076.

During the year ended December 31, 2021, the net cash used in investing activities mainly includes payments for acquisition of IP assets amounting to $225,000 and payments for construction in progress of $744,191. Comparatively, investing activity for the year ended December 31, 2020 mainly included a $170,000 deposit for purchase of land.

Cash provided by financing activities for the year ended December 31, 2021 mainly represents cash proceeds from the IPO of $13,360,616, net of underwriting discount and issue costs, proceeds from issuance of senior secured debentures, net of transaction costs, of $531,000, proceeds from exercise of warrants of $238,800, as well as proceeds from long-term loan of $15,932, which was offset by repayment of senior secured debentures of $750,000. The net cash provided by financing activities for the year ended December 31, 2020 represents proceeds from exercise of warrants of $666,878 and proceeds from the Canada Emergency Business Account Program of $31,417 (CAD 40,000), which was partially off-set by payments of IPO costs amounting to $93,495.

Recent Financings

On July 12, 2021, the Company completed its IPO whereby it sold a total of 3,127,998 units, each consisting of one common share and one Series A warrant to purchase one common share, at a public offering price of $5.00 for gross proceeds of $15,639,990. The Company received net proceeds from the IPO of $14,388,791, after deducting underwriting discounts and commissions of 1,251,199.

42

On March 24, 2021, the Company entered into a securities purchase agreement with certain accredited investors for the purchase of $750,000 in principal amount ($600,000 subscription amount) of senior secured debentures originally due June 24, 2021 (the “Bridge Loan”). On June 24, 2021, the due date was extended to July 12, 2021. The imputed interest rate is encompassed within the original issue discount of the debentures and no additional cash interest shall be due. The debentures were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, to certain purchasers who are accredited investors within the meaning of Rule 501 under the Securities Act of 1933, as amended. Each debenture holder received a warrant to purchase shares of common stock in an amount equal to 50% of the principal amount divided by 80% of the initial public offering price of the Company’s common stock. The warrants were exercisable at $3.99. Transaction costs of $69,000 have been incurred in connection with the Bridge Loan. The senior secured debenture was repaid in full on July 13, 2021 by the Company. On October 27, 2021, the Company issued 36,275 common shares as a result of cashless exercise of 93,938 common stock purchase warrants related to the senior secured debentures.

Off Balance Sheet Arrangements

None.

Significant Accounting Policies

Cash

The Company’s cash consists of cash maintained in checking and interest-bearing accounts. The Company accounts for financial instruments with original maturities of three months or less at the date of purchase as cash equivalents. The Company held no cash equivalents as of December 31, 2021 and 2020.

Property and Equipment

Property and equipment are initially recognized at acquisition cost or manufacturing cost, including any costs directly attributable to bringing the assets to the location and condition necessary for them to be capable of operating in the manner intended by the Company’s management. Property, plant and equipment are subsequently measured at cost less accumulated depreciation and impairment losses.

Depreciation is recognized on a straight-line basis to write down the cost less estimated residual value of computer equipment and furniture and fixtures. The following useful lives are applied:

Computer equipment3 years
Furniture and fixtures7 years

Gains or losses arising on the disposal of property, plant and equipment are determined as the difference between the disposal proceeds and the carrying amount of the assets and are recognized in profit or loss within other income or other expenses.

Construction in progress includes construction progress payments, deposits, engineering costs, interest expense for debt financing on long-term construction projects and other costs directly related to the construction of the facilities. Expenditures are capitalized during the construction period and construction in progress is transferred to the relevant class of property and equipment when the assets are available for use, at which point the depreciation of the asset commences.

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are grouped and tested at the lowest level for which identifiable independent cash flows are available (“asset group”). An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach or cost approach. The reversal of impairment losses is prohibited.

 

43

Equity-linked instruments

Deferred IPO Costs

Deferred IPO costs represent legal, accounting and other direct costs related to the Company’s efforts to raise capital through an initial public offering of the Company’s common stock (“IPO”). There were no IPO costs incurred prior to 2020. The Company completed the IPO in July 2021 and accordingly all deferred IPO costs were reclassified to additional paid-in capital as a reduction of the IPO proceeds.

 

Revenue Recognition

The Company has not recorded any revenues since its inception. However, in the future, the Company expects to generate returns from any or all the revenue sources below from its customers:

Rental income from facilities.
Intellectual property income from the license of the facilities
Management and advisory fees from management service contracts and

On January 1, 2018, the Company early adopted ASU No. 2014-09, Revenue from Contracts with Customers and all related amendments (“ASC 606” or “the new revenue standard”). ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The new revenue standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The new revenue standard also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, and costs to obtain or fulfill contracts. The Company will apply ASC 606 prospectively to all contracts.

Loss per Common Share

The Company presents basic and diluted loss per share data for its common shares. Basic loss per common share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year. Diluted loss per common share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potentially dilutive share equivalents, such as stock options and warrants and assumes the receipt of proceeds upon exercise of the dilutive securities to determine the number of shares assumed to be purchased at the average market price during the year. Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the years ended December 31, 2021 and December 31, 2020, since the effect of the Company’s stock options and warrants are anti-dilutive.

Research and Development

Expenditure on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized as expense when incurred.

44

Foreign Currency Transactions

The financial statements of the Company and its subsidiaries whose functional currencies are the local currencies are translated into U.S. dollars for consolidation as follows: assets and liabilities at the exchange rate as of the balance sheet date, shareholders’ equity at the historical rates of exchange, and income and expense amounts at the average exchange rate for the period. Translation adjustments resulting from the translation of the subsidiaries’ accounts are included in “Accumulated other comprehensive income” as equity in the consolidated balance sheets. Transactions denominated in currencies other than the applicable functional currency are converted to the functional currency at the exchange rate on the transaction date. At period end, monetary assets and liabilities are remeasured to the reporting currency using exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are remeasured at historical exchange rates. Gains and losses resulting from foreign currency transactions are included within non-operating expenses.

Fair Value of Financial Instruments

The fair value of the Company’s accounts receivable, accounts payable and other current liabilities approximate their carrying amounts due to the relative short maturities of these items.

As part of the issuance of debentures on March 24, 2021, the Company issued warrants having strike price denominated in U.S. Dollars. This creates an obligation to issue shares for a price that is not denominated in the Company’s functional currency and renders the warrants not indexed to the Company’s stock, and therefore, must be classified as a derivative liability and measured at fair value. On the same basis, the Series A Warrants and the representative warrants issued as part of the IPO are also classified as a derivative liability and measured at fair value.

The fair value of the Company’s warrants is determined in accordance with FASB ASC 820, “Fair Value Measurement,” which establishes a fair value hierarchy that prioritizes the assumptions (inputs) to valuation techniques used to price assets or liabilities that are measured at fair value. The hierarchy, as defined below, gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The guidance for fair value measurements requires that assets and liabilities measured at fair value be classified and disclosed in one of the following categories:

 

Level 1: Defined as observable inputs, such as quoted (unadjusted) prices in active markets for identical assets or liabilities.
  
Level 2: Defined as observable inputs other than quoted prices included in Level 1. This includes quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
  
Level 3: Defined as unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.

 

AsThe Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815, Derivatives and Hedging (“ASC 815”), which provides that if three criteria are met, the Company is required to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which;

(a) the economic characteristics and risks of December 31, 2021, the Company’s warrant liabilityembedded derivative instrument are not clearly and closely related to IPO warrantsthe economic characteristics and representative’s warrant amounting to $1,418,964 (December 31, 2020 - $nil)risks of the host contract;

(b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is reportednot re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur; and

(c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.”

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.”

The debenture conversion features are categorized as a Level 1 inputs. Whereas,3 financial instrument. The Company utilized the Monte Carlo option-pricing for valuing the convertible features.

The Debenture Warrants are categorized as a Level 3 financial instrument. The Company utilized the Monte Carlo option-pricing model to value the Debenture Warrants.

The most subjective assumptions in such option pricing models include the implied volatility, expected term, risk-free rate and the probability of triggering the down-round provisions.

Share Based Compensation

The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of warrant liability relatedstock-based awards to Bridge warrants that were issuedemployees and exercised duringdirectors using the year was categorizedBlack-Scholes option-valuation model (the “Black-Scholes model”). .. This model incorporates certain assumptions for inputs including a risk-free market interest rate, expected dividend yield of the underlying common stock, expected option life, and expected volatility in the market value of the underlying common stock. The Company recognizes any forfeitures as level 3 inputs. (See Note 9 and Note 11)

they occur.

32

Income Taxes

 

Current tax expense is the expected tax payable on the taxable income for the period, using tax rates enacted at period-end.

 

Deferred tax assets, including those arising from tax loss carryforwards, requires management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted.

 

45

The Company operates in various tax jurisdictions and is subject to audit by various tax authorities.

The Company records uncertain tax positions based on a two-step process whereby (1) a determination is made as to whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold the Company recognizes the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Significant judgment is required in the identification of uncertain tax positions and in the estimation of penalties and interest on uncertain tax positions.

There were no material uncertain tax positions as of December 31, 2021 and 2020.

Share Based CompensationLiquidity and Capital Resources

 

The Company generally usesCompany’s primary need for liquidity is to fund working capital requirements, capital expenditures, and for general corporate purposes. The Company’s ability to fund operations and make planned capital expenditures and debt service obligations depends on future operating performance and cash flows, which are subject to prevailing economic conditions, financial markets, business and other factors. We have recorded a net loss of $12,873,102 for the straight-line methodyear ended December 31, 2022 compared to allocate compensation cost$6,643,116 for the year ended December 31, 2021; and recorded an accumulated deficit of $32,774,094 as of December 31, 2022 ($19,900,992 – December 31, 2021). Net cash used in operating activities for the year ended December 31, 2022 was $12,079,359 compared to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards to employees and directors using the Black-Scholes option-valuation model (the “Black-Scholes model”). The Black-Scholes model requires the input of subjective assumptions, including volatility, the expected term and the fair value of the underlying common shares on the date of grant, among other inputs. The Company recognizes any forfeitures as they occur.

Recent Accounting Pronouncements$5,136,947 for year ended December 31, 2021.

 

We had $2,269,320 in cash as at December 31, 2022 as compared to $7,775,290 as at December 31, 2021.

Our future capital requirements will depend on many factors, including:

the cost and timing of our regulatory activities, especially the process to obtain regulatory approval for our intellectual properties in the U.S. and foreign countries;
the costs of R&D activities we undertake to further develop our technology;
the costs of constructing our grow houses, including any impact of complications, delays, and other unknown events;
the costs of commercialization activities, including sales, marketing and production;
the costs of our M&A activity;
the level of working capital required to support our growth; and
our need for additional personnel, information technology or other operating infrastructure to support our growth and operations as a public company.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company is at an “emerging growth company,” as defined in Section 2(a)early stage of the Securities Act of 1933, as amended, as modifieddevelopment. As such it is likely that additional financing will be needed by the Jumpstart Our Business Start-ups Act of 2012, (the “JOBS Act”). Section 107 ofCompany to fund its operations and to develop and commercialize its technology. These factors raise substantial doubt about the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 13(a) of the Securities Exchange Act of 1934,Company’s ability to continue as amended, for complying with new or revised accounting standards applicable to public companies. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.a going concern.

 

Effective January 1, 2021,For the next twelve months from issuance of these financial statements, the Company adopted ASU 2019-12, “Income Taxes (Topic 740): Simplifyingwill seek to obtain additional capital through the Accounting for Income Taxes.” ASU 2019-12 simplifiessale of debt or equity financings or other arrangements to fund operations; however, there can be no assurance that the accounting for income taxes by removing exceptions withinCompany will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding common shares. Issued debt securities may contain covenants and limit the general principles of Topic 740 regardingCompany’s ability to pay dividends or make other distributions to shareholders. If the calculation of deferred tax liabilities, the incremental approach for intra-period tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarificationsCompany is unable to obtain such additional financing, future operations would need to be scaled back or discontinued. Due to the accounting for franchise tax (or similar tax). which is partially based on income, evaluating tax basis of goodwill recognized from a business combination, and reflecting the effect of any enacted changes in tax laws or ratesuncertainty in the annual effective tax rate computationCompany’s ability to raise capital, management believes that there is substantial doubt in the interim period that includesCompany’s ability to continue as a going concern for twelve months from the enactment date. The adoptionissuance of this new guidance did not have a material impact to these financial statements.

 

In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity” (“ASU 2020-06”). The intention of ASU 2020-06 is to address the complexities in accounting for certain financial instruments with a debt and equity component. Under ASU 2020-06, the number of accounting models for convertible notes will be reduced and entities that issue convertible debt will be required to use the if-converted method for the computation of diluted “Earnings per share” under ASC 260. ASC 2020-06 is effective for fiscal years beginning after December 15, 2021 and may be adopted through either a modified retrospective method of transition or a fully retrospective method of transition. We are currently assessing the impact this guidance will have on our financial statements.

46

In May 2021, the FASB issued ASU 2021-04 - Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. Modifications and exchanges should be treated as an exchange of the original instrument for a new instrument. The amendment requires entities to measure the effect as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged if the modification or the exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements.

For all other modifications or exchanges, the effect should be measured as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged for all other modifications or exchanges. The amendments require entities to recognize the effect on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. The amendments also require entities to recognize the effect in accordance with the guidance in Topic 718, Compensation - Stock Compensation. ASU No. 2021-04 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. ASU 2021-04 will be adopted on January 1, 2022 and will not have a material impact to these financial statements.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses.” The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and requires the modified retrospective approach. Early adoption is permitted. Based on the composition of the Company’s trade receivables and other financial assets, current market conditions, and historical credit loss activity, the Company is currently in the process of evaluating the impact of this guidance on our financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases, and has subsequently issued several supplemental and/or clarifying ASU’s (collectively, “Topic 842”), which requires a dual approach for lease accounting under which a lessee would account for leases as finance leases or operating leases. Both finance leases and operating leases may result in the lessee recognizing a right of use asset and a corresponding lease liability. For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset, and for operating leases, the lessee would recognize lease expense on a straight-line basis. This ASU is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, and allows a modified retrospective approach. Early adoption is permitted. The Company is currently in the process of evaluating the impact of this guidance on our financial statements.

In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. Under ASU 2021-08, an acquirer must recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. The guidance is effective for interim and annual periods beginning after December 15, 2022, with early adoption permitted. The Company is currently in the process of evaluating the impact of this guidance on our financial statements.

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Related Party TransactionsCash Flows

 

The net cash used by operating activities for the year ended December 31, 2022 is attributable to a net loss of $12,873,102 due to operating costs which are mentioned above. The net loss was adjusted primarily by the following non-cash expenses:

As

Amortization of debt issuance costs of $3,057,825 from the issuance of $14,025,000 convertible debentures during the year.
Share issuances for consulting services and compensation as well as share-based compensation from vesting stock options of $760,162, $520,230 and $420,715, respectively due to increased business consulting and executive compensation.
This was partially offset by a non-cash change in the fair value of derivative liabilities of $3,719,869 due to decreased securities prices.

For the year ended December 31, 2021 $47,461 (December 31, 2020 - $3,223) in totalnet cash used by operating activities was attributable to net loss of $6,643,116 owing to officerswages, consulting expenses, professional fees, research and directors or to companies owneddevelopment expenses and general administrative expenses. The net loss was adjusted primarily by officers and directors of the Company for services and expenses. These amounts owing have been included in accounts payable and accrued liabilities.following non-cash expenses:

 

Shared based compensation of $796,141; and
Shares issued for consulting services amounting to $321,121.

4733

 

During the year ended December 31, 20212022, the net cash used in investing activities is related to the payment against acquisition of IP intangible asset of $500,000 and 2020, the Company incurred $66,246acquisition of equipment and $38,395, respectively,leasehold improvements amounting to our U.S. general counsel firm, D R Welch against legal services, a corporation controlled by a director of the Company. An aggregate of 13,158 shares (62,500 shares before the Reverse Split) were issued$104,986 due to David Welch as part of the payment.

Duringincreased staffing and office renovations, respectively. Comparatively, investing activity for the year ended December 31, 2021 mainly included payments for acquisition of IP assets amounting to $225,000 and December 31, 2020, the Company paid $Nil and $8,862, respectively,payments for consulting services to 0902550 BC Ltd. where Don Nicholson, former Chairmanconstruction in progress of the Board, is the principal consultant.$744,191.

 

On May 1, 2019, the Company entered into a 12 month consulting agreement with Arni Johannson, a beneficial owner of the Company, to provide Investor Relations services for a monthly fee of CAD 10,000. As of December 31, 2020, the Company owed $nil pursuant to the said agreement.

There were no other payments to related partiesCash provided by financing activities for the year ended December 31, 20202022 represents net proceeds from debentures of $12,750,000. This was partially offset by financing costs of debentures of $1,634,894 and 2019 other than expense reimbursements inrepayments of $2,805,000 as well as payment of $750,000 for the ordinary courseacquisition of business.an intangible asset. The net cash provided by financing activities for the year ended December 31, 2021 mainly represents cash proceeds from the IPO of $13,360,616, net of underwriting discount and issue costs, proceeds from issuance of senior secured debentures, net of transaction costs of $531,000, proceeds from exercise of warrants of $238,800, as well as proceeds from long-term loan of $15,932, which was offset by repayment of senior secured debentures of $750,000.

 

Financial InstrumentsRecent Financings

 

Fair ValueOn June 30, 2022, the Company entered into security purchase agreements with certain accredited investors for the purchase of $14,025,000 in principal amount of convertible debentures due December 31, 2024. On July 7, 2022, $12,750,000 of proceeds were received net of $1,275,000 in original issuance discount, less financing costs of $1,634,894.

 

Our financial instruments consist

On January 17 and 18, 2023, the investors purchased additional tranches of cash, other receivables, accounts payableconvertible debentures for the principal amount of $5,076,923 due July 17 and accrued liabilities, notes payable and warrants liability. There are no significant differences between the carrying amounts of the items reported on the statements of financial position and their estimated fair values. Our risk exposures and their impact on our financial instruments are summarized below.18, 2025.

Off Balance Sheet Arrangements

 

Liquidity RiskNone.

We are exposed to liquidity risk. Liquidity risk is the exposure of our Company to the risk of not being able to meet our financial obligations as they fall due. Our approach to managing liquidity risk is to regularly evaluate our projected cash from operations and to seek additional capital through equity and debt financings to ensure that we will have sufficient liquidity to meet liabilities when due. Our future liquidity is dependent on factors such as the ability to generate cash from operations and to raise money through debt or equity financing.

Foreign Currency Risk

Foreign exchange risk arises from the changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

As a registrant that qualifies as a smaller reporting company, AgriFORCEAgriFORCE™ is not required to provide the information required by this Item.

 

4834

Item 8. Financial Statements and Supplementary Data

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and Board of Directors of

AgriFORCE Growing Systems Ltd.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of AgriFORCE Growing Systems Ltd. (the “Company”) as of December 31, 20212022 and 2020,2021, the related consolidated statements of comprehensive loss, changes in shareholdersshareholders’ equity and cash flows for each of the two years in the period ended December 31, 2021,2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 20212022 and 2020,2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021,2022, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph – Going Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Explanatory Paragraph – Change in Accounting Principle

As discussed in Note 2 to the financial statements, the Company changed its method of accounting for leases in 2022 due to the adoption of ASU No. 2016-02, Leases (Topic 842), as amended, effective January 1, 2022, using the modified retrospective approach.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits providesprovide a reasonable basis for our opinion.

 

/s/ Marcum LLP 
Marcum llp 
  
We have served as the Company’s auditor since 2020.2020 

 

Costa Mesa, CA

March 29, 202213, 2023

 

F-1

 

AGRIFORCE GROWING SYSTEMS LTD.

CONSOLIDATED BALANCE SHEETS

(Expressed in US dollars)

 

  Note  December 31, 2021  December 31, 2020 
          
ASSETS            
             
Current            
Cash     $7,775,290  $653,410 
Other receivables      32,326   8,973 
Prepaid expenses and other current assets  6   309,040   213,038 
Total current assets      8,116,656   875,421 
             
Non-current            
Property and equipment, net  4   40,971   28,443 
Intangible asset  7   1,477,237   - 
Lease deposit, non-current      50,608   - 
Deferred IPO costs      -   390,932 
Construction in progress  5   2,079,914   2,071,093 
Total assets     $11,765,386  $3,365,889 
             
LIABILITIES AND SHAREHOLDERS’ EQUITY            
             
Current            
Accounts payable and accrued liabilities  8  $1,532,312  $1,930,988 
Contingent consideration payable  7   753,727   - 
Total current liabilities      2,286,039   1,930,988 
             
Non-current            
Deferred rent      12,954   - 
Warrants liability  11   1,418,964   - 
Long term loan  10   47,326   31,417 
Total liabilities      3,765,283   1,962,405 
Commitments and contingencies  16   -    -  
             
Shareholders’ equity            
Preferred Shares, 0 par value per share - unlimited shares authorized; nil and 2,258,826 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively*  12   -   6,717,873 
Common shares, 0 par value per share - unlimited shares authorized; 15,176,698 and 8,441,617 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively*  12   25,637,543   5,696,050 
Additional paid-in-capital  12   2,203,343   1,297,566 
Obligation to issue shares  12   93,295   94,885 
Accumulated deficit      (19,900,992)  (12,521,944)
Accumulated other comprehensive income (loss)      (33,086)  119,054 
Total shareholders’ equity      8,000,103   1,403,484 
             
Total liabilities and shareholders’ equity     $11,765,386  $3,365,889 

*reflects the 1:4.75 reverse stock split effected on November 29, 2020.

  Note  December 31, 2022  December 31, 2021 
          
ASSETS            
             
Current            
Cash     $2,269,320  $7,775,290 
Other receivable      48,941   32,326 
Prepaid expenses and other current assets  4   598,342   309,040 
Total current assets      2,916,603   8,116,656 
             
Non-current            
Property and equipment, net  5   121,672   40,971 
Intangible asset  7   13,089,377   1,477,237 
Operating lease right-of-use asset  16   1,540,748   - 
Lease deposit, non-current      -   50,608 
Construction in progress  6   2,092,533   2,079,914 
Land deposit  4   2,085,960   - 
Total assets     $21,846,893  $11,765,386 
             
LIABILITIES AND SHAREHOLDERS’ EQUITY            
             
Current            
Accounts payable and accrued liabilities  8  $1,147,739  $1,532,312 
Contingent consideration payable  7   -   753,727 
Debentures  9   3,941,916   - 
Lease liability – current  16   271,110   - 
Total current liabilities      5,360,765   2,286,039 
             
Non-current            
Deferred rent      -   12,954 
Lease liability – non-current  16   1,250,060   - 
Derivative liabilities  11   4,649,115   1,418,964 
Long term loan  10   44,300   47,326 
Total liabilities      11,304,240   3,765,283 
Commitments and contingencies  17   -   - 
             
Shareholders’ equity            
Common shares, no par value per share - unlimited shares authorized; 15,795,798 and 15,176,698 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively  12   27,142,762   25,637,543 
Additional paid-in-capital  12   16,816,695   2,203,343 
Obligation to issue shares  12   -   93,295 
Accumulated deficit      (32,774,094)  (19,900,992)
Accumulated other comprehensive loss      (642,710)  (33,086)
Total shareholders’ equity      10,542,653   8,000,103 
             
Total liabilities and shareholders’ equity     $21,846,893  $11,765,386 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-2

 

AGRIFORCE GROWING SYSTEMS LTD.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Expressed in US dollars)

For the years ended December 31, 20212022 and 20202021

 

  Note  2021  2020 
          
OPERATING EXPENSES            
Consulting     $1,088,413  $441,021 
Depreciation  4   11,797   9,059 
Office and administrative      780,135   189,813 
Investor and public relations      748,349   121,126 
Professional fees      882,146   445,158 
Rent      168,315   20,898 
Research and development  15   474,338   123,915 
Share based compensation  12   796,141   571,210 
Shareholder and regulatory      143,095   337,878 
Travel and entertainment      69,598   13,426 
Wages and salaries      1,766,491   1,071,867 
Operating loss      (6,928,818)  (3,345,371)
             
OTHER EXPENSES / (INCOME)            
Foreign exchange gain      (162,976)  (17,650)
Write-off of deposit      151,711   - 
Accretion of interest on senior secured debentures      483,529   - 
Change in fair value of warrants  11   (1,191,383)  - 
Issuance cost related to warrants      374,465   - 
Loss on extension of debt term      58,952   - 
SR&ED tax incentive income  15   -   (106,195)
             
Net loss      (6,643,116)  (3,221,526)
             
Dividend paid to preferred shareholders      735,932   948,064 
             
Net loss attributable to common shareholders      (7,379,048)  (4,169,590)
             
Other comprehensive loss            
Foreign currency translation      (152,140)  (45,856)
             
Comprehensive loss attributable to common shareholders     $(7,531,188) $(4,215,446)
             
Basic and diluted net loss attributed to common share*     $(0.66) $(0.53)
             
Weighted average number of common shares outstanding – basic and diluted*      11,164,311   7,907,233 

*reflects the 1:4.75 reverse stock split effected on November 29, 2020.

  Note  2022  2021 
          
OPERATING EXPENSES            
Wages and salaries     $3,923,329  $1,766,491 
Professional fees      2,669,022   882,146 
Consulting      2,561,908   1,088,413 
Office and administrative      1,327,739   780,135 
Investor and public relations      907,436   748,349 
Research and development  15   615,693   474,338 
Share based compensation  12   420,715   796,141 
Sales and marketing      387,130   - 
Lease expense  16   318,962   168,315 
Travel and entertainment      280,838   69,598 
Shareholder and regulatory      221,083   143,095 
Depreciation  5   22,413   11,797 
Operating loss      (13,656,268)  (6,928,818)
             
OTHER EXPENSES / (INCOME)            
Foreign exchange gain      (290,079)  (162,976)
Gain on conversion of convertible debt  9   (93,973)  - 
Change in fair value of derivative liabilities  11   (3,719,869)  (1,191,383)
Accretion of interest on debentures  9   3,396,578   483,529 
Write-off of deposit      -   151,711 
Issuance cost related to warrants      -   374,465 
Loss on extension of debt term      -   58,952 
Other income      (75,823)  - 
             
Net loss      (12,873,102)  (6,643,116)
             
Dividend paid to preferred shareholders      -   735,932 
             
Net loss attributable to common shareholders      (12,873,102)  (7,379,048)
             
Other comprehensive loss            
Foreign currency translation      (609,624)  (152,140)
             
Comprehensive loss attributable to common shareholders     $(13,482,726) $(7,531,188)
             
Basic and diluted net loss attributed to common share     $(0.71) $(0.66)
             
Weighted average number of common shares outstanding – basic and diluted      18,080,318   11,164,311 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

AGRIFORCE GROWING SYSTEMS LTD.

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(Expressed in US dollars, except share numbers)

 

  Note  # of Shares  Amount  # of Shares  Amount  Paid-in-capital  shares  Deficit  income (loss)  Equity 
     Common Shares*  Series A Preferred Shares*   Additional  Obligation to issue  Accumulated  Accumulated other comprehensive  Total Shareholders’ 
  Note  # of Shares  Amount  # of Shares  Amount  Paid-in-capital  shares  Deficit  income (loss)  Equity 
Balance, December 31, 2019        7,705,209  $3,725,454   2,258,826  $6,717,873  $726,356  $12,463  $(8,352,354) $164,910  $2,994,702 
Shares issued for cash                                        
Shares issued for cash, shares                                        
Shares issued for conversion of series A Preferred Stock                                        
Shares issued for conversion of series A Preferred Stock, shares                                        
Shares issued on exercise of warrants      365,112   666,878   -   -   -   -   -   -   666,878 
Shares issued on cashless exercise of warrants                                        
Shares issued on cashless exercise of warrants, shares                                        
Shares issued on exercise of options                                        
Shares issued on exercise of options, shares                                        
Shares issued on cashless exercise of options                                        
Shares issued on cashless exercise of options, shares                                        
Shares issued for bonus and compensation                                        
Shares issued for bonus and compensation, shares                                        
Shares issued for consulting services      100,237   355,654   -   -   -   82,422   -   -   438,076 
Share issued for settlement of accrued director’s fee                                        
Share issued for settlement of accrued director’s fee, shares                                        
Shares issued for dividend on Preferred Shares      271,059   948,064   -   -   -   -   (948,064)  -   - 
Share issue costs                                        
Share based compensation      -   -   -   -   571,210   -   -   -   571,210 
Net loss      -   -   -   -   -   -   (3,221,526)  -   (3,221,526)
Foreign currency translation      -   -   -   -   -   -   -   (45,856)  (45,856)
Balance, December 31, 2020      8,441,617  $5,696,050   2,258,826  $6,717,873  $1,297,566  $94,885  $(12,521,944) $119,054  $1,403,484 
Beginning Balance,      8,441,617  $5,696,050   2,258,826  $6,717,873  $1,297,566  $94,885  $(12,521,944) $119,054  $1,403,484 
Shares issued for cash      3,127,998   13,262,712   -   -   -   -   -   -   13,262,712 
Shares issued for conversion of series A Preferred Stock      2,258,826   6,717,873   (2,258,826)  (6,717,873)  -   -   -   -   - 
Shares issued on exercise of warrants      39,800   238,800   -   -   44,644   -   -   -   283,444 
Shares issued on cashless exercise of warrants      36,275   -   -   -   64,992   -   -   -   64,992 
Shares issued on exercise of options      7,018   9,123   -   -   -   -   -   -   9,123 
Shares issued on cashless exercise of options      820,029   -   -   -   -   -   -   -   - 
Shares issued for bonus and compensation      159,775   648,449   -   -   -   -   -   -   648,449 
Shares issued for consulting services      76,364   381,663   -   -   -   (1,590)  -   -   380,073 
Share issued for settlement of accrued director’s fee      19,992   46,783   -   -   -   -   -   -   46,783 
Shares issued for dividend on Preferred shares      189,004   735,932   -   -   -   -   (735,932)  -   - 
Share issue costs      -   (2,099,842)  -   -   -   -   -   -   (2,099,842)
Share based compensation      -   -   -   -   796,141   -   -   -   796,141 
Net loss      -   -   -   -   -   -   (6,643,116)  -   (6,643,116)
Foreign currency translation      -   -   -   -   -   -   -   (152,140)  (152,140)
Balance, December 31, 2021      15,176,698  $25,637,543   -  $-  $2,203,343  $93,295  $(19,900,992) $(33,086) $8,000,103 
Ending Balance      15,176,698  $25,637,543   -  $-  $2,203,343  $93,295  $(19,900,992) $(33,086) $8,000,103 

*reflects the 1:4.75 reverse stock split effected on November 29, 2020.
  Note  # of Shares  Amount  # of Shares  Amount  capital  shares  Deficit  income (loss)  Equity 
     Common Shares  Series A Preferred Shares  Additional Paid-in-  Obligation to issue  Accumulated  Accumulated other comprehensive  Total Shareholders’ 
  Note  # of Shares  Amount  # of Shares  Amount  capital  shares  Deficit  income (loss)  Equity 
Balance, December 31, 2020      8,441,617  $5,696,050   2,258,826  $6,717,873  $1,297,566  $94,885  $(12,521,944) $119,054  $1,403,484 
Shares issued for cash      3,127,998   13,262,712   -   -   -   -   -   -   13,262,712 
Shares issued for conversion of series A Preferred Stock      2,258,826   6,717,873   (2,258,826)  (6,717,873)  -   -   -   -   - 
Shares issued on exercise of warrants      39,800   238,800   -   -   44,644   -   -   -   283,444 
Shares issued on cashless exercise of warrants      36,275   -   -   -   64,992   -   -   -   64,992 
Shares issued on exercise of options      7,018   9,123   -   -   -   -   -   -   9,123 
Shares issued on cashless exercise of options      820,029   -   -   -   -   -   -   -   - 
Shares issued for bonus and compensation      159,775   648,449   -   -   -   -   -   -   648,449 
Shares issued for consulting services      76,364   381,663   -   -   -   (1,590)  -   -   380,073 
Share issued for settlement of accrued director’s fee      19,992   46,783   -   -   -   -   -   -   46,783 
Shares issued for dividend on Preferred shares      189,004   735,932   -   -   -   -   (735,932)  -   - 
Share issue costs      -   (2,099,842)  -   -   -   -   -   -   (2,099,842)
Share based compensation      -   -   -   -   796,141   -   -   -   796,141 
Net loss      -   -   -   -   -   -   (6,643,116)  -   (6,643,116 
Foreign currency translation      -   -   -   -   -   -   -   (152,140)  (152,140)
Balance, December 31, 2021      15,176,698  $25,637,543   -  $-  $2,203,343  $93,295  $(19,900,992) $(33,086) $8,000,103 
Balance, value      15,176,698  $25,637,543   -  $-  $2,203,343  $93,295  $(19,900,992) $(33,086) $8,000,103 
Shares issued for conversion of convertible debt   9 & 12   67,568   131,532                           131,532 
Shares issued for bonus and compensation  12   266,765   520,230                           520,230 
Shares issued for consulting services  12   284,767   853,457               (93,295)          760,162 
Share issued for settlement of accrued director’s fee                                        
Prefunded warrants issued  7                   14,192,637               14,192,637 
Share based compensation  12                   420,715               420,715 
Net loss              -    -            (12,873,102)      (12,873,102)
Foreign currency translation                                  (609,624)  (609,624)
Balance, December 31, 2022      15,795,798  $27,142,762   -   $-   $16,816,695  $-  $(32,774,094) $(642,710) $10,542,653 
Balance, value      15,795,798   27,142,762   -    -    16,816,695   -   (32,774,094)  (642,710)  10,542,653 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

AGRIFORCE GROWING SYSTEMS LTD.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Expressed in US Dollars)

For the years ended December 31, 20212022 and 20202021

 

 2021 2020  Note  2022 2021 
CASH FLOWS FROM OPERATING ACTIVITIES                  
Net loss for the year $(6,643,116) $(3,221,526)     $(12,873,102) $(6,643,116)
Adjustments to reconcile net loss to net cash used in operating activities:                  
Depreciation  11,797   9,059  5   22,413   11,797 
Share based compensation  796,141   571,210  12   420,715   796,141 
Shares issued for consulting services  321,121   438,076  12   760,162   321,121 
Shares issued for compensation  134,383   - 
Shares issued for compensation and bonuses 12   520,230   134,383 
Amortization of debt issuance costs 9   3,057,825   483,529 
Loss on extension of debt term  58,952   -     -   58,952 
Write-off of deposit  151,711   -     -   151,711 
Issuance cost related to warrants  374,465   -     -   374,465 
Change in fair value of warrants  (1,191,383)  - 
Accretion of interest on senior secured debentures  483,529   - 
Change in fair value of derivative liabilities    (3,719,869)  (1,191,383)
Gain on debt conversion    (93,973)  - 
Changes in operating assets and liabilities:                  
Decrease (increase) in other receivables  (23,353)  38,724 
Decrease (increase) in prepaid expenses and other current assets  (235,713)  54,779 
Increase in accounts payable and accrued liabilities  662,173   257,967 
Other receivables    (16,615)  (23,353)
Prepaid expenses and other current assets    (274,302)  (235,713)
Accounts payable and accrued liabilities    75,552   662,173 
Right-of-use asset    297,034   - 
Lease liabilities    (255,429)  - 
Lease deposit, non-current  (50,608)  -     -   (50,608)
Deferred rent  12,954   -     -   12,954 
Net cash used in operating activities  (5,136,947)  (1,851,711)    (12,079,359)  (5,136,947)
                  
CASH FLOWS FROM INVESTING ACTIVITIES                  
Acquisition of equipment  (25,522)  (1,574)
Acquisition of intangibles  (225,000)  - 
Acquisition of equipment and leasehold improvements    (104,986)  (25,522)
Payment against acquisition of intangibles 7   (500,000)  (225,000)
Return of deposit on purchase of land    20,000   - 
Deposit for purchase of land  (12,000)  (170,000)    -   (12,000)
Cash paid for construction in progress  (744,191)  - 
Construction in progress    (55,028)  (744,191)
Net cash used in investing activities  (1,006,713)  (171,574)    (640,014)  (1,006,713)
                  
CASH FLOWS FROM FINANCING ACTIVITIES                  
Proceeds from Initial Public Offering  15,639,990   - 
IPO costs paid including underwriting discount  (2,279,374)  (93,495)
Proceeds from debentures – net of discount    12,750,000   - 
Repayment of convertible debentures    (2,805,000)  - 
Financing costs of debentures    (1,634,894)  (69,000)
Payment for acquisition of intangible asset 

7

   

(750,000

)  

-

 
Proceeds from initial public offering    -   15,639,990 
Payment of IPO costs    -   (2,279,374)
Proceeds from exercise of warrants  238,800   666,878     -   238,800 
Proceeds from long term loan  15,932   31,417     -   15,932 
Proceeds from senior secure debentures - net  600,000   - 
Financing costs of senior secured debentures  (69,000)  - 
Repayment of Senior Secured Debentures  (750,000)  - 
Proceeds from senior secured debentures - net    -   600,000 
Repayment of senior secured debentures    -   (750,000)
Proceeds from exercise of options  9,123   -     -   9,123 
Net cash provided by financing activities  13,405,471   604,800     7,560,106   13,405,471 
                  
Effect of exchange rate changes on cash  (139,931)  (86,996)    (346,703)  (139,931)
Change in cash  7,121,880   (1,505,481)    (5,505,970)  7,121,880 
Cash, beginning of year  653,410   2,158,891     7,775,290   653,410 
Cash, end of year $7,775,290  $653,410    $2,269,320  $7,775,290 
                  
Supplemental cash flow information:                  
Cash paid during the period for interest $-  $-    

$

338,753

  $

-

 
Cash paid during the period for income taxes $-  $- 
                  
Supplemental disclosure of non-cash investing and financing transactions                  
Fair value of warrants liability $374,028  $- 
Initial fair value of warrants issued in connection with issuance of debentures   $4,080,958  $- 
Initial fair value of conversion feature of debentures    3,336,535   - 
Prefunded warrants issued related to intangible assets    12,106,677   - 
Prefunded warrants related to land deposit    2,085,960   - 
Shares issued for conversion of convertible debt    131,532   - 
Initial operating lease liability recognized under Topic 842    1,776,599   - 
Initial lease right-of-use asset recognized under Topic 842    1,837,782   - 
Initial fair value of warrants liability    -   374,028 
Preferred stock dividend paid in common shares $735,932  $948,064     -   735,932 
Unpaid amount related to construction in progress
included in accounts payable
 $-  $744,191 
Conversion of Series A preferred stock to common shares $6,717,873  $-     -   6,717,873 
Unpaid IPO costs $-  $297,437 
Unpaid amount related to intangible assets included in accrued expenses $500,000  $-     -   500,000 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the Years Ended December 31, 20212022 and 20202021

(Expressed in US Dollars, except where noted)

 

1.BUSINESS OVERVIEW

1.BUSINESS OVERVIEW

 

AgriFORCE Growing Systems Ltd. (the(“AgriFORCE™” of the “Company”) was incorporated as a private company by Articles of Incorporation issued pursuant to the provisions of the Business Corporations Act (British Columbia) on December 22, 2017. The Company’s registered and records office address is at 300 – 2233 Columbia Street, Vancouver, British Columbia, Canada, V5Y 0M6. On February 13, 2018, the Company changed its name from 1146470 B.C. Ltd to Canivate Growing Systems Ltd. On November 22, 2019 the Company changed its name from Canivate Growing Systems Ltd. to AgriFORCE Growing Systems Ltd.

The Company is an innovative agriculture-focused technology company that delivers reliable, financially robust solutions for high value crops through our proprietary facility design and automation Intellectual Property to businesses and enterprises globally. The Companyglobally through our AgriFORCE™ Solutions division (“Solutions”) and delivers nutritious food products through our AgriFORCE™ Brands division (“Brands”).

Solutions intends to operate in the plant based pharmaceutical, nutraceutical, and other high value crop markets using its unique proprietary facility design and hydroponics based automated growing system that enable cultivators to effectively grow crops in a controlled environment. The Company calls its facility design and automated growing system the “AgriFORCE grow house”.environment(“FORCEGH+™”) The Company has designed its AgriFORCE grow houseFORCEGH+™ facilities to produce in virtually any environmental condition and to optimize crop yields to as near their full genetic potential possible whilst substantially eliminating the need for the use of pesticides and/or irradiation.

Brands is focused on the development and commercialization of plant-based ingredients and products that deliver healthier and more nutritious solutions. We will market and commercialize both branded consumer product offerings and ingredient supply.

2.BASIS OF PREPARATION

2.BASIS OF PREPARATION

 

Basis of Presentation

 

The accompanying consolidated financial statements (the “financial statements”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

 

The financial statements and accompanying notes are the representations of the Company’s management, who is responsible for their integrity and objectivity. In the opinion of the Company’s management, the financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation.

 

Principal of Consolidation

 

Our consolidated financial statements include the accounts of our wholly owned subsidiaries. We consolidate variable interest entities (VIEs) when we have variable interests and are the primary beneficiary.

 

All inter-company balances and transactions have been eliminated on consolidation. These consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries:

 SCHEDULE OF CONSOLIDATED FINANCIAL STATEMENTS

Name of entity: Country of Incorporation Purpose Date of Incorporation
AgriFORCE Growing Systems Ltd. Canada Parent Company Dec 22, 2017
Canivate Growing Solutionsun(Think) Food Company Canada Ltd.** Canada Management CompanyMay 22, 2018
Daybreak Ag Systems Ltd.CanadaIntellectual Property DevelopmentFood Product Manufacturing Dec 4, 2019
AgriFORCE Holdings Inc.*United StatesIntellectual PropertyAug 31, 2018
West Pender Holdings, Inc. United States Real Estate Holding and Development Company Sep 1, 2018
AgriFORCE Investments Inc. United States Holding Company Apr 9, 2019
West Pender Management Co. United States Management Advisory Services Jul 9, 2019
AGI IP Co. United States Intellectual Property Mar 5, 2020
un(Think) Food Company United StatesFood Product ManufacturingJune 20, 2022

 

*AgriFORCE Holdings Inc. was dissolved during the year ended December 31, 2020.
**Canivate Growing Solutionsun(Think) Food Company Canada Ltd. was dissolved during the year ended December 31, 2021.changed its name from Daybreak AG Systems Ltd. on August 19, 2022.

 

F-6

 

During the year ended December 31, 2019, AgriFORCE Investments Inc., West Pender Holdings, Inc. and AgriFORCE Holdings Inc.,un(Think) Food Company, a wholly owned subsidiaries of the Company,subsidiary commenced operations in 2022 and their financial results are consolidated into the results of the Company.  West Pender Management Co., a wholly owned subsidiary commenced operations in 2021 and its results are consolidated into the results of the Company. All other subsidiaries have been created and did not have any operating activities or Financial Statements as at December 31, 2021 and 2020.

 

Functional and Reporting Currency

 

The functional currency for each entity included in these consolidated financial statements is the currency of the primary economic environment in which the entity operates. These consolidated financial statements are presented in United States dollars (“U.S. dollars”). Currency conversion to U.S. dollars is performed in accordance with ASC 830, Foreign Currency Matters.

 

Use of Estimates

 

The preparation of our financial statements in accordance with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Significant estimates reflected in these financial statements include, but are not limited to, accounting for share-based compensation, valuation of warrant liability,derivative liabilities, valuation of embedded conversion feature, going concern, impairment as well as depreciation method. Actual results could differ from these estimates and those differences could be material.

 

Going Concern

 

The Company has incurred substantial operating losses since its inception, and expects to continue to incur significant operating losses for the foreseeable future.future and may never become profitable. As reflected in the financial statements, for the year endedCompany had an accumulated deficit of approximately $32.8 million at December 31, 2021, the Company had2022, a net loss of approximately $6.612.9 million, and approximately $5.112.1 million of net cash used in operating activities andfor the Company had working capital of $5.8 million.

year ended December 31, 2022. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. The Company is at the stage of developmentanticipates incurring additional losses until such time, if ever, that it can obtain marketing approval to sell, and then generate significant sales, of its first facility and other Intellectual Property.technology that is currently in development. As such it is likely that additional financing will be needed by the Company to fund its operations and to develop and commercialize its technology. These factors raise substantial doubt about the Company’s ability to continue as a going concern. For the next twelve months from issuance of these financial statements, theThe Company will seekis seeking additional financing to obtain additional capital through the sale of debt or equity financings or other arrangements to fund operations; however, there can be no assurance that the Company will be able to raise needed capital under acceptable terms, if at all.support its growth plans. The sale of additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to our currently outstanding common shares. Issued debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to shareholders. If the Company is unable to obtain such additional financing, future operations would need to be scaled back or discontinued. Due to the uncertainty in the Company’s ability to raise capital, management believes that there is substantial doubt in the Company’s ability to continue as a going concern for twelve months from the issuance of these financial statements.

Reverse Stock Split

On November 29, 2020, the Company effectuated a one-for-4.75 reverse stock split of the Company’s common shares (the “Reverse Split”). As a result of the Reverse Split, every 4.75 shares of the Company’s old common shares were converted into one share of the Company’s new common shares. Fractional shares resulting from the reverse split were rounded to the nearest whole number. The Reverse Split automatically and proportionately adjusted, based on the 1:4.75 split ratio, all issued and outstanding shares of the Company’s common shares, as well as common shares underlying convertible preferred shares, convertible debentures, stock options and warrants outstanding at the time of the effectiveness of the Reverse Split. The exercise price on outstanding equity based-grants was proportionately increased, while the number of shares available under the Company’s equity-based plans was also proportionately reduced. Share and per share data (except par value) for the periods presented reflect the effects of the Reverse Split. References to numbers of common shares and per share data in the accompanying financial statements and notes thereto for periods ended prior to November 29, 2020 have been adjusted to reflect the Reverse Split on a retroactive basis.

 

F-7

3. SIGNIFICANT ACCOUNTING POLICIES

3.SIGNIFICANT ACCOUNTING POLICIES

 

Cash

 

The Company’s cash consists of cash maintained in checking and interest-bearing accounts. The Company accounts for financial instruments with original maturities of three months or less at the date of purchase as cash equivalents. The Company held 0no cash equivalents as of December 31, 20212022 and 2020.2021.

 

Property and Equipment

 

Property and equipment are initially recognized at acquisition cost or manufacturing cost, including any costs directly attributable to bringing the assets to the location and condition necessary for them to be capable of operating in the manner intended by the Company’s management. Property, plant and equipment are subsequently measured at cost less accumulated depreciation and impairment losses.

 

Depreciation is recognized on a straight-line basis to write down the cost less estimated residual value of computer equipment and furniture and fixtures. The following useful lives are applied:

 SCHEDULE OF ESTIMATED RESIDUAL VALUE OF COMPUTER EQUIPMENT AND FURNITURE AND FIXTURES

Computer equipment3 years
Furniture and fixtures7 years
Leasehold improvementsLower of estimated useful life or remaining lease term

 

Gains or losses arising on the disposal of property, plant and equipment are determined as the difference between the disposal proceeds and the carrying amount of the assets and are recognized in profit or loss within other income or other expenses.

 

Construction in progress includes construction progress payments, deposits, engineering costs, interest expense for debt financing on long-term construction projects and other costs directly related to the construction of the facilities. Expenditures are capitalized during the construction period and construction in progress is transferred to the relevant class of property and equipment when the assets are available for use, at which point the depreciation of the asset commences.

Definite Lived Intangible Asset

Definite lived intangible asset consists of a granted patent. Amortization is computed using the straight-line method over the estimated useful lives of the asset. Estimated useful lives of the granted patent is 20 years. Amortization expense is allocated to general and administrative expense. No amortization expense has been taken on the granted patent as it was available for use starting January 2023.

 

Impairment of Long-Lived Assets

 

The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In order to determine if assets have been impaired, assets are grouped and tested at the lowest level for which identifiable independent cash flows are available (“asset group”). An impairment loss is recognized when the sum of projected undiscounted cash flows is less than the carrying value of the asset group. The measurement of the impairment loss to be recognized is based on the difference between the fair value and the carrying value of the asset group. Fair value can be determined using a market approach, income approach or cost approach. The reversal of impairment losses is prohibited.

 

F-8

Deferred IPO CostsConvertible Instruments

The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with ASC 815, Derivatives and Hedging (“ASC 815”), which provides that if three criteria are met, the Company is required to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments. These three criteria include circumstances in which;

(a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract;

(b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur; and

(c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of Conventional Convertible Debt Instrument.”

The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. ASC 815 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.

Leases

 

Deferred IPO costs represent legal, accountingThe Company determines at the inception of a contract if the arrangement is or contains a lease. A contract is or contains a lease if the contract gives the right to control the use of an identified asset for a period of time in exchange for consideration. The Company classifies leases at the lease commencement date as operating or finance leases and other direct costs related torecords a right-of-use asset and a lease liability on the Company’s efforts to raise capital throughbalance sheet for all leases with an initial public offeringlease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded on the Company’s common stock (“IPO”). There were no IPO costs incurred prior to 2020. The Company completedbalance sheet, but payments are recognized as expense on a straight-line basis over the IPO in July 2021 and accordingly all deferred IPO costs, except for the portion allocated to warrant liability, were reclassified to additional paid-in capital as a reduction of the IPO proceeds. The portion allocated to warrant liability was expensed in the statement of comprehensive loss.lease term.

 

F-8

The Company’s contracts can contain both lease and non-lease components. The non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its leases as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities. These costs are expensed when the event determining the amount of variable consideration to be paid occurs.

Lease liabilities and their corresponding right-of-use assets are recorded based on the present value of future lease payments over the expected lease term. The Company determines the present value of future lease payments by using its estimated secured incremental borrowing rate for that lease term as the interest rate implicit in the lease is not readily determinable. The Company estimates its incremental borrowing rate for each lease based on the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments over a similar term.

F-9

 

Revenue Recognition

 

The Company has not recorded any revenues since its inception. However, in the future, the Company expects to generate returns from any or all the revenue sources below from its customers:

 

Rental income from facilities.facilities
Sales revenue from nutritious food products
Intellectual property income from the license of the facilities
Management and advisory fees from management service contracts and

On January 1, 2018, the Company early adopted ASU No. 2014-09, Revenue from Contracts with Customers and all related amendments (“ASC 606” or “the new revenue standard”). ASC 606 is a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The new revenue standard is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 provides that an entity should apply the following steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The new revenue standard also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, and costs to obtain or fulfill contracts. The Company will apply ASC 606 prospectively to all contracts.

 

Loss per Common Share

 

The Company presents basic and diluted loss per share data for its common shares. Basic loss per common share is calculated by dividing the profit or loss attributable to common shareholders of the Company by the weighted average number of common shares outstanding during the year. The number of common shares used in the loss per shares calculation includes all outstanding common shares plus all common shares issuable for which there are no conditions to issue other than time. Diluted loss per common share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potentially dilutive share equivalents, such as stock options and warrants and assumes the receipt of proceeds upon exercise of the dilutive securities to determine the number of shares assumed to be purchased at the average market price during the year. Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the years ended December 31, 2021 and December 31, 2020, since the effect of the Company’s stock options and warrants are anti-dilutive.

Research and Development

 

Expenditure on research and development activities, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, is recognized as expense when incurred.

 

Foreign Currency Transactions

 

The financial statements of the Company and its subsidiaries whose functional currencies are the local currencies are translated into U.S. dollars for consolidation as follows: assets and liabilities at the exchange rate as of the balance sheet date, shareholders’ equity at the historical rates of exchange, and income and expense amounts at the average exchange rate for the period. Translation adjustments resulting from the translation of the subsidiaries’ accounts are included in “Accumulated other comprehensive income” as equity in the consolidated balance sheets. Transactions denominated in currencies other than the applicable functional currency are converted to the functional currency at the exchange rate on the transaction date. At period end, monetary assets and liabilities are remeasured to the reporting currency using exchange rates in effect at the balance sheet date. Non-monetary assets and liabilities are remeasured at historical exchange rates. Gains and losses resulting from foreign currency transactions are included within non-operating expenses.

 

Fair value of Financial Instruments

 

The fair value of the Company’s accounts receivable, accounts payable and other current liabilities approximate their carrying amounts due to the relative short maturities of these items.

 

F-9F-10

 

As part of the issuance of debentures on March 24, 2021 and June 30, 2022, the Company issued warrants having strike price denominated in U.S. Dollars. This creates an obligation to issue shares for a price that is not denominated in the Company’s functional currency and renders the warrants not indexed to the Company’s stock, and therefore, must be classified as a derivative liability and measured at fair value. On the same basis, the Series A Warrants and the representative warrants issued as part of the IPO are also classified as a derivative liability and measured at fair value.

 

The fair value of the Company’s warrants is determined in accordance with FASB ASC 820, “Fair Value Measurement,” which establishes a fair value hierarchy that prioritizes the assumptions (inputs) to valuation techniques used to price assets or liabilities that are measured at fair value. The hierarchy, as defined below, gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The guidance for fair value measurements requires that assets and liabilities measured at fair value be classified and disclosed in one of the following categories:

 

Level 1: Defined as observable inputs, such as quoted (unadjusted) prices in active markets for identical assets or liabilities.
  
Level 2: Defined as observable inputs other than quoted prices included in Level 1. This includes quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
  
Level 3: Defined as unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.

 

As of December 31, 2021,2022, the Company’s warrant liability related to IPO warrants and representative’s warrant amounting to $1,418,964275,115 (December 31, 20202021 - $nil1,418,964) is reported at fair value and categorized as Level 1 inputs. Whereas, theThe fair value of warrant liabilityderivative liabilities related to the Debenture Warrants and Debenture Convertible Feature that were issued during the year amounted to $4,374,000 (December 31, 2021 - $nil) and were categorized as level 3 inputs. The Bridge warrantsWarrants that were issued and exercised duringin the year wasended December 31, 2021 were also categorized as level 3 inputs. (See Note 9 and Note 11)

Reclassifications

The Company has reclassified certain amounts in the 2020 consolidated financial statements to comply with the 2021 presentation.

 

Income Taxes

 

Current tax expense is the expected tax payable on the taxable income for the period, using tax rates enacted at period-end.

 

Deferred tax assets, including those arising from tax loss carryforwards, requires management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted.

 

The Company operates in various tax jurisdictions and is subject to audit by various tax authorities.

 

F-10F-11

 

The Company records uncertain tax positions based on a two-step process whereby (1) a determination is made as to whether it is more likely than not that the tax positions will be sustained based on the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold the Company recognizes the largest amount of tax benefit that is greater than 50% likely to be realized upon ultimate settlement with the related tax authority. The Company’s policy is to recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Significant judgment is required in the identification of uncertain tax positions and in the estimation of penalties and interest on uncertain tax positions.

 

There were no material uncertain tax positions as of December 31, 20212022 and 2020.2021.

 

Share Based Compensation

 

The Company generally uses the straight-line method to allocate compensation cost to reporting periods over each optionee’s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards to employees and directors using the Black-Scholes option-valuation model (the “Black-Scholes model”). The Black-Scholes.. This model requiresincorporates certain assumptions for inputs including a risk-free market interest rate, expected dividend yield of the input of subjective assumptions, includingunderlying common stock, expected option life, and expected volatility in the expected term and the fairmarket value of the underlying common shares on the date of grant, among other inputs.stock. The Company recognizes any forfeitures as they occur.

 

Recent Accounting Pronouncements

 

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act of 1933, as amended, as modified by the Jumpstart Our Business Start-ups Act of 2012, (the “JOBS Act”). Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 13(a) of the Securities Exchange Act of 1934, as amended, for complying with new or revised accounting standards applicable to public companies. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.

 

EffectiveIn February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which requires lessees to recognize leases on balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASU No. 2018-01, Land Easement Practical Expedient for Transition to Topic 842; ASU No. 2018-10, Codification Improvements to Topic 842, Leases; and ASU No. 2018-11, Targeted Improvements. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement.

The Company adopted ASC 842 as of January 1, 2021,2022 using the optional transition method to apply the standard as of the effective date. Accordingly, previously reported financial statements, including footnote disclosures, have not been recast to reflect the application of the new standard to all comparative periods presented.

The new standard also provides practical expedients for an entity’s ongoing accounting as a lessee. The Company elected to utilize the practical expedient to not separate lease and non-lease components for its existing lease. The Company has also elected not to present short-term leases on the consolidated balance sheet as these leases have a lease term of 12 months or less at lease inception and do not contain purchase options or renewal terms that the Company adopted ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.” ASU 2019-12 simplifies the accounting for income taxes by removing exceptions within the general principles of Topic 740 regarding the calculation of deferred taxis reasonably certain to exercise. All other lease assets and lease liabilities the incremental approach for intra-period tax allocation, and calculating income taxes in an interim period. In addition, the ASU adds clarifications to the accounting for franchise tax (or similar tax). which is partiallyare recognized based on income, evaluating tax basisthe present value of goodwill recognized from a business combination, and reflectinglease payments over the effectlease term at commencement date. Because the Company’s lease does not provide an implicit rate of any enacted changesreturn, it used its incremental borrowing rate based on the information available at adoption date in tax laws or rates indetermining the annual effective tax rate computation inpresent value of lease payments.

Adoption of the interim period that includes the enactment date. The adoption of this new guidance did not havelease standard on January 1, 2022 had a material impact to theseon the Company’s consolidated financial statements. The most significant impacts related to the recognition of ROU assets of $1,776,599 and lease liabilities of $1,837,782 for operating leases on the consolidated balance sheet. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The standard did not materially impact the Company’s consolidated statements of comprehensive loss and consolidated statement of cash flows.

 

In August 2020, the FASB issued ASU 2020-06 “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity” (“ASU 2020-06”). The intention of ASU 2020-06 is to address the complexities in accounting for certain financial instruments with a debt and equity component. Under ASU 2020-06, the number of accounting models for convertible notes will be reduced and entities that issue convertible debt will be required to use the if-converted method for the computation of diluted “Earnings per share” under ASC 260. ASC 2020-06 is effective for fiscal years beginning after December 15, 2021 and may be adopted through either a modified retrospective method of transition or a fully retrospective method of transition. ASC 2020-06 is effective for emerging growth companies for fiscal years beginning after December 15, 2023. We are currently assessing the impact this guidance will have on our financial statements.

 

In May 2021, the FASB issued ASU 2021-04 - Earnings Per Share (Topic 260), Debt - Modifications and Extinguishments (Subtopic 470-50), Compensation - Stock Compensation (Topic 718), and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). ASU 2021-04 clarifies and reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options that remain equity classified after modification or exchange. Modifications and exchanges should be treated as an exchange of the original instrument for a new instrument. The amendment requires entities to measure the effect as the difference between the fair value of the modified or exchanged written call option and the fair value of that written call option immediately before it is modified or exchanged if the modification or the exchange that is a part of or directly related to a modification or an exchange of an existing debt instrument or line-of-credit or revolving-debt arrangements.

F-11F-12

For all other modifications or exchanges, the effect should be measured as the excess, if any, of the fair value of the modified or exchanged written call option over the fair value of that written call option immediately before it is modified or exchanged for all other modifications or exchanges. The amendments require entities to recognize the effect on the basis of the substance of the transaction, in the same manner as if cash had been paid as consideration. The amendments also require entities to recognize the effect in accordance with the guidance in Topic 718, Compensation - Stock Compensation. ASU No. 2021-04 is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. ASU 2021-04 will be adopted on January 1, 2022 and will not have a material impact to these financial statements.

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses.” The standard, including subsequently issued amendments, requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and requires the modified retrospective approach. Early adoption is permitted. Based on the composition of the Company’s trade receivables and other financial assets, current market conditions, and historical credit loss activity, the Company is currently in the process of evaluating the impact of this guidance on our financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases, and has subsequently issued several supplemental and/or clarifying ASU’s (collectively, “Topic 842”), which requires a dual approach for lease accounting under which a lessee would account for leases as finance leases or operating leases. Both finance leases and operating leases may result in the lessee recognizing a right of use asset and a corresponding lease liability. For finance leases, the lessee would recognize interest expense and amortization of the right-of-use asset, and for operating leases, the lessee would recognize lease expense on a straight-line basis. This ASU is effective for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, and allows a modified retrospective approach. Early adoption is permitted. The Company is currently in the process of evaluating the impact of this guidance on our financial statements.

 

In October 2021, the Financial Accounting Standards Board (“FASB”) issued ASU 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. Under ASU 2021-08, an acquirer must recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. The guidance is effective for interim and annual periods beginning after December 15, 2022, with early adoption permitted. The Company is currently in the process of evaluating the impact of this guidance on our financial statements.

 

Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

4.PREPAID EXPENSES AND OTHER CURRENT ASSETS AND LAND DEPOSIT

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

  December 31, 2022  December 31, 2021 
Deposits $12,000  $32,000 
Legal retainer  24,457   33,692 
Prepaid expenses  436,496   214,445 
Deferred offering costs  100,337   - 
Others  25,052   28,903 
Prepaid expenses, other current assets $598,342  $309,040 

On August 31, 2022, the Company signed a purchase and sale agreement with Stronghold Power Systems, Inc. (“Stronghold”), to purchase approximately seventy acres of land located in the City of Coachella as well as the completion of certain permitting, zoning, and infrastructure work by Stronghold for a total purchase price of $4,300,000. The purchase price consists of:

 

4.(i)PROPERTY AND EQUIPMENT$1,500,000 in cash due on March 31, 2023.
(ii)A first stock deposit of $1,700,000 in prefunded warrants. The Company issued 695,866 prefunded warrants on September 9, 2022 to Stronghold.
(iii)A second stock deposit $1,100,000 in prefunded warrants. The Company issued 450,266 prefunded warrants on September 9, 2022 to Stronghold.

At December 31, 2022 the $2,085,960 of prefunded warrants were recorded under land deposit in relation to the Stronghold agreement. The prefunded warrant issuance may be rescinded and the warrants null and void if Stronghold does not meet all escrow performance conditions by March 31, 2023.

5.PROPERTY AND EQUIPMENT

 

Property and equipment consist of the following:

 SCHEDULE OF PROPERTY AND EQUIPMENT

  December 31, 2021  December 31, 2020 
Computer equipment $22,708 $13,473 
Furniture and fixtures  39,997   36,323 
Total property and equipment  62,705   49,796 
Less: Accumulated depreciation  (21,734)  (21,353)
Property and equipment, net $40,971  $28,443 

  December 31, 2022  December 31, 2021 
Leasehold improvements $86,979  $- 
Computer equipment  39,112   22,708 
Furniture and fixtures  37,590   39,997 
Total property and equipment  163,681   62,705 
Less: Accumulated depreciation  (42,009)  (21,734)
Property and equipment, net $121,672  $40,971 

 

Depreciation expense on property and equipment, was $11,79722,413 and $9,05911,797 for the years ended December 31, 20212022 and 2020,2021, respectively.

 

F-12F-13

 

5.CONSTRUCTION IN PROGRESS

6.CONSTRUCTION IN PROGRESS

 

The Company engaged outside contractors to begin construction work on its first facility. As of December 31, 2021,2022, $2,079,9142,092,533 (December 31, 20202021 – $2,071,0932,079,914) represents progress payments related to facility construction.

6.PREPAID EXPENSES AND DEPOSITS

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS

  December 31, 2021  December 31, 2020 
Deposits $32,000  $170,000 
Legal retainer  33,692   43,038 
Prepaid expenses  214,445   - 
Others  28,903   - 
Prepaid Expense and Other Assets  $309,040  $213,038 

 

During the year ended December 31, 2020, the Company entered into a land purchase agreement in relation to construction of a facility in Coachella, California. A deposit of $170,0007. has been paid and the balance of the purchase price is subject to financing. On April 6, 2021, the scheduled close of escrow was extended to April 30, 2021 and the purchase price was increased to $4.4 million. The Company wrote off the non-refundable portion of the deposit amounting to $150,000 as the close of escrow period has lapsed; however the Company is currently renegotiating the terms of the agreement.

Others include an office lease deposit amounting to $77,774, of which $50,608 is recorded under non-current assets. (December 31, 2020 - $Nil).

7.INTANGIBLE ASSET

 

Intangible asset represents $13,089,377 (December 31, 2021 - $1,477,237 of Intellectual Property) for intellectual property (“Manna IP”) acquired under an Assetasset purchase agreement fromwith Manna Nutritional Group, LLC (“MNG”Manna”) ondated September 10, 2021. The Manna IP encompasses patent-pending technologies to naturally process and convert grain, pulses and root vegetables, resulting in low-starch, low-sugar, high-protein, fiber-rich baking flour products, as well as a wide range of breakfast cereals, juices, natural sweeteners and baking enhancers. The termsCompany paid $1,475,000 in cash and issued 7,379,969 prefunded warrants valued at $12,106,677 (the “Purchase Price”) adjusted for foreign exchange differences of $492,300. Subject to a 9.99% stopped and SEC Rule 144 restrictions the agreement are as below:prefunded warrants will vest in tranches up until March 10, 2024. When vested the tranches of prefunded warrants will be converted into an equal number of common shares.

 

The aggregate purchase price for the Purchased Assets (the “Purchase Price”) is up to $14,475,000, and shall consist of the following, subjectSubsequent to the termsyear end, Manna satisfied all of its contractual obligations when the patent was approved by the US Patents Office and conditions of this Agreement, as follows:

(i)The number of shares of Company’s common stock (rounded up to the nearest whole number), restricted as to resale under Section 4(a)(2) of the Securities Act, equal to the quotient of (i) $5,000,000 divided by (ii) a per share price equal to the average of the volume weighted average price (“VWAP”) of the Company’s common shares for the ten trading days immediately preceding the Due Diligence Deadline (as defined below) (the “Closing Shares”). The Closing Shares, to be due on the Closing Date, which Closing Shares are restricted as to resale and issued under a private placement exempt from registration under Section 4(a) (2) of the Securities Act, are subject to release of restriction and lockup on a quarterly basis over ten quarters commencing on the Closing Date in equal amounts of shares over ten consecutive calendar quarters. The Closing Shares are due and will be issued to MNG upon the date that is 180 days from the Effective Date (September 10, 2021) (the “Due Diligence Deadline”), with such due diligence being comprised of (the following three bullet points are the key performance indicators “KPIs”):

Receipt and Tasting of Flours and Sweeteners by the Company;

Independent Lab Testing of Flours and Sweeteners by the Company to confirm fiber, protein, and starch content of such products meets the specifications provided by MNG; and

Completion by the Company of Third-Party Engineering Process Analysis, included in the scope of work outlined by Covert Engineers, dated August 11, 2021, for conceptual and preliminary plant design for a Pilot Manufacturing Facility.

F-13

(ii)$1,475,000 in cash, minus any amounts paid to MNG under (iii), payable to MNG at Closing;

(iii)$725,000 in cash payable follows: (a) $225,000 payable on the Effective Date; and (b) $500,000 payable within 120 days after the Effective Date, to reimburse MNG for, without limitation, satisfaction of all the secured debt as listed in Section 2.04 of the Disclosure Schedules to the Agreement (the “Secured Debt”).

(iv)The number of shares of Company’s common stock (rounded up to the nearest whole number) to be issued in two tranches that equals (i) $8,000,000 divided by (ii) a per share price equal to the VWAP of the Company’s common shares for the ten trading days immediately before the issuance date of those shares (“Post Closing Shares”). $5,000,000 of the Post-Closing Shares will be issued on June 30, 2022, to be held in Escrow. $3,000,000 of the Post-Closing Shares will be issued to MNG on December 31, 2022, to be held in Escrow. All distributions and dividends attributable to the Post-Closing Shares (collectively, “Dividends”) will accrue for the benefit of MNG and will be held in Escrow pending release of the Post-Closing Shares, in which case all Dividends will be released to MNG at the same time as the Post-Closing Shares are so released. Until Post-Closing Shares are released from Escrow, all voting rights thereto shall be exercised as directed by the Company’s Board of Directors. If a Patent is issued within 24 months of the Closing Date, and such Patent istitle was transferred to the Company free and clear of all encumbrances, then the Post-Closing Shares shall be released from Escrow in four equal amounts commencing on the date of issuance of the Patent and then for the three subsequent three-month anniversaries thereof.

In the event that after 24 months from the closing date, a Patent does not issue from the IP, Buyer’s obligation to issue the Post-Closing Shares and Dividends to MNG will be deemed null and void ab initio and will no longer be due and owing to MNG, and the Post-Closing Shares shall be released from escrow and returned to the Company. The Company and the Purchase Price shall be adjusted downward dollar for dollar.issued 1,637,049 shares in relation to this transaction on January 3, 2023.

 

Based on the terms above and in conformity with US GAAP, the Company accounted for purchase as an asset acquisition and has deemed the asset purchased as an in-process research and development. The Company has further deemed the asset to be of indefinite life until the completion of the associated research and development (“R&D”) activities. Once completed and commercialized, the asset will be amortized over its useful life. The recognition of the IP asset is based on the payments made to date of $225,000 and contingent consideration that is probable and reasonably estimable as of the reporting date. Subsequent changes in contingent consideration are recorded against cost. As of December 31, 2021, the company has recorded $500,000 under accrued expenses, related to reimbursement for satisfaction of secured debt of seller. Further, the company has recorded $753,727 as contingent consideration, which is considered probable and due on closing. The remaining amounts payable as described above were not deemed to be probable at December 31, 2021, and accordingly have not been accrued for.

 

Subsequent to the year end, the Company paid $500,0008. to satisfy the secured debt of seller.ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

8.ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

 December 31, 2021  December 31, 2020  December 31, 2022 December 31, 2021 
Accounts payable $414,117  $991,565  $498,188  $414,117 
Accrued expenses  981,027   905,629   365,521   981,027 
Others  137,168   33,794   284,030   137,168 
Accounts Payable and Accrued Liabilities $1,532,312  $1,930,988  $1,147,739  $1,532,312 

 

Accounts payable includes $Nil (December 31, 2020 - $744,191) payable to outside contractor in relation to facility construction. Accrued expenses include bonus payableas of December 31, 2021, included $Nil500,000 (December 31, 2020 - $487,983), withholding taxes payable $89,236 (December 31, 2020 - $Nil) and Directors fees payablerelated to the purchase of $39,309 (December 31, 2020 - $128,448). Accounts payable and accrued liabilities include a total unpaid IPO cost of $Nil (December 31, 2020 - $297,437).the Manna IP.

 

F-14

9.

9.SENIOR SECURED DEBENTURES

 

On March 24, 2021, the Company entered into a securities purchase agreement with certain accredited investors for the purchase of $750,000 in principal amount ($600,000 subscription amount) of senior secured debentures originally due June 24, 2021 (the “Bridge Loan”). The imputed interest rate is encompassed within the original issue discount of the debentures and no additional cash interest shall be due. The debentures were issued pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, to certain purchasers who are accredited investors within the meaning of Rule 501 under the Securities Act of 1933, as amended. Transaction costs of $69,000 have been recorded in connection with the Bridge Loan.

 

On June 24, 2021, the due date was extended, for which the Company paid an extension fee of 10,000 common shares with a fair value of $60,000. The senior secured debentures were repaid in full on July 13, 2021.2021.

 

As part of the bridge loan, the debenture holder was issued warrants (the “Bridge Warrants”) to purchase 93,938common shares for up to three years of the issuance date with a strike price of $3.99per share.

On June 30, 2022, the Company executed the definitive agreement with certain institutional investors (the “Investors”) for a $14,025,000 principal debentures with a 10% original issue discount (the “Debentures”) for net proceeds of $12,750,000. The interest rates on the Debentures are 5% for the first 12 months, 6% for the subsequent 12 months, and 8% per annum thereafter. Principal repayments will be made in 25 equal monthly installments and began on September 1, 2022. The Debenture may be extended by six months at the election of the Company by paying a sum equal to six months interest on the principal amount outstanding at the end of the 18th month, at the rate of 8% per annum. The Debentures are convertible into common shares at $2.22 per share. The termInvestors have the right to purchase additional tranches of $5,000,000 each, up to a total additional principal amount of $33,000,000. In addition, the Investors received 4,106,418 warrants at a strike price of $2.442, which expire on December 31, 2025 (the “Debenture Warrants”). The Debenture Warrants and Debentures each have down round provisions whereby the conversion and strike prices will be adjusted downward if the Company issues equity instruments at lower prices. The Debenture Warrants strike price and the Debenture conversion price will be adjusted down to the effective conversion price of the warrants was three years. In accordance with U.S. GAAP, the fair value of the warrants was initially recorded as a liability in the balance sheet using Black-Scholes option-pricing model. The Company remeasures the fair value of the warrants liability at each reporting date until the warrants are exercised or have expired. Changes in the fair value of the warrants liability is reported in the statements of comprehensive income / (loss) as income or expense. The fair value of the warrants liability is subject to significant fluctuation based on changes in the inputsissued equity instruments. Due to the Black-Scholes option-pricing model, including our common stock price, expected volatility, expected term,currency of these features being different from the risk-free interest rateCompany’s functional currency the Debenture Warrants and dividend yield.Debentures’ convertible features were classified as derivative liabilities and are further discussed in Note 11. The market price for our common stock may be volatile. Consequently, future fluctuationstransaction costs incurred in relation to the price of our common stock may cause significant increases or decreases in the fair value of the warrants.Debentures were $1,634,894.

 

The changes in the fair valuefollowing table summarizes our outstanding debentures as of the Bridgedates indicated:

SCHEDULE OF OUTSTANDING DEBENTURES

  Maturity  Cash Interest Rate December 31, 2022 
Principal (initial)  12/31/2024  5.00% - 8.00% $14,025,000 
Repayments and conversions        (2,955,000)
Debt issuance costs and discounts (Note 9 & 11)        (7,128,084)
Total Debentures (current)       $3,941,916 

During the year ended December 31, 2022, the Investors converted $150,000 of convertible debentures into 67,568 shares of the Company resulting in a $93,973 gain on the conversion of convertible debentures.

Subsequent to the year end, the Investors purchased an additional tranche of $5,076,923. The convertible debt and warrants were issued with an exercise price of $1.24. The issuance of the additional tranche triggered the down round provision, adjusting the exercise prices of the Debentures and the Debenture Warrants amounting to $203,4561.24 is charged to the statement of comprehensive income / (loss). The warrants were exercised on October 27, 2021 and accordingly, the warrant liability was extinguished. The fair value of the warrants prior to exercise was estimated at $

64,992, determined using the Black-Scholes option pricing model and the following assumptions; stock price $

2.16, dividend yield –

F-15

nil, expected volatility 73%, risk free rate of return 0.94%, expected term of 3 years.

10.LONG TERM LOAN

10.LONG TERM LOAN

 

During the year ended December 31, 2020, the Company entered into a loan agreement with Alterna Bank for a principal amount of $29,533 (December 31, 2021 - $31,417) (CAD$40,000) under the Canada Emergency Business Account Program (the “Program”).

 

The Program, as set out by the Government of Canada, requires that the funds from this loan shall only be used by the Company to pay non-deferrable operating expenses including, without limitation, payroll, rent, utilities, insurance, property tax and regularly scheduled debt service, and may not be used to fund any payments or expenses such as prepayment/refinancing of existing indebtedness, payments of dividends, distributions and increases in management compensation.

 

In April 2021, the Company applied for an additional loan with Alterna Bank under the Program and received $14,767 (CAD$20,000) (December 31, 2021 - $15,909 (CAD $60,000)). The expansion loan is subject to the original terms and conditions of the Program.

The loan is interest free for an initial term that ends on December 31, 2023. Repaying the loan balance on or before December 31, 2023 will result in loan forgiveness of up to a third of loan value (up to CAD $20,000). Any outstanding loan after initial term carries an interest rate of 5% per annum, payable monthly during the extended term i.e. January 31, 2024 to December 31, 20252025.

The balance at December 31, 2022 was $44,300(CAD $60,000) (December 31, 2021 - $47,326 (CAD $60,000)).

 

In April 2021,11. DERIVATIVE LIABILITIES

The Company’s derivative liabilities consist of warrants, denominated in a currency other than the Company applied for additional loan with Alterna Bank underCompany’s functional currency (the “Warrant Liabilities”) and conversion rights embedded in the Program and received $15,909 (CAD$20,000Debentures, see Note 9 (the “Debenture Convertible Features”). The expansion loan is subject to the original terms and conditions of the Program.

Warrant Liabilities

11.WARRANTS LIABILITY

 

As of December 31, 2021,2022, the warrant liability representsWarrant Liabilities represent aggregate fair value of publicly traded 3,088,198 Series A Warrants andwarrants (“IPO Warrants”), 135,999 representative’s warrants.warrants (“Rep Warrants”) and 4,106,418 Debenture Warrants.

 

The representative’s warrant isfair value of the IPO Warrants and Rep Warrants amount to $275,115 (December 31, 2021 - $1,418,964) and were categorized as a Level 1 financial instrument. The Rep Warrants are exercisable one year from the effective date of the IPO registration statement for the IPO and will expire three years after the effective date.

The exercise pricefair value of the representative’s warrant is $6 per share.Debenture Warrants amounted to $2,917,000 (June 30, 2022 - $4,080,958) and were categorized as a Level 3 financial instrument. As at December 31, 2022 the Company utilized the Monte Carlo option-pricing model (June 30, 2022 – Black-Scholes option-pricing model) to value the Debenture Warrants using the following assumptions: stock price $1.13 (June 30, 2022 - $2.31), dividend yield – nil (June 30, 2022 – nil), expected volatility 95.0% (June 30, 2022 – 58.3%), risk free rate of return 4.22% (June 30, 2022 – 3.14%), and expected term of 3 years (June 30, 2022 – expected term of 3.5 years).

The changes in the fair value of the Bridge Warrants ($203,456 – 2021) was charged to the statement of comprehensive loss. The warrants have been deemed compensation by FINRAwere exercised on October 27, 2021 and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1) of FINRA.accordingly, the warrant liability was extinguished. The underwriter (or permitted assignees under Rule 5110(e)(1)) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic dispositionfair value of the warrants orprior to exercise was estimated at $64,992, determined using the underlying securitiesBlack-Scholes option pricing model and the following assumptions; stock price $2.16, dividend yield – nil, expected volatility 73%, risk free rate of return 0.94%, expected term of 3 years.

Debenture Convertible Features

On June 30, 2022, the Company issued Debentures with an equity conversion feature, see Note 9. The fair value of the Debentures’ convertible features was $3,336,535 on the issuance date and $1,457,000 as at December 31, 2022. These conversion features are categorized as a Level 3 financial instrument. As at December 31, 2022 the Company utilized the Monte Carlo option-pricing model (June 30, 2022 – Black-Scholes option-pricing model) for a periodvaluing the convertible feature using the following assumptions: stock price $1.13 (June 30, 2022 - $2.31), dividend yield – nil (June 30, 2022 – nil), expected volatility 95.0% (June 30, 2022 – 101.0%), risk free rate of 180 days fromreturn 4.41% (June 30, 2022 – 3.14%), discount rate 13.65% (June 30, 2022 – not applicable), and expected term of 2 years (June 30, 2022 – 1 year).

Changes in the datefair value of this prospectus. The exercise priceCompany’s Level 1 and number of shares issuable upon exercise3 financial instruments for the year ended December 31, 2022 were as follows:

SCHEDULE OF CHANGES IN THE FAIR VALUE OF COMPANY'S LEVEL 3 FINANCIAL INSTRUMENTS

                 
  Level 1  Level 3  Level 3    
  IPO and Rep Warrants  Debenture Warrants  

Debenture

Convertible

Feature

  Total 
Balance at December 31, 2021 $1,418,964  $-  $-  $1,418,964 
Additions  -   4,080,958   3,336,535   7,417,493 
Conversions  -   -   (63,723)  (63,723)
Change in fair value  (1,086,562)  (966,141)  (1,667,166)  (3,719,869)
Effect of exchange rate changes  (57,287)  (197,817)  (148,646)  (403,750)
Balance at December 31, 2022 $275,115  $2,917,000  $1,457,000  $4,649,115 

Due to the expiry date of the warrants may be adjusted in certain circumstances including inand conversion feature being subsequent to December 31, 2023, the event of a stock dividend, extraordinary cash dividend or recapitalization, reorganization, merger or consolidation.liabilities have been classified as non-current.

 

F-15F-16

 

The change in fair value on the warrant liability amounting to $1,191,38312. is recorded in the statement of comprehensive loss for the year ended December 30, 2021. This includes change in fair value related to the Bridge Warrants amounting to $203,456.

SHARE CAPITAL

12.SHARE CAPITAL

 

 a)Authorized Share Capital

 

On March 1, 2019, the Company changed its share structure with a Directors’ resolution to replace Class – A voting shares with Common voting Shares, and to eliminateeliminated Class-B non-voting shares, (where nil were issued), and created a new series of Preferred shares with no par value and unlimited number of shares. Holders of Preferred shares shall be entitled to receive distribution ahead of holders of Common shares. In addition, Preferred shareholders are also entitled to a fixed premium (if specifically provided in the special rights and restrictions attached to a specific series of Preferred shares), prior to any distributions to holders of Common shares in the event of dissolution, liquidation or winding-up of the Company.

 

 b)Issued Share Capital

 

The Company had the following common share transactions during the year ended December 31, 2020:2022:

 SCHEDULE OF SHARE CAPITAL

On May 2, 2020, the Company declared and issued 86,739 common shares at $3.37 (CAD $4.75) (412,008 common shares at $0.71 (CAD $1.00) before the Reverse Split) as stock dividend to holders of Series A Preferred shares issued on May 2, 2019.
On May 10, 2020, the Company declared and issued 48,791 common shares at $3.42 (CAD $4.75) (231,758 common shares at $0.72 (CAD $1.00) before the Reverse Split) as stock dividend to holders of Series A Preferred shares issued on May 10, 2019.
On November 2, 2020, the Company declared and issued 86,739 common shares at $3.56 (CAD $4.75) (412,008 common shares at $0.75 (CAD $1.00) before the Reverse Split) as stock dividend to holders of Series A Preferred shares issued on May 2, 2019.
On November 10, 2020, the Company declared and issued 48,791 common shares at $3.66 (CAD $4.75) (231,758 common shares at $0.77 (CAD $1.00) before the Reverse Split) as stock dividend to holders of Series A Preferred shares issued on May 10, 2019.
During the year ended December 31, 2020, 365,113 (1,734,285 before the Reverse Split) warrants were exercised at a price of CAD $2.38 (CAD $0.50 before the Reverse Split).
At various times during the year ended December 31, 2020, the Company issued 100,237 common shares (476,126 before the Reverse Split) to various consultants for services rendered.

  # of shares  Amount 
Common shares issued for bonuses and compensation  266,765  $520,230 
Common shares issued for conversion of convertible debt  67,568   131,532 
Common shares issued to consultants  284,767   853,457 
Total common shares issued  619,100  $1,505,219 

 

The Company had the following common share transactions during the year ended December 31, 2021:

 

On March 29, 2021, the Company issued 30,000 common shares with a fair value of $179,700 against consulting services from a third party.
On May 10, 2021, the Company declared, and on May 11, 2021 issued, 86,739 common shares as stock dividend to holders of Series A Preferred shares issued on May 2, 2019.
On May 10, 2021, the Company declared, and on May 11, 2021 issued, 48,791 common shares as stock dividend to holders of Series A Preferred shares issued on May 10, 2019.
On May 27, 2021, the Company issued to consultants a total of 7,237 common shares.
On May 27, 2021, the Company issued 820,029 common shares as a result of 1,113,701 stock options exercised on a cashless basis at various exercise prices.

F-16

On May 28, 2021, the Company’s officers opted to receive a total of 98,356 common shares as bonus compensation for services rendered and accrued for in 2019 and 2020.
On June 24, 2021, the Company issued to a consultant working with the senior secured debentures holders, a total of 10,000 common shares on their behalf, for the term extension of the Bridge Loan (see Note 6).
On July 12, 2021, the Company completed its IPO whereby it sold a total of 3,127,998 units, each consisting of one common share and one Series A warrant to purchase one common share, at a public offering price of $5.00 for gross proceeds of $15,639,990. The Company received net proceeds from the IPO of $14,388,791, after deducting underwriting discounts and commissions of 1,251,199.
On July 12, 2021, with the closing of the IPO, 2,258,826 common shares were issued upon the conversion of all of its issued and outstanding Series A Preferred Shares.
On July 13, 2021, the Company declared and issued, 53,474 common shares as final stock dividend to the holders of Series A Preferred shares.
On July 13, 2021, the Company issued to consultants a total of 15,000 common shares.
On July 15, 2021, the Company issued 39,800 common shares as a result of exercise of 39,800 Series A warrants on cash basis at an exercise price of $6 per warrant.
On July 28, 2021, 93,938 common stock purchase warrants were issued to the purchaser of the senior secured debentures, with a term of three years and a strike price per share of $3.99.
On September 01, 2021, the Company issued to Directors 19,992 common shares as settlement of accrued directors’ fee.
On October 1, 2021, the company issued 36,379 common share as part of compensation to Company’s officers and executives.
On October 1, 2021, the Company issued to a consultant 3,188 common shares against services.
On October 27, 2021, the Company issued 36,275 common shares as a result of cashless exercise of 93,938 common stock purchase warrants related to the senior secured debentures.
On November 27, 2021, the Company issued 7,018 common shares on as a result of exercise of 7,018 stock options at an exercise price of $1.30 (CAD $1.66).
On December 31, 2021, the Company issued 35,979 common share as part of compensation to Company’s officers.

  # of shares  Amount 
Common shares issued for cash  3,127,998  $13,262,712 
Common shares issued for conversion of series A preferred stock  2,258,826   6,717,873 
Common shares issued on exercise of warrants  39,800   238,800 
Common shares issued on cashless exercise of warrants  36,275   - 
Common shares issued on exercise of options  7,018   9,123 
Common shares issued on cashless exercise of options  820,029   - 
Common shares issued for bonus and compensation  159,775   648,449 
Common shares issued for consulting services  76,364   381,663 
Common shares issued for settlement of accrued director’s fee  19,992   46,783 
Common shares issued for dividend on preferred shares  189,004   735,932 
Share issue costs  -   (2,099,842)
Total common shares issued  6,735,081  $19,941,493 

 

 c)Stock Options

 

The Company has adopted a stock option plan (the “Plan”“Option Plan”) for its directors, officers, employees and consultants to acquire common shares of the Company. The terms and conditions of the stock options are determined by the Board of Directors.

 

On May 28, 2019, at the Company’s annual general meeting, shareholders approved an amendment to the Stock Option Plan to increase the number of authorized shares subject to the stock option planOption Plan to 15% of the issued and outstanding shares of the Company (including any unconverted Series A Preferred Shares).

 

For the year ended December 31, 2021,2022, the Company recorded aggregate share-based compensation expense of $796,141420,715 (December 31, 20202021 - $571,210796,141) for all stock options on a straight-line basis over the vesting period.

 

F-17

 

As of December 31, 2022, 1,382,629 (December 31, 2021 717,019 (December 31, 2020 - 1,450,918) Stock Options were outstanding at a weighted average exercise price of $5.633.30 (CAD 7.14) [December(December 31, 20202021 - $2.01 (CAD 2.56)]5.63), of which 414,305 (December 31, 2021 – 280,938 (December 31, 2020 - 1,161,726) were exercisable.

 

The amounts recognized as share-based payments and stock options are included in share-based compensation on the Statement of Loss and Comprehensive Loss.

 

As of December 31, 2021,2022, there was $634,626538,358 (December 31, 20202021 - $275,150634,626) of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the stock option plan;granted; that cost is expected to be recognized over a period of 32 years (December 31, 202020212 years3) years).

 

The following summarizes stock option activity during the years ended December 31, 20212022 and 2020:2021:

 SCHEDULE OF STOCK OPTION ACTIVITY

  Number of Options*  Weighted Average Exercise Price*  Weighted Average Remaining Life (years) 
          
Balance at December 31, 2019  1,106,711  $1.35   4.98 
Granted  387,760  $3.73   5.46 
Forfeited  (25,132) $1.31   - 
Cancelled  (18,421) $1.31   - 
Balance at December 31, 2020  1,450,918  $2.01   4.38 
Granted  509,788  $7.00   4.47 
Exercised  (1,120,719)  3.23   - 
Forfeited  (28,947) $4.75   - 
Cancelled  (94,021) $6.70   - 
Balance at December 31, 2021  717,019  $5.84   4.48 

  Number of Options  Weighted Average Exercise Price  Weighted Average Remaining Life (years) 
          
Balance at December 31, 2020  1,450,918  $2.01   4.38 
Granted  509,788  $7.00   4.47 
Exercised  (1,120,719) $3.23   - 
Forfeited  (28,947) $4.75   - 
Cancelled  (94,021) $6.70   - 
Balance at December 31, 2021  717,019  $5.63   4.48 
Granted  747,060  $1.14   4.48 
Forfeited  (25,542) $7.00   - 
Cancelled  (55,908) $4.27   - 
Balance at December 31, 2022  1,382,629  $3.30   4.24 

 

*reflects the 1:4.75 reverse stock split effected on November 29, 2020.

The Company’s outstanding and exercisable stock options at December 31, 20212022 were:

 SCHEDULE OF OUTSTANDING AND EXERCISABLE STOCK OPTIONS

  Outstanding Options*  Exercisable Options* 
Expiry Date Number  Weighted Average Remaining Life (years)  Weighted Average Exercise Price  Weighted Average Exercise Price  Number  Weighted Average Exercise Price 
           CAD $   $       $ 
January 31, 2026  921   4.09   4.75   3.75   921   3.75 
June 30, 2026  255,594   4.50   4.75   3.75   211,993   3.75 
May 31, 2026  355,775   4.42   8.87   7.00   59,296   7.00 
July 15, 2026  55,445   4.54   8.87   7.00   4,620   7.00 
September 30, 2026  49,284   4.75   8.87   7.00   4,108   7.00 
Total Share Options  717,019   4.48   7.40   5.84   280,938   4.53 

*reflects the 1:4.75 reverse stock split effected on November 29, 2020.

  Outstanding Options  Exercisable Options 
Expiry Date Number  Weighted Average Remaining Life (years)  Weighted Average Exercise Price  Number  Weighted Average Exercise Price 
        $     $ 
June 30, 2026  210,489   3.50   3.51   210,489   3.51 
May 31, 2026  320,351   3.42   7.00   160,176   7.00 
July 15, 2026  55,445   3.54   7.00   23,100   7.00 
September 30, 2026  49,284   3.75   7.00   20,540   7.00 
November 18, 2027  747,060   4.88   1.14   -   - 
Total Share Options  1,382,629   4.24   3.30   414,305   5.23 

 

F-18

 

Stock-based compensation expense recognized is based onThe following table summarizes the Company’s assumptions used in the valuation of options expected to vest, the fair value of each employee option grantgranted during the yearsyear ended December 31, 20212022 and 2020 was estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions:December 31, 2021:

 SCHEDULE OF WEIGHTED AVERAGE ASSUMPTIONS

 December 31, 2021  December 31, 2020  December 31, 2022  December 31, 2021 
Expected volatility  80.00%  79.60%  78.05%  80.00%
Expected term (in years)  3.31   3.44   3.07   3.31 
Risk-free interest rate  0.92%  0.45%  3.35%  0.92%
Fair value of options $2.59  $1.90  $0.60  $2.59 

 

 d)Warrants

 

The Company’s outstanding warrants as of December 31, 20212022 were:

 SCHEDULE OF OUTSTANDING WARRANTS

  Number of warrants*  Weighted average exercise price*  Weighted average exercise price*  Expiry Date
       CAD   $   
               
Outstanding, December 31, 2019  3,398,996   7.70   6.05   
Exercised during quarter 4, 2020  (365,112)  2.38   1.87  December 21, 2021**
Expired during quarter 4, 2020  (63,157)  2.38   1.87  October 15, 2021**
Expired during quarter 4, 2020  (163,610)  2.38   1.87  December 21, 2021**
Expired during quarter 4, 2020  (33,684)  1.66   1.30  December 31, 2021**
Expired during quarter 4, 2020  (210,526)  2.38   1.87  January 16, 2022**
Expired during quarter 4, 2020  (16,842)  1.66   1.30  January 21, 2022**
Outstanding, December 31, 2020  2,546,065   9.50   7.46   
Granted during quarter 3, 2021  3,263,997   7.48   6.00  July 12, 2024
Granted during quarter 3, 2021  93,938   4.98   3.99  July 28, 2024
Exercised during quarter 3, 2021  (39,800)  7.48   6.00  July 12, 2024
Exercised during quarter 4, 2021  (93,938)  4.98   3.99  July 28, 2024
Outstanding, December 31, 2021  5,770,262   7.49   5.91   
  Number of warrants  Weighted average exercise price  Expiry Date
     $   
Outstanding, December 31, 2020  2,546,065   7.46   
Granted July 12, 2021  3,263,997   6.00  July 12, 2024
Granted July 28, 2021  93,938   3.99  July 28, 2024
Exercised in 2021  (133,738)  4.59  n/a
Outstanding, December 31, 2021  5,770,262   5.91   
Granted June 30, 2022  4,106,418   2.44a December 30, 2025
Outstanding, December 31, 2022  9,876,680   4.91   

*reflects the 1:4.75 reverse stock split effected on November 29, 2020.
**pursuant to the terms of the warrants, the warrants were accelerated to expire on October 10, 2020 due to

occurrence of an acceleration event. Accordingly, any unexercised warrants were terminated.

(a) Subsequent to the year end, the issuance of additional tranches of Debentures triggered the down round provision, adjusting the exercise prices of the Debenture Warrants to $1.24 (Note 9).

**e)pursuant to the terms of the warrants, the warrants were accelerated to expire on October 10, 2020 due to occurrence of an acceleration event. Accordingly, any unexercised warrants were terminated.Loss per Common Share

Diluted net loss attributable to common shareholders per share does not differ from basic net loss attributable to common shareholders per share for the years ended December 31, 2022 and December 31, 2021, since the effect of the Company’s warrants, stock options and convertible debentures are anti-dilutive.

Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):

ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

         
  

December 31, 2022

  

December 31, 2021

 
Warrants  9,876,680   5,770,262 
Options  1,382,629   717,019 
Prefunded warrants  1,146,132   - 
Convertible debentures  4,986,486   - 
Total anti-dilutive weighted average shares  17,391,927   6,487,281 

 

F-19

13.INCOME TAXES

13.INCOME TAXES

 

For the year ended December 31, 20212022 and 2020,2021, loss before income tax provision consisted of the following:

 SUMMARY OF INCOME TAX PROVISION

  December 31, 2021  December 31, 2020 
       
Domestic operations - Canada $(6,202,837) $(2,732,888)
Foreign operations - United States  (440,279)  (488,638)
Total loss before taxes $(6,643,116) $(3,221,526)

  December 31, 2022  December 31, 2021 
       
Domestic operations - Canada $(11,753,662) $(6,202,837)
Foreign operations - United States  (1,119,440)  (440,279)
Total loss before taxes $(12,873,102) $(6,643,116)

 

Income tax expense (benefit) consists of the following for the years ended December 31, 20212022 and December 31, 2020:2021:

 SCHEDULE OF COMPONENTS OF INCOME TAX

 December 31, 2021  December 31, 2020  December 31, 2022  December 31, 2021 
          
Loss before taxes $(6,643,116) $(3,221,526) $(12,873,102) $(6,643,116)
Statutory tax rate  27.00%  27.00%  27.00%  27.00%
Income taxes at the statutory rate $(1,793,641) $(869,812) $(3,475,738) $(1,793,641)
Change in fair value of warrants  

(321,674

)  - 
Other permanent differences  93,375  - 
Change in fair value of derivative liabilities  (1,032,824)  (321,674)
Non-deductible accretion interest  747,719   - 
Stock-based compensation  253,556   154,227   484,035   253,556 
Share issue costs  (112,812)  (45,854)  (108,685)  (112,812)
Others  18,499   (41,388)
Foreign currency translation  298,876   - 
Other  63,035   111,874 
Total $(1,862,697) $(720,051) $(3,023,582) $(1,862,697)
                
Change in valuation Allowance $1,862,697  $720,051 
Change in valuation allowance $3,023,582  $1,862,697 
Total income tax expense (benefit) $-  $-  $-  $- 

 

The Company is subject to Canadian federal and provincial tax for the estimated assessable profit for the years ended December 31, 20202022 and 2021 at a rate of 27%27%.

 

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not that we will not realize those tax assets through future operations. Significant components of the Company’s deferred taxes are as follows:

 SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

  December 31, 2021  December 31, 2020 
Deferred tax assets:        
Unused net operating losses carry forward - Canada and United States $4,459,457  $2,669,781 
Unused capital losses carry forward  

40,962

   - 
Share issue costs  174,377   142,318 
Property and equipment  -   - 
Total deferred tax assets $4,674,796  $2,812,099 
Deferred tax asset not recognized  -   - 
         
Net deferred tax assets  4,674,796   2,812,099 
         
Deferred tax liability:        
         
Total deferred tax liability  -   - 
         
Valuation Allowance $(4,674,796) $(2,812,099)
Net deferred tax assets (liabilities) $-  $- 

  December 31, 2022  December 31, 2021 
Deferred tax assets:        
Unused net operating losses carry forward - Canada and United States $7,572,932  $4,459,457 
Unused capital losses carry forward  

-

   40,962 
Share issue costs  130,732   

174,377

 
Other  (5,286)  - 
Total deferred tax assets  7,698,378   4,674,796 
Valuation allowance  (7,698,378)  (4,674,796)
  $-  

$

- 

 

The Company has Non-Capital Lossesnon-capital losses of $25.8 million as of December 31, 2022 and $15.7 million as of December 31, 2021, and $9.3 million as of December 31, 2020, which are due to expire between 20392038 and 20412042 and which can be used to offset future taxable income in Canada. For foreign operations in United States, aggregate net operating losses are $2.2 million as of December 31, 2022 and $0.9 million as of December 31, 2021 (2020 - $0.6 million) which can be carried forward indefinitely. The Company has Capital Lossesno capital losses of as of December 31, 2022 and $0.2million as of December 31, 2021 and $Nil as of December 31, 2020, which expires after 5 years and can be used to offset future taxable capital gains in the United States.2021. Non-Capital Losses in Canada can be carried forward after change of ownership, if the particular business which gave rise to the loss is carried on by the company for profit or with a reasonable expectation of profit. Certain accumulated net operating losses in United States are subject to an annual limitation from equity shifts, which constitute a change of ownership as defined under Internal Revenue Code (“IRC”) Section 382. These rules will limit the utilization of the losses.

 

The Company files income tax returns in Canada and the United States and is subject to examination in these jurisdictions for all years since the Company’s inception in 2017. As at December 31, 2021,2022, no tax authority audits are currently underway.

The Company currently has no uncertain tax position and is therefore not reflecting any adjustments.

 

F-20

14.RELATED PARTY TRANSACTIONS

14.RELATED PARTY TRANSACTIONS

 

Key management personnel include those persons having the authority and responsibility of planning, directing, and executing the activities of the Company. The Company has determined that its key management personnel consist of the Company’s officers and directors.

 SCHEDULE OF RELATED PARTY TRANSACTIONS

  December 31, 2021  December 31, 2020 
Accounting fees (included in professional) $3,473  $15,225 

As of December 31, 2021,2022, $47,46132,500 (December 31, 2020 -2021, $3,22347,461) in total was owing to officers and directors or to companies owned by officers and directors of the Company for services and expenses. These amounts owing have been included in accounts payable and accrued liabilities.

 

During the year ended December 31, 20212022 and 2020,2021, the Company incurred $66,24679,457 and $38,39566,246, respectively, to our U.S. general counsel firm, D RDR Welch against legal services, a corporation controlled by a director of the Company. AnNo shares were issued in the year ended December 31, 2022 (an aggregate of13,158 shares (62,500 shares before the Reverse Split) were issued to David Welch as part of the payment.

Duringduring the year ended December 31, 2021 and December 31, 2020, the Company paid $Nil and $8,862, respectively, for consulting services to 0902550 BC Ltd. where Don Nicholson, former Chairman of the Board, is the principal consultant.

On May 1, 2019, the Company entered into a 12 months consulting agreement with Arni Johannson to provide Investor Relations services for a monthly fee of CAD 10,000David Welch). As of December 31, 2020, the Company owed $nil pursuant to the said agreement.

 

There were no other payments to related parties for the year ended December 31, 20212022 and 20202021 other than expense reimbursements in the ordinary course of business.

 

15.RESEARCH AND DEVELOPMENT

15.RESEARCH AND DEVELOPMENT

 

During the year ended December 31, 2021,2022, the Company spent $615,693 as compared to $474,338 (Decemberfor the year ended December 31, 2020 - $123,915)2021 in research and development costs in relation to the development of a biosphere facilitylicense agreement with Radical Clean Solutions Ltd (“Radical”), the testing, nutrient and micro analysis for UN(THINK)™ food product development in relation toas well as costs of design and construction for the IP asset purchase from Manna Nutritional Group, LLC (see Note 7).Coachella land and its future structure architecture. The following represents the breakdown of research and development activities:

SCHEDULE OF RESEARCH AND DEVELOPMENT COSTS

  December 31, 2021  December 31, 2020 
Architectural fees $-  $28,397 
Engineering consultants  -   16,962 
Design and construction  177,407   4,406 
Product development  296,931   74,150 
 Research and development costs $474,338  $123,915 

The Company recorded Scientific Research and Experimental Development (“SR&ED”) tax incentive income of $Nil during the year ended December 31, 2021 (December 31, 2020 - $106,195). SR&ED tax incentive income is recognized when there is reasonable assurance that the income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The Company’s SR&ED tax incentive income has been recognized as other income as it is not indicative of the core operating activities or revenue producing goals of the Company.

  December 31, 2022  December 31, 2021 
License agreement $

256,703

  $- 
Product development 179,563  296,931 
Design and construction  179,427   177,407 
 Research and development costs $615,693  $474,338 

 

F-21

16.COMMITMENTS AND CONTINGENCIESLEASES

Lease commitments

The Company has entered into an operating lease for office space. At December 31, 2022, the remaining lease term is seven years and the discount rate is 7.0%. The Company has no finance leases.

The components of lease expenses were as follows:

SCHEDULE OF LEASE EXPENSES

  December 31, 2022 
Operating lease cost $295,601 
Short-term lease cost  23,361 
Total lease expenses $318,962 

The minimum future payments under the lease for our continuing operations in each of the years ending December 31 is as follows:

 SCHEDULE OF FUTURE PAYMENTS UNDER LEASE

       
2022 $283,952 
2023 $289,628  $271,110 
2024 $299,563   280,409 
2025 $316,593   296,350 
2026 $316,593   296,350 
2027  296,350 
Subsequent years $870,631   518,613 
Total $2,376,960 
Total minimum lease payments  1,959,182 
Less: imputed interest  (438,012)
Total lease liability  1,521,170 
Current portion of lease liability  (271,110)
Non-current portion of lease liability $1,250,060 

17.COMMITMENTS AND CONTINGENCIES

 

Debenture principal repayments

The following table summarizes the future principal payments related to our outstanding debt as of December 31, 2022:

SUMMARY OF FUTURE PRINCIPAL PAYMENTS OUTSTANDING

     
2023 $6,732,000 
2024  4,338,000 
Long Term Debt $11,070,000 

Contingencies

 

LitigationAs at December 31, 2022, the Company had no contingencies or litigation to disclose.

 

During the years ended December 31, 2021 and December 31, 2019, the Company had no new contingencies to disclose.

During the year ended December 31, 2018, the Company entered into a purchase agreement with certain parties representing proprietary technology. As consideration for the purchase of the technology and attendant intellectual property rights, the Company issued an aggregate of 5,263,15818. (25,000,000 before the Reverse Split) Class A common voting shares (the “Class A Shares”).

An additional 105,263 (500,000 before the Reverse Split) Class A Shares was issued for consulting services to assist with application of the proprietary technology to the Company’s business.

Subsequent to the execution of these agreements, the Company was notified as to certain issues relating to the transaction agreements that were executed and the intellectual property risks that were purportedly transferred. After several months of analysis with various professionals, the Company determined that the technology was in fact invalid and therefore without any value.

On May 15, 2019, a claim by HydroHaus Horticulture, Inc., Stuart Brazier and Christopher Gielnik was filed in BC Supreme Court. The basic allegations against AgriFORCE Growing Systems Ltd. are:

1.The Company breached the manufacturing agreement under which HydroHaus Horticulture claims it had the exclusive right to build hydro houses for the Company;
2.The Company advised HydroHaus Horticulture that it was in breach of the licensing agreement relating to its project to build a hydro house for the Nak’azdli causing HydroHaus Horticulture to spend approximately $130,000 to change the way it was to perform that contract;

3.The Company owes approximately $100,000 for expenses paid for by HydroHaus Horticulture, which has not been accrued for at this time as management does not believe the merits are valid. Should any amounts be required to be paid as a result of the claim, the Company will appropriately record at that time; and
4.The Company wrongfully rescinded its agreements with HydroHaus Horticulture.

F-22

The plaintiffs are seeking general and special damages, alternatively rescission of the agreements or specific performance of those agreements and payment for expenses incurred by HydroHaus Horticulture for the benefit of the Company. The plaintiffs are also seeking an order that the Hydrohaus IP (allegedly comprising certain cladding materials and methods of insulating greenhouses, regulating humidity, moving growing plants, and managing the movement of air, and any derivative works), and an associated patent application, be transferred to the them. The Plaintiffs are also seeking an order prohibiting the Company from using the words, “Canivate”, “ the Canivate Way”, “HydroFilm”, “Hydrohouse” and “Hydrohaus”.

On May 24, 2019, the Company filed a Response to the claim. That response denies the allegations in the claim, raises the defense that the plaintiffs wrongfully purported to sell intellectual property which they falsely stated they had invented and owned and states that the intellectual property was unworkable to build greenhouses. The Company also alleges that the plaintiffs falsely represented that their work for the Kak’adzdli would benefit the Company when it would not. The Response asks that the claim be dismissed.

The Company has also filed a Counterclaim based upon its allegations that the plaintiffs wrongfully induced the Company to enter agreements with the plaintiffs based on fraudulent misrepresentations regarding the existence of ownership of intellectual property. Further, the counterclaim alleges that Mr. Brazier breached his fiduciary duties to Canivate in preferring the interests of Hydrohaus over those of the Company.

The counterclaim seeks a declaration that the agreements which the Company rescinded were properly rescinded based upon the misrepresentations of the plaintiffs as well as general, special, aggravated and punitive damages, an accounting for profits, and legal costs.

SUBSEQUENT EVENTS

17.SUBSEQUENT EVENTS

 

The Company evaluated subsequent events through March 29, 2022,13, 2023, the date on which these financial statements were available to be issued, to ensure that this filing includes appropriate disclosure of events both recognized in the financial statements as of December 31, 2021,2022, and events which occurred subsequent to December 31, 20212022 but were not recognized in the financial statements. Except as disclosed below, there were no events that required recognition, adjustment to or disclosure in the financial statements.

 

On February 10,January 17 and 18, 2023, the Investors purchased additional tranches totaling $5,076,923 in convertible debentures and received 2,661,289 warrants. The convertible debentures and warrants were issued with an exercise price of $1.24. The issuance of the additional tranches triggered the down round provision, adjusting the exercise prices of the Debentures and the Debenture Warrants to $1.24 (Note 9 & 11). Subsequent to the year ended December 31, 2022, the investors converted $881,400 of convertible debentures into 710,807 shares.

Subsequent to the year ended December 31, 2022, the Company signedissued 1,637,049 shares to Manna upon exercise of their prefunded warrants.

Subsequent to the year ended December 31, 2022, the Company issued 12,500 shares to a definitive agreementconsultant for services rendered.

On January 24, 2023, the Company entered a binding letter of intent (“BP LOI”) to acquire Delphy Groep BVBerry People LLC (“Delphy”Berry People”), a Netherlands-based AgTech consultancy firm, for $U.S. based berry business. 26The BP LOI sets forth a purchase price of $28 million, through a combinationconsisting of $18.2 million in cash and stock. The closing$9.8 million in restricted shares to acquire 70% of the transaction is expected to occur within 60 days of the signing date.Berry People.

 

F-23F-22

Item 9. Changes in and Disagreements Withwith Accountants on Accounting and Financial Disclosure

 

None.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a—15(e) and 15d—15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”Exchange Act)), as of the end of the period covered by this Annual Report on Form 10-K. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of such date, our disclosure controls and procedures were effective.

 

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

Management’s Annual Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act). Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including the individuals serving as our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013 Framework). Based on this assessment, our management concluded that, as of December 31, 2022, our internal control over financial reporting was effective based on those criteria.

Attestation Report on Internal Control over Financial Reporting.

This Annual Report on Form 10-K does not include aan attestation report of management’s assessment regarding internal control over financial reporting or an attestation report of the Company’sour independent registered public accounting firm due to the deferral allowed given we are neither an accelerated nor a transition period established by the rules of the SEC for newly public companies.large accelerated filer.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information

 

None.

 

35

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

The information required by this Item is incorporated by reference from our definitive proxy statement for our 20212022 Annual Meeting of Stockholders (the “Proxy Statement”Proxy Statement). The definitive Proxy Statement will be filed with the SEC within 120 days after the close of the fiscal year covered by this Annual Report on Form 10-K.

Name   Age Position Served Since
Ingo W. Mueller* 5657 Chairman, Director, Chief Executive Officer December 2017
Donald Nicholson*82Chairman, Director, Audit CommitteeJuly 2018
William J. Meekison 5758 Director, Audit Committee, Compensation Committee June 2019
David Welch 4041 Director, Nominating and Governance Committee, Compensation Committee June 2019
Richard Levychin 6364 Director, Audit Committee Chair, Nominating and Governance Committee, Compensation Committee, July 2021
Amy Griffith 4950 Director, Audit Committee, Compensation Committee Chair, Nominating and Governance Committee July 2021
Richard S. Wong 5758 Chief Financial Officer October 2018
Troy T. McClellan 6061 President, AgriFORCEAgriFORCE™ Solutions February 2018
Mauro Pennella 5657 Chief Marketing Officer and President AgriFORCEAgriFORCE™ Brands division. July 2021
Dr. Laila Benkrima 5960 Chief Scientist May 2018

 

*Donald Nicholson resigned as Director and Chairman of the Board effective September 24, 2021. Ingo Mueller was appointed as Chairman of the Board effective September 24, 2021.

 

49

Directors serve until the next annual meeting and until their successors are elected and qualified. Officers are appointed to serve for one year until the meeting of the Board of Directors following the annual meeting of shareholders and until their successors have been elected and qualified.

Ingo Wilhelm Mueller – Chairman, Director and Chief Executive Officer

 

Mr. Mueller has been involved in the finance and advisory business for the past 25 years having been involved in the financing of companies and projects. Mr. Mueller is the founder and currently the CEO of the Company since inception and has been responsible for the development of the Company’s intellectual property, business model and financing. He is full time with the Company. He is also currently the CEO of St. George Capital Corp. (since 1998), doing business as Capital Fusion Group, a private financial advisory firm. Mr. Mueller was Chairman and CEO of International Coal Company Ltd. from 2008-2010 before it was sold to London Mining plc, after which Mr. Mueller was named Chairman and CEO of London Mining Colombia Ltd. (2010 to 2012). Mr. Mueller was also the CEO and Chairman of WIGU City Edutainment Centers Plc (2014 to 2017). Mr. Mueller has a Bachelor Commerce (major in Finance and minor in Urban Land Economics) from the University of British Columbia. The Board has determined that Mr. Mueller is suited to serve on the Board due to his long standing involvement in the financial community. Mr. Mueller was appointed as the Chairman of the Board effective September 24, 2021.

 

Don Nicholson, Chairman, Director

Mr. Nicholson began his career as an engineer at Shell Canada Ltd. and went on to serve as President, Vice President and Chief Executive Officer of several multinational companies. Mr. Nicholson has been retired for the past five years. Prior to his retirement, he acted as President of Pan Pacific Aggregates plc from January 2005 to August 2008.

Mr. Nicholson was responsible for executing major projects in the LNG, power generation, mining, nuclear, natural gas production, and pipeline construction industries. Prior to his retirement, he was a member of the Registered Professional Engineers of the Province of British Columbia, a Member of Prospector and Developers Association of Canada, of the Canadian Institute of Mining and Metallurgy, and the Institute of Corporate Directors of Canada. Mr. Nicholson earned a B.A. Sc., in Electrical Engineering at the University of British Columbia and a DIC in Automatic Control Systems at the Imperial College in London, England. Mr. Nicholson resigned as Chairman and Board member effective September 24, 2021.

David Welch, Director, Nominating and Governance Committee

 

Mr. Welch is thea founding partner at D|R Welch Law, a law firmENSO LAW, LLP, based in Los Angeles, California for which he has been employed full time for the past five years..Angeles. He has a broad base of experience in representing US, Canadian and Mexican corporate clients in the areas of litigation, corporate governance and financing, intellectual property and government regulatory advisement and defense. Mr. Welch has represented recognizable businesses in the agriculture and food services space in Federal Court, California state courts and before the USPTO.  Mr. Welch has also focusesargued before the California Supreme Court and the US 9th Circuit Court of Appeals on complex commercial transactionsconstitutional issues related to preemption and finance.the application of US law to various companies. Mr. Welch obtained his Juris Doctorate degree from Loyola Law School with an emphasis in international trade and has received various accolades for his Bachelor of Artswork in Political Scienceintellectual property and regulatory law, including Top 40 under 40 by the Daily Journal; National Law Journal Intellectual Property Trail Blazer, and Super Lawyers from the California State University, Fullerton. He2013 until 2023. In his business ventures, Mr. Welch is a member of the Los Angeles Countyregistered aquaculturist and American Bar Associations.farmer focusing on sustainable and regenerative agricultural practices.  He is suited to serve as a director due to his long standing experience in international intellectual property.property and business.

 

5036

 

William John Meekison, Director, Audit Committee, Compensation Committee

 

Mr. Meekison is a career Chief Financial Officer and former investment banker. He has spent the last fifteen years serving in a variety of executive management and CFO roles with both private and public companies, currently as the CFO and Director of Exro Technologies Inc. (since October 2017), a technology company that creates energy management system, and CFO and DirectorCFO of ArcWest Exploration Inc. (since December 2010), a mining exploration company in British Columbia. He is currently on the board of directors of Pike Mountain Minerals Inc.Telo Genomics Corp. (since July 2018) and Quest PharmatechAdven Inc. (since November 2017)April 2021).  Prior to his position at Exro Technologies Inc., and other CFO roles, Mr. Meekison spent fifteen years in corporate finance with a focus on raising equity capital for North American technology companies, including nine years at Haywood Securities Inc. Mr. Meekison received his Bachelor of Arts from the University of British Columbia and is a Chartered Professional Accountant, Professional Logistician and Certified Investment Manager. He is suited to serve as a director due to his long time experience as a CFO.

 

Richard Levychin, Director, Audit Committee Chair, Nominating and Governance Committee, Compensation Committee

 

Richard Levychin, CPA, CGMA, is a Partner in Galleros Robinson’s Commercial Audit and Assurance practice where he focuses on both privately and publicly held companies. Prior to taking this position in October 2018, Richard was the managing partner of KBL, LLP, a PCAOB certified independent registered accounting firm, since 1994. Mr. Levychin has over 25 years of accounting, auditing, business advisory services and tax experience working with both privately owned and public entities in various industries including media, entertainment, real estate, manufacturing, not-for-profit, technology, retail, technology, and professional services. His experience also includes expertise with SEC filings, initial public offerings, and compliance with regulatory bodies. As a business adviser, he advises companies, helping them to identify and define their business and financial objectives, and then provides them with the on-going personal attention necessary to help them achieve their established goals. Mr. Levychin is well suited to serve on our Board due to his decades of experience as the managing partner of a PCAOB certified independent registered accounting firm, which included decades of expertise with SEC filings and initial public offerings.

 

Amy Griffith, Director, Audit Committee, Compensation Committee Chair, Nominating and Governance Committee

 

AmyMs. Griffith iscurrently serves as Group Director for the North America Operating unit of the Coca-Cola Company, in this capacity she oversees public affairs, government relations, sustainability and communications in Canada and the Northeastern United States.  Previously, she served as Wells Fargo’s State & Local Government Relations Senior Leader for the Keystone Region encompassing Pennsylvania, Delaware and West Virginia.Vice President.  She was recruited to Wells Fargo’s Government Relations and Public Policy team in 2019. In this role, Griffith leadsled Wells Fargo’s legislative and political agenda in her region and managesmanaged relationships with a state and local policymakers and community stakeholders. From 2008-2019, Ms. Griffith led government relations for sixteen states in the Eastern United States for TIAA for over a decade. Prior to that, she worked in the aerospace, high tech, education, private and public sectors, and has managed multiple high-profile political campaigns at the local, state and national level. Griffith is active in her community and has co-chaired The Baldwin School Golf Outing to raise funds for girls’ athletics programs. She is a graduate of Gwynedd-Mercy College and holds a Bachelor of Arts in History. Ms. Griffith is well qualified to serve as a director due to her significant experience in government relations, policy and politics and yearsas well as decades of experience working with companies in both the private and public sectors.

 

Richard Wong, Chief Financial Officer

 

Mr. Wong, who works full time for the Company, has over 25 years of experience in both start-up and public companies in the consumer goods, agricultural goods, manufacturing, and forest industries. Prior to joining the Company in 2018, he was a partner in First Choice Capital Advisors from 2008-2016 and a partner in Lighthouse Advisors Ltd. from 2016-2018. Mr. Wong has also served as the CFO of Emerald Harvest Co., Dan-D Foods, Ltd., and was the Director of Finance and CFO of SUGOI Performance Apparel and had served positions at Canfor, Canadian Pacific & other Fortune 1000 companies. Mr. Wong is a Chartered Professional Accountant, and a member since 1999. Mr. Wong has a Diploma in Technology and Financial Management from the British Columbia Institute of Technology.

 

Troy McClellan, President AgriFORCEAgriFORCE™ Solutions

 

Mr. McClellan, who works full time for the Company, has focused on innovative design and construction technologies throughout his career. Most recently, he was V.P. of Design and Development at WIGU City from 2015-2018, at which time he joined the Company. Mr. McClellan was the VP Design and Development of MGM Macau. Previously, he was a Project Manager at Wynn Design & Development and a Design Manager at Universal Studios (Japan). Mr. McClellan is a registered professional architect and received his Master’s Degree in Architecture from Montana State University.

 

5137

 

Mauro Pennella, Chief Marketing Officer and President, AgriFORCE Brands

 

Mr. Pennella, who works full time for the Company, is a consumer products veteran with more than 30 years of experience in the consumer-packaged goods industry. From May 2018 until January 2021, he was Chief Growth & Sustainability Officer at McCain Foods, a Canadian multinational frozen food company. In that role, he was responsible for global marketing, sales, research and development (R&D) and sustainability. From October 2014 to April 2018, Mr. Pennella served as the President, International of Combe Incorporated, a personal care products company where he oversaw the international division, R&D and the internal advertising agency. He was also a member of the Executive Committee at Combe Incorporated, where he was responsible for the P&L - overseeing eight subsidiaries with more than 100 employees around the world. Prior to that, Mr. Pennella led the Retail and International businesses at Conagra’s Lamb Weston division and developed his career at Diageo and Procter & Gamble. Mr. Pennella received a Master of Business from Audencia, a premier European business school, as well as an M.A.B.A. in Marketing and Finance from The Ohio State University Fisher College of Business.

 

Dr. Laila Benkrima, Chief Scientist

 

Dr. Benkrima, who consults part-time for the Company, holds a PhD from the University of Paris in horticulture with a specialization in tissue culture and the hybridization and selection of plant varietals. Her employment history includes Inflazyme Pharmaceuticals, the University of British Columbia, and Celex Laboratory.

 

Corporate Governance

 

The business and affairs of our Company are managed under the direction of the Board of Directors.

Term of Office

Directors serve until the next annual meeting and until their successors are elected and qualified. Officers are appointed to serve until the Company requires them to be replaced.

 

Director Independence

 

We use the definition of “independence” of The NASDAQ Stock Market to make this determination. We are not yet listed on NASDAQ, and although we use its definition of “independence,” its rules are inapplicable to us until such time as we become listed on NASDAQ. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director” is a person other than an officer or employee of our Company or any other individual having a relationship which, in the opinion of the Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ rules provide that a director cannot be considered independent if:

 

 the director is, or at any time during the past three years was, an employee of our Company;
   
 the director or a family member of the director accepted any compensation from our Company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among other things, compensation for board or board committee service);
   
 a family member of the director is, or at any time during the past three years was, an executive officer of our Company;
   
 the director or a family member of the director is a partner in, controlling shareholder of, or an executive officer of an entity to which our Company made, or from which our Company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);
   
 the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three years, any of the executive officers of our Company served on the compensation committee of such other entity; or
   
 the director or a family member of the director is a current partner of our Company’s outside auditor, or at any time during the past three years was a partner or employee of our Company’s outside auditor, and who worked on our Company’s audit.

 

5238

 

Under the following three NASDAQ director independence rules a director is not considered independent: (a) NASDAQ Rule 5605(a)(2)(A), a director is not considered to be independent if he or she also is an executive officer or employee of the corporation, (b) NASDAQ Rule 5605(a)(2)(B), a director is not consider independent if he or she accepted any compensation from our Company in excess of $120,000 during any period of twelve consecutive months within the three years preceding the determination of independence, and (c) NASDAQ Rule 5605(a)(2)(D), a director is not considered to be independent if he or she is a partner in, or a controlling shareholder or an executive officer of, any organization to which our Company made, or from which our Company received, payments for property or services in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenues for that year, or $200,000. Under such definitions, we have four independent directors.

 

Family Relationships

 

There are no family relationships among any of the directors and executive officers, with the exception of Donald Nicholson and Ingo Mueller, as Mr. Nicholson is the stepfather of the Mr. Mueller, although they do not live in the same household. Mr. Nicholson resigned as Chairman and Director of the Board effective September 24, 2021.officers.

 

Board Committees

 

Our Board has established the following three standing committees: audit committee; compensation committee; and nominating and governance committee, or nominating committee. Our board of directors has adopted written charters for each of these committees. Copies of the charters will be available on our website. Our board of directors may establish other committees as it deems necessary or appropriate from time to time.

 

Audit Committee

 

Our Audit Committee is comprised of at least three individuals, each of whom are independent director and at least one of whom will be an “audit committee financial expert,” as defined in Item 407(d)(5)(ii) of Regulation S-K. Our audit committee is currently comprised of Richard Levychin (Chair), John Meekison and Amy Griffith, who are independent, and Mr. Levychin is our financial expert.

 

Our Audit Committee will oversee our corporate accounting, financial reporting practices and the audits of financial statements. For this purpose, the Audit Committee will have a charter (which will be reviewed annually) and perform several functions. The Audit Committee will:

 

 evaluate the independence and performance of, and assess the qualifications of, our independent auditor and engage such independent auditor;
   
 approve the plan and fees for the annual audit, quarterly reviews, tax and other audit-related services and approve in advance any non-audit service to be provided by our independent auditor;
   
 monitor the independence of our independent auditor and the rotation of partners of the independent auditor on our engagement team as required by law;
   
 review the financial statements to be included in our future Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and review with management and our independent auditor the results of the annual audit and reviews of our quarterly financial statements; and
   
 oversee all aspects our systems of internal accounting control and corporate governance functions on behalf of the Board of Directors.

 

5339

Compensation Committee

 

Our Compensation Committee comprises of at least three individuals, each of whom will be an independent director, Our Compensation committee is currently comprised of Amy Griffith (Chair), Richard LevychinDavid Welch and John Meekison and who are independent.

 

The Compensation Committee will review or recommend the compensation arrangements for our management and employees and also assist our Board of Directors in reviewing and approving matters such as company benefit and insurance plans, including monitoring the performance thereof. The Compensation Committee will have a charter (which will be reviewed annually) and perform several functions.

 

The Compensation Committee will have the authority to directly engage, at our expense, any compensation consultants or other advisers as it deems necessary to carry out its responsibilities in determining the amount and form of employee, executive and director compensation.

 

Nominating and Corporate Governance Committee (the “N&CG Committee”)

 

Our Nominating and Corporate GovernanceN&CG Committee is comprised of at least three individuals, each of whom will be an independent director. Currently Amy Griffith, Richard Levychin and David Welch (Chair) are members of the committee.

 

The NC&G Committee is charged with the responsibility of reviewing our corporate governance policies and with proposing potential director nominees to the Board of Directors for consideration. This committee also has the authority to oversee the hiring of potential executive positions in our Company. The NC&G Committee also has a charter, which is to be reviewed annually.

 

Item 11. Executive Compensation

Name & Principal Position Year  Salary  Bonus  Share-Based Awards  Option-Based Awards  All Other Compensation  Total Compensation 
Ingo W. Mueller,  2021   299,299   282,808   155,668   279,632   14,958   1,032,365 
Chief Executive Officer  2020   111,048   -       221,877   84,784   417,709 
Richard S. Wong,  2021   237,582   132,070   37,397   186,422   -   593,471 
Chief Financial Officer  2020   173,919                   173,919 
Troy T. McClellan,  2021   206,280   80,774   35,456   167,778   -   490,288 
Vice President Design & Construction  2020   149,363           99,261       248,624 
Mauro Pennella  2021   128,841   -   55,179   85,693   -   269,713 
Chief Marketing Officer, President AgriFORCE Brands  2020   -   -   -   -   -   - 

Name & Principal Position Year  Salary  Bonus  Share-Based Awardsc   Option-Based Awards  All Other Compensation  Total Compensation 
Ingo W. Mueller,  2022   392,464   375,718   359,881   6,866   1,741   1,136,670 
Chief Executive Officer  2021   299,299   282,808   155,668   279,632   14,958   1,032,365 
Richard S. Wong,  2022   295,216    134,696a  86,456   28,831   1,741   546,940 
Chief Financial Officer  2021   237,582   132,070   37,397   186,422   -   593,471 
Troy T. McClellan,  2022   246,732   69,162b  76,846   30,132   1,741   424,613 
Vice President Design & Construction  2021   206,280   80,774   35,456   167,778   -   490,288 
Mauro Pennella  2022   268,962   -   115,269   45,593   1,741   431,565 
Chief Marketing Officer, President AgriFORCE™ Brands  2021   128,841   -   55,179   85,693   -   269,713 

(a)Bonus was paid out $101,022 in shares and $33,674 in cash.
(b)Bonus was paid out $69,162 in shares
(c)

Some share-based awards were issued net of income taxes. The Company repurchased shares on the issuance date to remit as income taxes to the appropriate government revenue service agencies.

5440

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

The following table sets forth information known to us regarding the beneficial ownership of our common stock as of March 29, 202213, 2023 by:

 

each person known to us to be the beneficial owner of more than 5% of our outstanding common stock;
each of our executive officers and directors; and
all of our executive officers and directors as a group.

  Common shares  

Options Granted vested within 60 days of

March 29, 2022

  Warrants  Series A Preferred Shares  Total  Percentage beneficially owned 
Directors and Officers:                        
Ingo Mueller  964,625a 123,086   -   -   1,087,711   7.1%
Richard Wong  81,217   46,976   -   -   128,193   0.8%
Troy McClellan  412,921   33,029   -   -   445,950   2.9%
Mauro Pennella  11,853   13,860   -   -   25,713   0.2%
Don Nicholson*  581,520b  28,715   -   -   610,235   4.0%
John Meekison  43,208   16,310   -   -   59,518   0.4%
David Welch  52,450   12,928   -   -   65,378   0.4%
Amy Griffith  -   4,108   -   -   4,108   0.0%
Richard Levychin  -   4,108   -   -   4,108   0.0%
Total all officers and directors (9 persons)*  2,147,794   283,120           2,430,914   15.7%
                         
5% or Greater Beneficial Owners                        
Ingo Mueller  964,625a  123,086   -   -   1,087,711   7.1%
Arni Johannson  823,615c  -           823,615   5.4%

Canadian Nexus Team Ventures Corp

  583,278   -   317,243   -   900,521   5.8%

*Mr. Nicholson resigned from the Board effective September 24, 2021.

  Common shares  

Options Granted vested

within 60 days of

March 13, 2023

  Warrants  Total  Percentage beneficially owned 
Directors and Officers:                    
Ingo Mueller  1,060,083a  169,592   -   1,229,675   6.7%
Richard Wong  130,244   77,980   -   208,224   1.1%
Troy McClellan  445,581   64,126   -   509,707   2.8%
Mauro Pennella  56,073   37,141   -   93,214   0.5%
John Meekison  43,208   30,405   -   73,613   0.4%
David Welch  52,450   26,459   -   78,909   0.4%
Amy Griffith  -   16,511   -   16,511   0.1%
Richard Levychin  -   16,511   -   16,511   0.1%
Total all officers and directors (8 persons)*  1,787,639   438,725   

-

   2,226,364   12.1%
                     
5% or Greater Beneficial Owners                    
Ingo Mueller   1,060,083 a   169,592   -   1,229,675   6.7%
Manna Nutritional Group, LLC  1,637,049   -   -   1,637,049   9.0%

(a)Includes (1) 92,03060,757 common shares held by St. George Capital Corp. of which Mr. Mueller is the President, (2) 421,053193,766 common shares held by 1071269 BC Ltd. of which Mr. Mueller is the sole owner, and (3) 31,57914,532 common shares held by 1178196 BC Ltd. of which Mr. Mueller is an affiliate.
(b)Includes 437,290 common shares held by 0902550 BC Ltd. of which Mr. Nicholson is the sole owner.
(c)Includes 48,710 common shares held by Canadian Nexus Ventures Ltd. of which Mr. Johannson is the President.

 

Item 13. Certain Relationships and Related Transactions, and Director Independence

 

We have adopted a written related-person transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight of “related-party transactions.” For purposes of our policy only, and not for purposes of required disclosure, which will be all related party transactions, even if less than $120,000, a “related-party transaction” is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any “related party” are participants involving an amount that exceeds $120,000.

 

Transactions involving compensation for services provided to us as an employee, consultant or director are not considered related-person transactions under this policy. A related party is any executive officer, director or a holder of more than five percent of our common shares, including any of their immediate family members and any entity owned or controlled by such persons.

 

5541

 

At present, we have appointed three independent directors to the Nominating and Corporate GovernanceN&CG Committee. As a result, our Chief Financial Officer, Richard Wong, must present information regarding a proposed related-party transaction to the Nominating and Corporate Governance Committee. Under the policy, where a transaction has been identified as a related-party transaction, Mr. Wong must present information regarding the proposed related-party transaction to our Nominating and Corporate Governance Committee, once the same is established, for review. The presentation must include a description of, among other things, the material facts, the direct and indirect interests of the related parties, the benefits of the transaction to us and whether any alternative transactions are available. To identify related-party transactions in advance, we rely on information supplied by our executive officers, directors and certain significant shareholders. In considering related-party transactions, our Nominating and Corporate Governance Committee takes into account the relevant available facts and circumstances including, but not limited to:

 

 whether the transaction was undertaken in the ordinary course of our business;
   
 whether the related party transaction was initiated by us or the related party;
   
 whether the transaction with the related party is proposed to be, or was, entered into on terms no less favorable to us than terms that could have been reached with an unrelated third party;
   
 the purpose of, and the potential benefits to us from the related party transaction;
   
 the approximate dollar value of the amount involved in the related party transaction, particularly as it relates to the related party;
   
 the related party’s interest in the related party transaction, and
   
 any other information regarding the related party transaction or the related party that would be material to investors in light of the circumstances of the particular transaction.

 

The Nominating and Corporate Governance Committee shall then make a recommendation to the Board, which will determine whether or not to approve of the related party transaction, and if so, upon what terms and conditions. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.

 

Except as set forth below, we have not had any related party transactions, regardless of dollar amount:

 

As of December 31, 2021, $47,4612022, $32,500 (December 31, 2020 - $3,223)2021, $47,461) in total was owing to officers and directors or to companies owned by officers and directors of the Company for services and expenses. These amounts owing have been included in accounts payable and accrued liabilities.

 

During the year ended December 31, 20212022 and 2020,2021, the Company incurred $66,246$79,457 and $38,395,$66,246, respectively, to our U.S. general counsel firm, D R Welch against legal services, a corporation controlled by a director of the Company. AnNo shares were issued in the year ended December 31, 2022 (an aggregate of 13,158 shares (62,500 shares before the Reverse Split) were issued – December 31, 2021) to David Welch as part of the payment.

During the year ended December 31, 2021 and December 31, 2020, the Company paid $Nil and $8,862, respectively, for consulting services to 0902550 BC Ltd. where Don Nicholson is the principal consultant.

On May 1, 2019, the Company entered into a 12 months consulting agreement with Arni Johannson to provide Investor Relations services for a monthly fee of CAD 10,000. As of December 31, 2020, the Company owed $nil pursuant to the said agreement.

 

Item 14. Principal Accounting Fees and Services

 

Aggregate fees billed to us by Marcum LLP, the Company’s principal independent accountants, during the last two fiscal years were as follows:

 

  December 31, 2021  December 31, 2020 
Audit Fees $126,000  $97,850 
Audit – Related Fees  83,954   41,200 
Tax Fees  -   - 
All other Fees  -   - 
  $209,954  $139,050 
  December 31, 2022  December 31, 2021 
Audit Feesa $170,000  $126,000 
Audit – Related Fees  197,649   83,954 
  $367,649  $209,954 

(a)Amounts represent the contractual fees related to the fiscal year, not the accrued fees incurred during the year.

 

Audit Fees consist of fees billed for professional services rendered for the audit of our consolidated annual financial statements and review of the interim consolidated financial statements included in quarterly reports and services that are normally provided by our auditors in connection with statutory and regulatory filings or engagements.

 

Audit-Related Fees consist of services by our independent auditors that, including accounting consultations on transaction related matters including work related to our S-1 fillings, are reasonably related to the performance of the audit or review of our financial statements and are not reported above under Audit Fees.

 

During the years ended December 31, 20212022 and 2020,2021, Marcum LLP did not incur fees for any other professional services.

5642

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules

 

Financial Statements

 

The following Consolidated Financial Statements of the Company and the Report of Independent Registered Public Accounting Firm (PCAOB ID: 688) included in Part II, Item 8:

 

Consolidated Balance Sheets as of December 31, 20212022 and 20202021

 

Consolidated Statements of Comprehensive Loss for the years ended December 31, 20212022 and 20202021

 

Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 20212022 and 20202021

 

Consolidated Statements of Cash Flows for the years ended December 31, 20212022 and 20202021

 

Financial Statement Schedules

 

All schedules have been omitted because they are not required or because the required information is given in the Consolidated Financial Statements or Notes thereto set forth under Item 8.

 

Exhibits

The exhibits listed below are filed or incorporated by reference as part of this Annual Report on Form 10-K.

 

Exhibit

No.

 Description
3.1 Articles of Incorporation and Bylaws of Issuer*
4.1 Form of Series A Warrant and Representatives Warrant****
4.2 Amended and Restated Stock Option Plan – Form of Stock Option Certificate attached as Schedule A*
4.3 Form of Broker Compensation Warrant Certificate for $1.00 warrants issued to brokers in connection in May 2019 in connection with $1.00 preferred unit financing*
10.1 Vacant Land Purchase Agreement, dated July 13, 2020, between Company and Coachella Properties, Inc.*
10.2 Capital Funding Group-Commercial Loan Terms_Sheet_-_Re Coachella_3837v2*
10.3 Commercial Loan Agreement with Alterna Bank-2020-04-30*
10.4 Vacant Land Offer Extension_of_Time_Addendum_Coachella-IM Signed*
10.5 Employment Agreement - Ingo Mueller********
10.6 Employment Agreement - Richard Wong********
10.7 Employment Agreement - Troy McClellan********
10.8 Employment Agreement – Mauro Pennella **Pennella********
10.9 Second Vacant Land Offer Extension_of_Time_Addendum_Coachella-IM Signed***
10.10 Warrant Agent Agreement***
10.11 Capital Funding Term Sheet dated February 5, 2021 ****
10.12 Extension of Land Purchase Agreement ****
10.13 Pharmhaus Termination Agreements ******
10.14 Bridge Loan Agreement dated March 24, 2021******
10.15 Bridge Note, dated March 24, 2021******
10.16 Bridge Warrant, dated March 24, 2021******
10.17 Asset Purchase Agreement – Manna Nutritional Group********
10.18 Definitive Agreement with Humboldt Bliss, Ltd********
10.19 Share Purchase Agreement with Delphy Groep B.V. **********
10.20 Binding LOI to Acquire Deroose Plants NV **NV********
10.21 License Agreement with Radical Clean Solutions Ltd. **********
14.1 Code of Ethics**
21.1 List of Subsidiaries**
23.1 Consent of Marcum, LLP**
31.1 Certification of Chief Executive Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**
31.2 Certification of Chief Financial Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**
32.1 Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2 Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
101.INS Inline XBRL Instance Document
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed with our Registration Statement on Form S-1 filed with the Commission on December 16, 2020.

** Filed herewith

*** Filed with Amendment No. 1 to our Registration Statement on Form S-1 filed with the Commission on January 20, 2021.

**** Filed with Amendment No. 2 to our Registration Statement on Form S-1 filed with the Commission on March 3, 2021.

***** Filed with Amendment No. 3 to our Registration Statement on Form S-1 filed with the Commission on March 22, 2021.

****** Filed with Amendment No. 4 to our Registration Statement on Form S-1 filed with the Commission on June 3, 2021.

******* Filed with Amendment No. 5 to our Registration Statement on Form S-1 filed with the Commission on June 14, 2021.

******** Filed with Form 10-K filed with the Commission on March 30, 2022.

 

Item 16. Form 10-K Summary.

 

None.

 

5743

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 AGRIFORCE GROWING SYSTEMS, LTD.
   
Date: March 29, 202213, 2023By:/s/ Ingo Mueller
 Name:Ingo Mueller
 Title:Chief Executive Officer and Director (Principal Executive Officer)
   
Date: March 29, 202213, 2023By:/s/ Richard Wong
 Name:Richard Wong
 Title:Chief Financial Officer (Principal Financial and Accounting Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature Title Date

/s/ Ingo Mueller

 Chief Executive Officer, 

March 29, 2022

13, 2023
Ingo MuellerChairman of the Board of Directors
/s/ Richard WongChief Financial OfficerMarch 29, 202213, 2023
Richard Wong
/s/ John MeekisonDirectorMarch 29, 202213, 2023
John Meekison
/s/ Richard LevychinDirectorMarch 29, 202213, 2023
Richard Levychin
/s/ Amy GriffithDirectorMarch 29, 202213, 2023
Amy Griffith
/s/ David WelchDirectorMarch 29, 202213, 2023
David Welch

 

5844